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Abstract 
Despite many efforts, HIV-1 infection remains a global health problem; an effective vaccine 
would provide the best chance of controlling the pandemic. Recently, HIV vaccine research 
has been focusing on the gut mucosal immune system and early immunological events, which 
may set the stage for the later appearance of clinical immunodeficiency. 
This thesis describes a method to obtain mucosal tissue, isolate mucosal mononuclear cells 
(MMC) and study degranulation and intracellular cytokine memory responses using 
polychromatic flow cytometry. Consistent and reproducible data were generated by adhering 
to validated Standard Operating Protocols (SOPs). Qualification of such methods is essential 
for use in vaccine clinical trials. Differences between the magnitude of single CD8 cytokine 
and degranulation responses between blood and gut were seen; however, the quality of T cell 
responses at the single cell level was remarkably similar in both compartments. Differences 
between small bowel and colon were also described and introduce another layer of 
complexity in the interpretation of mucosal responses to HIV-1. Differences in memory 
phenotypes and function between blood and gut, in addition to small and large bowel allow 
for better characterization of the cytotoxic potential of CD8+ and CD4+ T cells against HIV-1 
infected cell targets. Finally, a significant positive correlation between IFNγ and 
degranulation responses were seen with the frequencies of central memory and granzyme B-
containing CD8+ in the mucosa, but not in the blood. A better understanding of memory 
responses and cytotoxic potential against HIV-1 targets will be important in vaccine research; 
it may also help reshaping the current practice of empirically and unselectively fast-tracking 
potential immunogens to large-scale trials. 
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Chapter 1  Introduction 
1.1 Human Immunodeficiency Virus infection and Acquired 
Immunodeficiency Syndrome 
The Human Immunodeficiency Virus-1 (HIV-1), along with HIV-2, are members of the 
lentiviridae subgroup of retroviruses (Piguet et al. 2001); both appear to have evolved 
following cross-species transmission of Simian Immunodeficiency Virus (SIV) strains, from 
chimpanzees (SIVcpz) and sooty mangabeys (SIVsmm) respectively (Hahn et al. 2000; Sharp 
et al. 2005). They preferentially infect CD4+ T lymphocytes, as well as other cells bearing the 
CD4 receptor (i.e. macrophages, dendritic cells etc)(Simon et al. 2006) and evade the host ’s 
immune system, despite an initial vigorous immune response. In the case of HIV-1, this 
results in a chronic progressive infection, which, if untreated, will almost universally progress 
to the Acquired Immune Deficiency Syndrome (AIDS). The outcome of the infection is more 
variable in the case of HIV-2, which causes AIDS in only a small proportion of individuals, 
whilst remaining asymptomatic in the majority of those infected (Lemey et al. 2003; de Silva 
et al. 2008). Since the present study was conducted in HIV-1 infected donors, only HIV-1 
will be reviewed here. 
1.1.1 Epidemiology of HIV-1 infection 
An estimated 33 million people were infected with HIV-1 worldwide in 2007 (UNAIDS, 
2008); during that year alone, 2.7 million new cases were reported and 2 million HIV-related 
deaths were recorded (UNAIDS, 2008). Sub-Saharan Africa remains the most heavily 
affected region worldwide, with 67 percent of all infected individuals residing in this part of 
the world and 75 percent of all AIDS-related deaths recorded in this region (UNAIDS, 2008); 
this reflects the fact that while access to treatment facilities and Antiretroviral Treatment 
(ART) is undoubtedly improving, it still remains inadequate (Quinn 2008). The impact of the 
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epidemic in this part of the world has been devastating, with profound socioeconomic and 
demographic changes (Kamali et al. 1996; Stephenson 2009). 
Unprotected heterosexual intercourse remains the most common mode of transmission 
worldwide. In all other regions outside sub-Saharan Africa, the infection is more prevalent 
among specific “high-risk” groups, such as intravenous drug users, men who have sex with 
men and commercial sex workers. Worldwide, men and women are equally affected, whereas 
in sub-Saharan Africa women account for 61% of infected individuals (UNAIDS, 2008). 
Undoubtedly, the HIV epidemic remains a global health problem of unprecedented 
dimensions. Despite the complexities and challenges in the attempt to control it, some 
encouraging data have begun to emerge. Globally, the percentage of adult carriers of HIV has 
leveled off since 2000. The rate of transmission has decreased in some countries (including 
some in the sub-Saharan Africa), although this is offset by increases in others (UNAIDS, 
2008). As access to ART has improved in the last decade, numbers of AIDS-related deaths 
have fallen. Emerging data suggest that increased availability of ART in sub-Saharan Africa 
is having a major impact in prevention of clinical immunodeficiency (AIDS) and 
improvement in the quality of life of those affected (Glynn et al. 2007; Nyirenda et al. 2007; 
Kiboneka et al. 2009). Notwithstanding these significant achievements, more coordinated 
efforts are needed to continuously implement and reinforce successful strategies, in order for 
those favourable trends to continue. 
1.1.2 Structural biology and replication cycle of HIV-1 
HIV-1 is a complex retrovirus which consists of a total of fifteen distinct proteins and the 
genomic RNA (Frankel et al. 1998). The mature HIV-1 virion consists of a cone-shaped 
capsid and two copies of the genomic RNA; this structure is enveloped by a lipid bilayer, 
which comes from the host cell’s membrane (Figure 1.1.) (Frankel et al. 1998) 
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Figure 1.1. Structure of the HIV-1 genome and virion (extracted from Frankel and Young , 1998 ), 
(see text) 
The envelope contains two surface glycoproteins encoded by the env open reading frame: 
gp120 (SU), which interacts with cell- surface CD4 to initiate entry into the target cell, and 
gp41 (TM), which facilitates fusion of viral and cellular membranes during that process (Turner 
et al. 1999). The gag open reading frame encodes for a large protein molecule, which is later 
proteolysed into the following structural elements: MA (matrix), CA (capsid), NC 
(nucleocapsid) and p6. These four gag-derived proteins along with the two envelope proteins 
form the virion and the outer envelope of HIV-1. Another open reading frame (pol) encodes 
three enzymes essential for the replication cycle of the virus: PR (protease), RT (reverse 
transcriptase) and IN (integrase); these three molecules are also found within the viral particle. 
Three further accessory proteins (Vif, Vpr and nef) are part of the mature virion, whereas Tat, 
Rev (gene regulatory proteins) and Vpu (which facilitates virion assembly) are not. 
Nef is a highly preserved protein in all primate lentiviruses, suggesting that is may afford a 
survival advantage to those pathogens (Niederman et al. 1992). There is data supporting an 
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important role for nef in viral replication: SIV lacking the expression of nef has been shown 
to have a replication disadvantage in macaques (Kestler et al. 1991), whereas several strains 
isolated from HIV-infected long-term non-progressors (LTNP) lack nef expression (Deacon 
et al. 1995; Kirchhoff et al. 1995). Some of the functions attributed to nef include the ability 
to down-regulate cell surface CD4, MHC-I and II molecules, as well as to increase infectivity 
and viral replication (Jere et al.). Of particular interest is the ability of nef to moderate the 
antiviral immune response and prevent excessively high levels of immune activation in 
natural SIV infection in sooty mangabeys, achieved largely by its ability to down-regulate the 
TCR-CD3 on the surface of T cells (Munch et al. 2002); this ability is not shared by the HIV-
expressed nef, which may, to some extend, account for the high levels of immune activation 
with its detrimental effects and progression to AIDS in humans (Schindler et al. 2006). 
The life cycle of HIV-1 begins with the binding of the gp120 receptor to the cell-surface 
CD4, which causes pore formation across the membrane, allowing access to the cytoplasm of 
the target cell. This process is facilitated by the interaction with chemokine co-receptors 
(CCR5, CXCR4) inducing a conformational change in the gp41 protein and facilitating 
fusion (Eckert et al. 2001). Once the capsid is inside the cell, the viral reverse transcriptase 
initiates the conversion of the genomic RNA to dsDNA. At this stage, the viral genome is 
transported into the cell nucleus; the viral integrase, Vpr, as well as signals present on the 
matrix protein facilitate this complex process. Integrase also mediates the insertion of the 
viral DNA into the cell chromosomal DNA. The integrated viral genome utilizes the host 
cell’s transcription and translation mechanisms to encode for the small regulatory proteins 
Tat and Rev, which amplify and facilitate the translocation of RNA fragments to the 
cytoplasm in preparation for protein synthesis. The envelope proteins are transported to the 
cell membrane, while the gag structural proteins form the capsid, incorporating two RNA 
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molecules in the process. In the final stage, the viral particle buds from the host cells, taking a 
fragment of the cell membrane with the envelope proteins (Lever et al. 2006). 
1.1.3 Natural History of HIV-1 
HIV-1 is primarily transmitted via mucosal surfaces and infects a small number of mucosal 
target cells bearing the CD4 receptor (i.e. T cells and DCs) and a chemokine co-receptor 
(mainly CCR5 and CXCR4) (Doms 2001). The virus then rapidly replicates and infects other 
CD4+ mucosal cells in the vicinity and in distant lymphoid organs (i.e. lymph nodes, spleen, 
thymus and other mucosal sites (Zhang et al. 1999; Schacker et al. 2001). 
 
Figure 1.2. The natural history of HIV-1 infection 
Changes in plasma viral load, blood CD4+ T cell count, and HIV-1-specific CD8+ T cell responses (extracted 
from  Douek, Picker et al., 2003). 
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This sequence of events marks the onset of the acute phase of the infection (Figure 1.2), 
which is often characterised by the presence of non-specific symptoms (Cooper et al. 1985); 
high levels of viraemia and CD4+ T cell depletion are universally observed at this stage 
(Henrard et al. 1995; Schacker et al. 1998). The virus is able to form a reservoir in latently 
infected CD4+ cells, capable of sustaining the infection at a later stage even amidst effective 
antiretroviral treatment (ART)(Finzi et al. 1997; Finzi et al. 1999; Siliciano et al. 2003). 
Besides the CD4+ T cells in the blood, there is emerging evidence that mucosal CD4+ T cells 
may play a role as a major viral reservoir; indeed, HIV-1 DNA and RNA can be consistently 
isolated from mucosal biopsies of patients on apparently suppressive ART (Anton et al. 
2003). Throughout the course of the disease there is extensive CD4+ T cell depletion in 
mucosal sites, which is established within the first few weeks of the infection (Brenchley et 
al. 2004). The CD4+ T cell numbers in the Mucosa Associated Lymphoid Tissue (MALT) do 
not appear to recover in the chronic phase of the infection, at least not to the extent their 
counterparts do in the blood (Mehandru et al. 2004). Other cells besides lymphocytes, such as 
lamina propria monocytes and macrophages may play an important role as viral reservoirs 
(Smith et al. 2003). An important development during this phase is the establishment and 
rapid expansion of HIV-1 specific CD8+ T cell responses, leading to a sharp decline in the 
plasma viral load and partial restoration of the blood CD4+ T cell counts (Figure 1.2.) 
(Borrow et al. 1994; Rosenberg et al. 1997); this marks the end of the acute and the onset of 
the chronic phase of the infection, which is characterised by slowly declining CD4+ counts 
and progressively increasing viral loads for an average period of 10 years, in the absence of 
clinical symptoms (Douek et al. 2003). The magnitude of the viraemia at the onset of the 
chronic phase is known at the “set-point” and it is thought to be predictive of the rate at 
which individuals will progress to AIDS (Lyles et al. 2000). 
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The chronic phase of the infection is immunologically dynamic, despite the fact that dramatic 
fluctuations in the levels of viraemia and blood CD4+ counts are generally not seen. High 
levels of immune activation of both CD4+ and CD8+ T cells are characteristic of this stage 
(Ascher et al. 1988) and appear to be a more accurate predictor of disease progression than 
plasma VL (Leng et al. 2001). Eventually, after approximately 10 years of infection and 
when the blood CD4+ count falls below 200 cells/µL, the vast majority of individuals will 
progress to AIDS. This phase is characterised by the presence of various opportunistic 
infections and often by a further precipitous drop in the CD4+ count and a marked increase in 
the level of viraemia (Pantaleo et al. 1993). 
Although in the majority of untreated patients HIV-1 infection will progress to AIDS, a small 
number of infected individuals are able to control the infection for very long periods of time, 
in the absence of ART. These individuals [often referred to as long-term non progressors 
(LTNP) or elite controllers], lack any clinical symptoms, can preserve CD4+ T cell numbers 
and maintain very low plasma viral loads (Pantaleo et al. 1995). It is unclear whether the 
“elite controller” status should be primarily attributed to viral factors (Deacon et al. 1995), or 
host genetic traits (Bansal et al. 2007); study of HIV-1 infection in these individuals has been 
the focus of intense research in an attempt to shed light on the mechanisms of immunological 
control of HIV-1 (Deeks et al. 2007). 
1.1.4 Pathogenesis of HIV, immune responses and mechanisms of evasion of the 
host’s immune system 
There is a complex interplay between the virus and the host’s immune system. Many aspects 
of this interaction have been well characterised; others, such as the role of immune activation 
in evading the host’s immune system, are less well described. The adaptive immune response 
to HIV-1 and its overall limited efficacy in containing the virus is thought to be central in the 
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immunopathogenesis of HIV-1 and has been the focus of intense research since the discovery 
of the virus. 
1.1.4.1 HIV-1 interaction with CD4+ and CD8+ T cells 
The hallmark of untreated HIV-1 infection is the gradual depletion of CD4+ T cells leading to 
immunodeficiency and AIDS. This CD4 depletion had been attributed to direct viral 
cytotoxic effects (Ho et al. 1995; Wei et al. 1995) and is extensive in the acute phase of the 
infection, following which CD4 numbers in the blood recover partially. However, it is now 
apparent that direct viral cytotoxicity cannot exclusively account for the massive destruction 
of CD4 cells, since the virus only infects a small proportion of these cells (1:100 to 1: 1,000) 
(Douek et al. 2008). Other host-related factors must, therefore, play an important role in the 
depletion of the CD4+ T cell pool. Chronic immune activation is thought to cause higher 
CD4+ and CD8+ T cell turnover (Hellerstein et al. 1999), which can overwhelm homeostatic 
mechanisms (Kovacs et al. 2001) and cause a decrease in the life span of CD4+ T cells 
(Hellerstein et al. 1997). The high levels of pro-inflammatory cytokines and chemokines 
characteristic of the state of immune activation reduce the ability of the thymus and the 
lymphoid tissue to reconstitute the immune system (Schacker et al. 2002; Dion et al. 2004). 
In addition, immune activation indirectly facilitates viral replication by providing target cells 
for the virus in the form of activated CD4+ T cells (Grossman et al. 1998). Thus, CD4+ 
depletion appears to be multifactorial and not entirely understood; in addition, depletion of 
particular subsets of CD4+ T cells (such as central memory CD4) may be more directly 
associated with progression to the clinical syndrome of AIDS (Okoye et al. 2007). 
As such, CD8+ T cells are not directly targeted by the virus and their numbers in the 
peripheral blood increase significantly during the acute phase of the infection (Pantaleo et al. 
1994); as previously discussed, the emergence of HIV-specific CD8+ T cell responses 
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coincides with dramatic reduction in the plasma viral load and transition from the acute to the 
chronic phase of the infection. Further support for the critical role of CD8+ T cells in the 
control of viraemia is provided by the observation that CD8+ depletion in SIV-infected rhesus 
macaques results in significant increase in plasma viral load, which promptly returns to 
baseline levels when these cells reappear (Schmitz et al. 2003). CD8+ T cells appear to be 
important in prevention of transmission, as evident by the study of a small cohort of Gambian 
female sex workers who remain uninfected despite repeatedly exposed to the virus; strong ex 
vivo HIV-specific CTL responses against viral peptides were detected in a significant 
proportion of these women compared to other HIV seropositive donors; furthermore, these 
CTL responses were associated with a specific HLA B haplotype (HLA B35), which is 
prevalent in the Gambian population (Rowland-Jones et al. 1995). 
The viraemic control coinciding with the emergence of CD8+ immune responses, however, 
appears to be transient and only partially effective and is eventually lost as the disease 
progresses, leading to the hypothesis that CD8+ T cells, although normal in numbers, may be 
functionally impaired. Indeed, a number of reports have described skewed CD8+ cell 
maturation (Champagne et al. 2001), tolerance induced by exposure to high viral antigenic 
burden (Zinkernagel 1996) and impaired CD4+ help (Rosenberg et al. 1997) as some of the 
mechanisms underlying the overall poor quality of the CD8+ immune response. Taking into 
account the qualitative differences between HIV-specific CD8+ T cells and those observed in 
other successfully contained infections (CMV, EBV), it appears that HIV-specific CD8+ T 
cells lack the ability to effectively proliferate and secrete IL-2 (Migueles et al. 2002; Pantaleo 
et al. 2004). Indeed, Migueles et al studied CD8+ responses in a group of HIV Long-Term 
Non-Progressors (LTNPs) and found increased proliferative capacity and cytolytic potential, 
compared to HIV progressors. More recently, a higher frequency of polyfunctional (i.e. 
positive for IFNγ, CD107, TNFα, IL-2 and MIP-1b) CD8+ T cells in LTNPs was described 
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(Betts et al. 2006). Notwithstanding the importance of the available data and the widely 
accepted concept that polyfunctional CD8 responses are associated with better viraemic 
control, there are no definitive correlates of protection identified as yet. One significant 
observation, which adds considerable complexity, is that the level of antigenic exposure (i.e. 
the level of viraemia) positively influences the magnitude and the quality of the response 
(Gea-Banacloche et al. 2000; Betts et al. 2001; Champagne et al. 2001; Tussey et al. 2003; 
Hess et al. 2004; Jansen et al. 2006; Streeck et al. 2008); therefore, the quantity and quality of 
the CD8+ response may reflect the inability of the immune system to suppress viral 
replication, rather than correlate with immune protection. 
CD8+ T cell cytotoxicity can also be mediated via the Fas/Fas-ligand and the cytolytic 
enzyme pathways; the former is a non-secretory pathway which involves interaction of the 
Fas ligand (upregulated during T cell activation) with the Fas receptor, located on the surface 
of the target cell; this interaction results in the apoptotic death of the target (Kagi et al. 1996). 
An alternative pathway used by cytotoxic lymphocytes (CTLs) and innate immune cells 
alike, is the secretory granule-mediated cell death pathway, of which major components are 
the cytolytic enzymes granzyme and perforin. This pathway involves the formation of an 
immunological synapse between effector and target cell, with resulting release of these 
enzymes into the cytoplasm of the target cell, where they initiate apoptotic signals and cell 
death (Voskoboinik et al.). These targets are recognized both by CTLs and innate immune 
system components, such as natural killer (NK) cells. The innate immune system forms the 
first line of defence against the viral or other pathogen, allowing for the maturation of the 
antigen-specific response, which will eventually clear the infection. Despite fundamental 
differences between the two types of immune responses, the secretory granule-dependent 
death pathway is remarkably similar in all types of cytotoxic immune cells (Kagi et al. 1994). 
Secretory granules contain a wide range of proteases also found in lysosomes, which are 
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activated in the cytosol of the target cells (Bird et al. 2009). Some of these proteolytic 
enzymes, collectively known as granzymes, are highly lethal upon release in the target cells 
and cause death by activating apoptotic pathways and degrading the extracellular matrix 
(Bovenschen et al.). There are five known members of the human granzyme family: 
granzymes A, B, H, K and M. Of those, granzymes A and B have been more extensively 
studied than the other three, which are occasionally referred to as “orphan granzymes”. 
The delivery of granzymes to their target is mediated by another component of the secretory 
granules, namely perforin. Upon activation of the cytotoxic cell, perforin is released into the 
immunological synapse and polymerizes to form a transmembrane route for delivery of the 
granzymes to the target (Voskoboinik et al.). The various steps in the synergy between 
granzymes and perforin are still controversial, with one model favouring passive diffusion of 
granzymes via the perforin pores and another suggesting co-transport of perforin and 
granzymes inside endocytic vesicles. Regardless of the exact mechanism, it is clear from 
experimental data from perforin-deficient mice (Kagi et al. 1994) that perforin is absolutely 
essential for optimal function of cytotoxic immune cells, whereas individual granzymes are 
relatively redundant, as their deficiencies are usually associated with susceptibility to a 
limited repertoire of pathogens and milder immunodeficiency symptoms (Ebnet et al. 1995; 
Mullbacher et al. 1996). 
The study of expression patterns of granzymes and perforin in CTLs may provide important 
information regarding their cytotoxic potential (Wolint et al. 2004). The ability for rapid 
cytolytic activity upon encounter with the target appears to differ significantly between 
effector, effector memory and central memory CD8+ cells, despite the fact that all these 
populations are capable of antigen-specific degranulation as measured by the cell surface 
expression of CD107 (Betts et al. 2003). 
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1.1.4.2 Chronic immune activation in HIV-1 infection 
There is no simple definition for chronic immune activation in the context of HIV-1 
infection. It is characterised by polyclonal B-cell expansion (Lane et al. 1983), high levels of 
pro-inflammatory cytokines and an “activated” T cell phenotype (most notably the expression 
of CD38 and HLA-DR on the surface of CD8+ T cells). 
One possible cause for generalized activation of the immune system in HIV-1 is the virus 
itself; indeed, HIV-1 can be recognized by innate immune system cells and cause activation 
via Toll-Like Receptor (TLR) 7/8 –mediated signaling (Beignon et al. 2005; Meier et al. 
2007). It is, however, difficult to attribute chronic immune activation exclusively to the 
replicating virus, as several observations challenge this notion. For instance, elite controllers 
may have high levels of immune activation in the face of undetectable plasma vireamia (Hunt 
et al. 2008). Similarly, in individuals on suppressive ART, high levels of immune activation 
may be seen (Hunt et al. 2003). Furthermore, sooty mangabeys with non-pathogenic SIV 
infection show persistently high viraemia in the chronic phase of the infection with 
simultaneously low levels of immune activation (Estes et al. 2008b). 
Recently, a number of observations have established a mechanistic link between immune 
activation and translocation of bacteria/bacterial products from the gut lumen in HIV-1 
infected individuals. This concept will be discussed in some detail in the second part of this 
Chapter, along with the other mucosal manifestations of immune dysregulation in HIV-1. 
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1.1.4.3 Role of innate and adaptive (other than CD4+ and CD8+) immune cells in 
defences against HIV-1 
Both the innate and adaptive arms of the immune system react to the presence of HIV-1 in ways 
aiming to control viral replication and eventually eliminate the virus, albeit with limited efficacy. 
Gamma-delta (γδ) T cells 
γδ T cells are capable of responding very early, before the adaptive immune response is 
effective and, in that sense, they are at the interface between innate and adaptive immunity. In 
HIV-infected individuals, the Vδ1 fraction is up-regulated, with simultaneous down-
regulation of the Vδ2 fraction (Autran et al. 1989). γδ T cells bear NKG2D receptors, able to 
recognize their MICA/MICB ligands (up-regulated in stress) and able to elicit effector 
responses (Moretta et al. 2000). They can also produce pro-inflammatory cytokines and other 
antiviral factors capable of mediating target cell lysis (Wallace et al. 1996). In addition, γδ 
cells in SIV-infected macaques have been shown to produce viral inhibitory factors, such as 
RANTES, MIP-1a and MIP-1b, which are able to block viral entry into the cell by binding 
and down-regulating the CCR5 co-receptor (Lehner et al. 2000a; Lehner et al. 2000b). 
Natural Killer (NK) cells 
Natural Killer (NK) cells play an important role in immunity against HIV-1. They can 
eliminate virus-infected cells by direct lysis (Bandyopadhyay et al. 1990) or via Antibody-
Dependent Cell-mediated Cytotoxicity (ADCC) (Ward et al. 2004). In addition, they are able to 
inhibit HIV-1 entry into the target cells by secreting large amounts of RANTES, MIP-1a and 
MIP-1b and blocking interaction with CCR5 (Fehniger et al. 1998). NK cells can also secrete 
cytokines such as IFNγ, TNFα and GM-CSF (Fauci et al. 2005) and prime adaptive responses 
to HIV-1 via cross-talk with dendritic cells (DCs)(Cooper et al. 2001). Eventually, however, 
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viral escape mechanisms, most notably the selective downregulation of HLA-A and HLA-B 
molecules on cell surfaces (Cohen et al. 1999), allow the virus to evade NK-mediated defences. 
Plasmacytoid dendritic cells (pDCs) 
Plasmacytoid dendritic cells (pDCs) are thought to play an important role in immunity 
against HIV-1. These cells express the main HIV receptor CD4, as well as the co-receptors 
CCR5 and CXCR4 and can, therefore, become substrates for productive infection by the 
virus (Patterson et al. 2001). Encounter with the virus induces maturation of the pDCs, which 
leads to the production of large amounts of interferon alpha (IFNa)(Yonezawa et al. 2003). 
IFNa has strong antiviral activity and is able to completely inhibit HIV replication in vitro 
(Bednarik et al. 1989) and in vivo murine models (Vieillard et al. 1999). IFNα also possesses 
indirect antiviral effects, having been shown to enhance survival of pDCs (Cella et al. 2000) 
and to facilitate lysis of virus-infected cells by NKs and cytotoxic T cells (Biron 2001). 
Recent evidence, however, suggests that pDCs may also play a negative role in HIV control 
by inducing apoptosis of CD4+ T cells via IFNa-mediated TNF-related apoptosis-inducing 
ligand (TRAIL) up-regulation (Herbeuval et al. 2005). The overall role of pDCs will need to 
be further explored, in order to understand the exact implications of those interactions in the 
immunopathogenesis of HIV-1. 
B cells and humoral immunity 
The humoral arm of the adaptive immune system responds to the infection by producing 
HIV-specific antibodies early in the course of the disease (Albert et al. 1990); however, 
unlike other viral infections where the host depends on humoral immunity for the clearance 
of the virus, neutralizing antibodies do not seem to play a vital role in the control of HIV-1 
(Letvin et al. 2003). In support of that, the dramatic reduction in plasma viral load seen at the 
interface between acute and chronic phase of the infection coincides with the development of 
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a robust CD8+ T cell response and precedes the appearance of any measurable neutralizing 
antibody in plasma (Pilgrim et al. 1997). Also, depletion of B cells by an anti-CD20 
monoclonal antibody in rhesus macaques infected with SIV has no noticeable impact on the 
kinetics of early viral clearance (Schmitz et al. 2003). Neutralizing antibodies to HIV target 
the third hypervariable loop of the envelope protein gp120, the binding site for the CD4 
receptor, or the transmembrane part of the gp41 molecule (Letvin et al. 2003). There are also 
a variety of non-neutralizing antibodies against elements of the HIV virion (Poignard et al. 
1999). Whilst these antibodies appear to be of no particular importance in the control of the 
virus in vivo (Jacobson 1998), there is evidence to suggest a protective role against the 
acquisition of the infection in non-human primates (Baba et al. 2000; Mascola et al. 2000), 
which has generated an interest in vaccine-induced neutralizing antibody responses. Indeed, 
the recent isolation of several antibodies with exceptional neutralization breadth and potency, 
such as the HJ16 (Corti et al.) and VRC01 (Li et al. 2007), both of which target epitopes of 
gp120 in proximity to the CD4 binding site, has renewed the interest in identifying 
immunogens capable of eliciting such responses; these findings will be discussed in some 
detail later in this Chapter when developments in the field of HIV vaccines are reviewed. 
1.1.5 Treatment of HIV-1 infection 
Antiretroviral treatment (ART) is currently the best option for long-term suppression of viral 
replication and reversal of the immunological defects caused by HIV-1. In the developed 
world, where access to these medications is easy, ART has transformed the profile of HIV-1 
infection from a universally fatal illness to a chronic manageable condition. Notwithstanding 
the tremendous benefits of introducing ART, it should be emphasized that eradication of the 
virus with the currently used regimes is still an unachievable target. In addition, since lifelong 
treatment is needed in the majority of affected individuals, the focus of attention has been 
shifted to the adverse effects of treatment and the impact on the individual’s quality of life. 
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There are currently six different classes of antiretroviral medications in use, of which the 
majority targets the viral reverse transcriptase or protease. These classes are as follows: 
Nucleoside reverse transcriptase inhibitors (NRTIs). 
Non-nucleoside reverse transcriptase inhibitors (NNRTIs). The first two categories inhibit 
the viral RT after HIV-1 has entered the target cell but prior to integration into the cell’s 
genome (Simon et al. 2006) 
Protease Inhibitors (PIs). These drugs inhibit the assembly and maturation of the intact viral 
particle, resulting in the production of virions with diminished infectivity (Simon et al. 2006). 
Fusion inhibitors. Currently the only member of this group is enfuvirtide, which targets the 
gp41 envelope protein and inhibits the fusion process, prior to the entry of the virus into the 
target cell 
Entry inhibitors. Currently the only compound in this category is Maraviroc, which acts by 
binding to the CCR5 co-receptor and preventing the entry of HIV-1 into the cell. This type of 
medication has no activity against viruses adapted to use the CXCR4 co-receptor instead 
(Gazzard 2008). 
Integrase inhibitors. Members of this group are raltegravir and elvitegravir; these 
compounds act by inhibiting viral integrase and thus preventing the incorporation of viral 
DNA in the host cell’s genome (Gazzard 2008) 
Early data from the 1980s have firmly established that treatment with a single agent 
(monotherapy) cannot control viral replication due to emergence of drug resistance. In order 
for ART to be effective, a combination of drugs from two or more classes should be 
administered. This strategy has proven largely successful in suppressing viraemia below what 
is currently the limit of detection for most commercially available assays (50 RNA copies 
/µL). The guidance on appropriate commencement of treatment should be based on evidence 
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from randomized trials (Gazzard 2008; Hammer et al. 2008). Such data are not always 
available, necessitating the use of less robust evidence and, in many cases, expert opinion in 
formulating current guidelines. With that in mind, it is recommended that in primary HIV 
infection individuals should be offered treatment (outside the context of a clinical trial) if 
there is neurological involvement or an AIDS-defining illness, or the CD4 count is less than 
200 cells/µL for more than 3 months (Gazzard 2008). For individuals with established 
infection, the most recent British HIV Association (BHIVA) Guidelines recommend that 
individuals with CD4 cell counts less than 350 cells/µL should be considered for treatment. 
Needless to say that these should be individualized and factors such as long-term drug 
toxicities and compliance ought to be taken into account. 
Treatment of HIV infected patients with ART results in partial restoration of immunological 
deficits associated with chronic infection. Suppressive ART has been associated with 
restoration of CD4+ and CD8+ specific T cell responses to HIV (Rosenberg et al. 1997); such 
restoration of CTL immune responses may in some cases maintain control of viral replication 
even after discontinuation of treatment (Rosenberg et al. 1997; Ortiz et al. 1999; Rosenberg et 
al. 2000). In the majority of patients, however, treatment interruption will lead to rapid 
rebound of plasma viraemia, since CTL responses alone will be unable to control ongoing 
viral replication. It should be emphasised that restoration of recall responses with suppressive 
ART is in most cases transient and a decline in those is seen after several months of 
successful treatment (Ogg et al. 1998). This has led to the emergence of the Structured 
Treatment Interruption (STI) concept, in an attempt to boost the HIV specific CD4+ and CD8+ 
T cell responses in chronically treated individuals (Binley et al. 2000; Haslett et al. 2000; El-
Sadr et al. 2006). 
In addition to the effects on HIV specific immune responses, suppressive ART has a positive 
effect in restoring T cell responses against a variety of opportunistic pathogens, such as CMV 
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(Deayton et al. 1999; Weinberg et al. 2003), Mycobacterium avium complex (MAC) and 
Mycobacterium tuberculosis (MTB) (Mallal et al. 1994; Kampmann et al. 2006). The success 
of ART in reinstituting pathogen specific immune responses, although desirable, may 
sometimes be associated with an overt inflammatory reaction often associated with 
significant morbidity, known as Immune Restoration Disease (IRD). The 
immunopathogenesis of IRD differs based on the pathogen targeted by the newly restored 
CTL responses; for example, IRD associated with immunity against mycobacteria is 
primarily mediated by delayed-type hypersensitivity responses; in contrast, CD8+ T cell 
responses appear to be the main mediators of IRD associated with herpes virus (Price et al. 
2009). Other more rare forms of IRD are associated with first presentation of autoimmune 
diseases, such as Grave’s disease or sarcoidosis, in ART recipients and probably have 
different immunopathogenesis (French et al. 2004) 
1.1.6 Prevention of HIV-1 infection 
The development of a safe and effective HIV-1 vaccine would undoubtedly be the most 
efficient way to control the epidemic worldwide. Despite the resources devoted, development 
of such a vaccine remains elusive and meaningful progress is hindered by many challenges. 
Perhaps the most significant obstacle is the unprecedented diversity of HIV-1, which has so 
far given rise to nine distinct clades and many recombinant forms (Gaschen et al. 2002). 
Another challenge is the ability of the virus to establish latent reservoirs (mainly in resting 
CD4+ T cells) early in the course of the infection, thus evading the host’s immune 
surveillance (Chun et al. 1998). Lack of clearly defined immune correlates of protection is yet 
another limitation in the attempt to design a successful vaccine. 
An ideal vaccine should be able to prevent infection and provide sterilizing immunity. It is 
possible that this goal may be unrealistic, especially considering that many successful 
vaccines against human viral pathogens merely prevent clinical disease (by containing the 
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virus), but not transmission. Such a vaccine, able to control viral replication and prevent the 
clinical syndrome of AIDS, although not ideal, would nonetheless be desirable. 
Efforts to develop a vaccine capable of eliciting broadly reactive neutralizing antibodies appear 
to be a promising strategy if sterile immunity is the target (Montefiori et al. 2007). Proof-of-
concept studies confirmed protection against transmission in non-human primates by 
administration of high-doses of broadly reactive monoclonal antibodies (Baba et al. 2000; 
Mascola et al. 2000). Unfortunately, attempts to elicit such broadly reactive neutralizing 
antibodies have so far been unsuccessful. Some of the immunogens tried include elements of 
the HIV-1 envelope gp120 protein (Moore et al. 1995; Mascola et al. 1996; Flynn et al. 2005). 
Newer generation immunogens are constantly engineered and will most likely enter clinical 
trials in the near future (Barouch 2008). Recently, several neutralizing antibodies of high 
potency and broad spectrum of activity, such as the PG9 and PG16 (Walker et al. 2009), HJ16 
and VRC01 (Corti et al; Wu et al.) have been isolated from HIV infected donors with the use of 
novel selection techniques; the last two target epitopes in close proximity to the CD4 binding 
site of gp120, whereas PG9 and PG16 target trimeric epitopes which span more than one 
subunits of the gp120 molecule. These exciting developments have rekindled the interest in the 
field and will undoubtedly boost the efforts to engineer a newer generation of immunogens 
capable of eliciting antibodies with similar potency and breadth profiles. 
A different vaccine development strategy aiming at eliciting cellular immune responses uses 
replication-incompetent viral vectors (such as recombinant adenovirus serotype 5, rAd5) 
expressing various HIV-1 proteins. Although some initial data showed that rAd5-based 
vaccines elicited cellular immune responses against HIV-1 epitopes, no clinical efficacy was 
observed (Barouch 2008). The STEP trial, a large scale clinical vaccine study which was 
conducted using rAd5 as vector and clade B gag, pol and nef as immunogens, had to be 
terminated prematurely, since preliminary data suggested increase susceptibility to infection 
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in the group of vaccinees compared to controls (Priddy et al. 2008). One possible explanation 
is that adenovirus-based vaccines may expand HIV-susceptible Ad5-specific CD4 cells in 
individuals with preexisting immunity against the vector, thus providing more targets for HIV 
in the mucosal surfaces (Benlahrech et al. 2009). Of note, immunogenicity data from the 
previous study, as assessed by IFNγ Elispot assay, correlate poorly with clinical efficacy; this 
observation, along with similar discrepancies observed in population-based studies (Addo et 
al. 2003) question the validity of IFNγ Elispot as the single assessment tool in vaccine 
efficacy trials. Somewhat more encouraging results were obtained in NHP, where induced 
SIV-specific CD8 responses were able to exert a degree of control on viral replication after 
challenge with the virus, although acquisition of the infection was not prevented (Liu et al. 
2009; Wilson et al. 2009). This was achieved to some extent with the use of CMV vectors 
expressing SIV gag, rev, tat and nef, which were used to immunize rhesus macaques in 
another SIV vaccine efficacy trial (Hansen et al. 2009); subsequent intrarectal challenge of 
the macaques with homologous virus showed that a fraction of the vaccinated animals was 
protected from systemic infection. 
The above encouraging results, as well as the study of natural transmission of the infection, 
may indicate that even modest immune response induction at the mucosal surfaces could be 
sufficient to dramatically reduce the risk of transmission. Indeed, a number of observations 
indicate that natural transmission of HIV across mucosal surfaces is not particularly efficient: 
sexual transmission occurs on average after 100 to 1000 exposures (Cohen et al. 2008) and 
vertical transmission only occurs in one third of infected mothers giving birth; also, small 
cohorts of commercial sex workers in Kenya and Gambia remain uninfected despite high 
levels of exposure (Fowke et al. 1996). One plausible explanation for the modest protective 
effect seen in the recent RV144 human vaccine efficacy trial, which used a recombinant 
canarypox-HIV vector and the HIV env peptide immunogen, may be the induction of some 
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degree of protective immunity in the mucosal surfaces; such vaccine-induced induced 
immune responses may have been sufficient to decrease the rate of transmission in the group 
of vaccinees by 30 percent, albeit without affecting the viral set-point in vaccinees who 
eventually acquired the infection (Rerks-Ngarm et al. 2009). 
1.2 The Gastrointestinal Immune System in HIV-1 infection 
1.2.1 Structure of the Mucosa-Associated Lymphoid Tissue 
The gastrointestinal (GI) immune system is the largest immune organ in the body, with the 
Mucosa-Associated Lymphoid Tissue (MALT) containing more than 40% of the total 
number of lymphocytes (Hein 1999). The gastrointestinal tract also constitutes by far the 
largest surface in direct contact with the external environment, with the total area of gut 
epithelium approximating 400m2, largely because of the formation of millions of fingerlike 
villi in the small bowel (Macdonald et al. 2005). It is, therefore, not surprising that the MALT 
immune system plays a key role in protecting the host from harmful environmental 
influences. On the other hand, the intestinal bacterial flora is important in the digestive 
functions of the GI tract and in maintaining local mucosal immune homeostasis (Magalhaes 
et al. 2007); much of what the gut immune system does is guided by the necessity to maintain 
a balance between the preservation of commensal gut flora and protection from invasion by 
pathogenic microorganisms (Mowat 2003; Cario et al. 2005). This separation from 
environmental antigens is primarily achieved by the presence an anatomical barrier, the gut 
epithelium, consisting of a single layer of epithelial cells joined together with tight junctions 
(Figure 1.3.). An additional layer of mucus and glycocalyx on the luminal side of the 
epithelium reinforces this physical barrier, whereas defensins and other antimicrobial 
substances secreted in the local microenvironment form a further biological barrier 
(Menendez et al. 2007). 
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From a functional perspective, the gut immune system can be divided into the inductive and 
the effector compartments (Fig. 1.3.). The inductive compartment of MALT consists of the 
mesenteric lymph nodes and the organized lymphoid structures of the mucosa (Peyer’s 
patches and single lymphoid follicles); within these structures, antigens from the gut lumen 
encounter cells of the adaptive immune system and immune responses are induced. 
Subsequently, antigen-experienced memory cells enter the effector sites where they engage 
their targets (Cheroutre et al. 2004). The effector immune cells are distributed in two distinct 
anatomical compartments of the mucosa, i.e. the intraepithelial layer and lamina propria. The 
lamina propria lymphocytes (LPL) consist mostly of “conventional” effector memory CD4 
and CD8αβ T cells; in contrast to T cells in lymph nodes and the spleen, these cells are 
oligoclonal, presumably as a result of repeated encounters with a limited repertoire of 
antigens from the gut lumen, a process leading to expansion of selected clones (Blumberg et 
al. 1993). The intraepithelial lymphocytes (IELs) are interspersed among the epithelial cells 
forming the single-layer barrier and are mostly memory CD8+ T cells capable of immediate 
cytolytic activity; they can be further divided into two categories: “conventional”, or type a 
IELs, which express either a CD4 or a CD8αβ co-receptor along with an αβ T-cell receptor 
(TCR), and “non-conventional” type b IELs, which express CD8αα along with either αβ or 
γδ TCR (Cheroutre 2005). 
The mucosal humoral immune system is characterised by its ability to produce abundant 
amounts of Immunoglobulin A (IgA), in contrast to the blood, where IgG is the dominant 
immunoglobulin class (Cerutti et al. 2008). The presence of IgA in the luminal secretions 
provides another layer of defence against invading bacteria, as well as a mechanism for 
selection of commensal bacteria. IgA+ secreting B cells are mainly in the germinal centre 
(GS) of the patches of Peyer (PP) as well as in the lymphoid follicles of the mucosa. The 
dominance of IgA+ secreting B cells in those locations is dependent on the key enzyme 
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activation-induced cytidine deaminase (AID), which controls class-switching recombination 
(CSR) and requires cross-talk with T cell subsets mediated by metabolic products and 
cytokines (Suzuki et al. 2009). IgA is indispensible in preventing excess activation of the 
mucosal immune system and preserving the balance between maintaining effective defences 
and minimizing “collateral damage” in the mucosa (Cerutti et al. 2008) 
 
Figure 1.3. Inductive and effector compartments of the mucosal immune system 
[Extracted from (Cheroutre et al. 2004)]. 
1.2.2 T cell differentiation in the MALT in HIV-1 
The innate immune response is the first line of defence against invading organisms and is 
summoned upon recognition of molecular patterns present in pathogens via evolutionary 
conserved sensors, the Toll-like Receptors (TLRs) (Kopp et al. 2003); it is the cross-talk 
between TLRs and dendritic cells (DCs) that produces signals for the adaptive branch of the 
immune system to generate the type of effector cell most appropriate for the specific 
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pathogen to which it is responding (Iwasaki et al. 2004). Intracellular bacteria encountered by 
myeloid dendritic cells (mDCs) will generally result in IL-12 secretion, which will promote 
the differentiation of T-helper 1 (Th1) cells and production of their “signature” cytokine 
IFNγ. Infestation with helminths, on the other hand, will lead to the production of IL-4 and 
differentiation of CD4+ T cells towards a T-helper 2 (Th2) phenotype; these cells secrete IL-
4, IL-5 and IL-13 and are involved in the control of parasitic infestation (Kapsenberg 2003). 
The Th1 and (to a lesser extend) the Th2 subsets are the dominant effector CD4+ T cell 
populations in the blood compartment and are capable of generating rapid pro-inflammatory 
protective responses against invading pathogens. Across the mucosal barriers, however, 
maintenance of a delicate balance between “aggressive” responses to pathogens and tolerance 
towards commensal microbiota is particularly important, if potential harm to the host from 
excessive inflammatory responses is to be avoided (Sansonetti 2004). Several recently 
described T cell subsets, such as the regulatory T cells (Treg), the T-helper 17 (Th17) and the 
T-helper 22 (Th22) are most abundant in the MALT and are primarily responsible for 
maintaining immune homeostasis (Littman et al.). 
Regulatory T cells are broadly defined by their ability to suppress antigen specific T cell 
responses and control inappropriate and excessive immune-mediated damage. Several subsets 
of regulatory T cells have been described, based on their origin and mechanism of action; 
perhaps the most important distinction is that between naturally occurring regulatory T cells, 
which express the transcription factor Foxp3, and inducible regulatory T cells, which are 
generated in the context of an immune response to a pathogen or other agents (Belkaid et al. 
2009). The inducible regulatory T cells can then be further divided into Tr1 (which secrete 
IL-10), Transforming Growth Factor (TGF)-β producing cells and inducible Foxp3+ 
regulatory T cells. Indeed, Foxp3 has been shown to be induced in peripheral CD4+ T cells in 
vivo in a variety of conditions (Apostolou et al. 2004; Kretschmer et al. 2005; Mucida et al. 
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2005), as well as in vitro (Bettelli et al. 2006; Wan et al. 2008), making the distinction 
between naturally occurring and inducible regulatory T cells less clear. 
Regulatory T cells share a common lineage with another recently described CD4+ T cell 
subset, the Th17 cells (Mucida et al. 2007; Quintana et al. 2008; Zhou et al. 2008). These 
cells are characterised by their ability to secrete interleukin 17 (IL-17) and were described as 
a separate lineage in mice (Harrington et al. 2005; Park et al. 2005) and subsequently in 
humans (Acosta-Rodriguez et al. 2007a; Acosta-Rodriguez et al. 2007b). Th17 CD4+ T cells 
produce IL-17, IL-17F and IL-22 and are capable of rapidly responding to pathogens at the 
mucosal surfaces (Dandekar et al. ; Wolk et al. 2006). These cells may mediate the immune 
tissue destruction in many autoimmune conditions (Steinman 2007; Bettelli et al. 2008; 
McGeachy et al. 2008). Th17 cells are also important in maintaining and renewing the 
mucosal epithelial monolayer via the secretion of IL-17 and the induction of key tight 
junction proteins in an ERK/MAPK-dependent manner (Kinugasa et al. 2000). Recently, 
Th22 cells capable of producing large amounts of IL-22 but not IL-17 were described as yet a 
separate committed lineage of CD4+ T cells (Duhen et al. 2009; Trifari et al. 2009). IL-22 has 
also been shown to promote epithelial regeneration by positive effects on migration and 
proliferation of epithelial cells (Wolk et al. 2006; Nograles et al. 2008). 
The precise role of these newly described CD4+ T cell subsets in the context of HIV-1 
infection in the gastrointestinal mucosa has not been completely defined yet. The Treg and 
Th17 subsets appear to be closely related since TGF-β is essential in the development of both 
lineages (Korn et al. 2009). Both Treg and Th17 cells are severely depleted in MALT in HIV 
infection as well as in NHP infected with SIV (Estes et al. 2006; Brenchley et al. 2008; 
Cecchinato et al. 2008; Raffatellu et al. 2008); the disproportional loss of Th17 cells has been 
linked to higher levels of immune activation in HIV-1 and pathogenic SIV infections, due to 
epithelial dysfunction caused by the absence of the protective effects of IL-17 and IL-22 
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(Favre et al. 2009). The role of regulatory T cells in this context is controversial. It is 
debatable whether these cells have an overall harmful effect by suppressing HIV-specific 
immune responses or beneficial, by moderating the detrimental effects of systemic immune 
activation (Aandahl et al. 2004; Weiss et al. 2004; Tsunemi et al. 2005). These controversies 
may to an extent result from lack of consistency in defining Treg populations in different 
studies. Perhaps rather than the frequencies of each of these T cell subsets in the MALT, the 
ratio of suppressive Treg to pro-inflammatory Th17 cells may be more relevant in the cross 
talk between these helper CD4+T cell subsets in the control of immune activation, HIV 
mucosal reservoir replication and preservation of the epithelial barrier. 
1.2.3 Mucosal dysfunction and immunopathogenesis of HIV-1 
A series of studies have established that early HIV/SIV infection is associated with rapid and 
dramatic depletion of CD4+ T cells in the gastrointestinal mucosa (Schneider et al. 1995; 
Veazey et al. 1998; Guadalupe et al. 2003). The factors responsible for the preferential loss of 
CD4+ T cells in the gut are not fully understood. The fact that the majority of CD4+ T cells in 
the lamina propria are activated CCR5+ cells would explain their preferential targeting by the 
virus (Zack et al. 1990; Zhang et al. 1999). Furthermore, it has recently been shown that the 
gut homing integrin alpha4beta7 (α4β7) interacts with the envelope protein gp120 of HIV-1, 
facilitating the entry of the virus into the host cell (Arthos et al. 2008). It has been suggested 
that depletion of CD4+ cells is a direct result of virus-mediated killing (Mattapallil et al. 
2005); however, the presence of viral RNA in only a small minority of gut CD4+ T cells in 
early SIV infection supports the notion that other indirect mechanisms may, at least partially, 
account for the depletion of gut CD4+ cells (Li et al. 2005). The recent observation that Th17 
and regulatory T cells are preferentially depleted in the MALT in HIV-1 and SIV infections 
was discussed in the previous section of this Chapter; these T cell subpopulations play a 
central role in defences against luminal bacteria (Blaschitz et al. 2010) and potential 
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imbalances causes by preferential targeting of some subsets by the virus may have significant 
impact on mucosal defences and the integrity of the epithelial barrier. In an attempt to link 
mucosal immune dysfunction (caused by the CD4 depletion, or preferential depletion of other 
T cell subsets) with the progression of the disease and the state of chronic immune activation, 
the microbial translocation hypothesis has emerged in recent years; according to this, early 
and profound loss of subsets of mucosal CD4+ T cells compromises the integrity of the gut 
epithelial barrier (anatomically and/or functionally), resulting in translocation of microbial 
products into the bloodstream; it is those products that sustain the state of chronic immune 
activation characteristic of HIV-1, with all the detrimental consequences for the host 
(Brenchley et al. 2006b; Paiardini et al. 2008; Sodora et al. 2008). Several lines of evidence 
support a mechanistic link between mucosal epithelial barrier dysfunction and chronic 
immune activation; Brenchley et al found significantly elevated levels of lipopolysaccharide 
(LPS), a wall component of gut-residing gram negative bacteria, in the blood of HIV-infected 
individuals and SIV-infected rhesus macaques, compared to controls (Brenchley et al. 2006a; 
Brenchley et al. 2006b). Furthermore, plasma levels of LPS in the HIV-positive group are 
sufficiently high to perpetuate a state of chronic immune activation (Suffredini et al. 1999) 
and correlate with parameters such as CD38 expression on CD8+ cells. Soluble CD14 
(sCD14), a marker of monocyte/macrophage activation, is elevated in HIV positive 
individuals; this molecule binds soluble LPS in vivo and its plasma concentration appears to 
be proportional to LPS levels (Lien et al. 1998; Kitchens et al. 2005). In keeping with the 
previous observations, suppressive ART resulted in decreased plasma LPS levels, which were 
also inversely related to the degree of CD4+ T cell reconstitution after treatment (Brenchley et 
al. 2006b). Further support for the link between epithelial barrier dysfunction and chronic 
immune activation in HIV-1 is provided by the finding that epithelial repair appears to be 
defective in primary HIV infection, as evident by down-regulation of genes encoding factors 
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essential for maintenance/regeneration of the mucosal monolayer (Sankaran et al. 2008). 
Finally, microbial translocation is documented in other disease entities in which damage to 
the gastrointestinal mucosa is a cardinal feature, such as Inflammatory bowel disease (IBD) 
(Caradonna et al. 2000) and acute Graft Versus Host Disease (GVHD) (Cooke et al. 1998; 
Cooke et al. 2002). 
While this theory appears to explain some key events in the pathogenesis of HIV/AIDS, it 
should be emphasized that a direct cause-effect relationship between microbial translocation 
and systemic immune activation is yet to be shown. Also, the fact that the epithelial barrier 
breakdown leading to immune activation is primarily caused by the CD4 depletion in the 
mucosa is speculative and would not explain the observation that SIV natural hosts, such as 
sooty mangabeys, suffer dramatic CD4 depletion in the gut, yet they show no evidence of 
systemic immune activation and progression to clinical immunodeficiency (Gordon et al. 
2007; Pandrea et al. 2007). This and other observations would suggest that other forms of 
mucosal immune dysfunction, besides the loss of CD4+ cells, or even direct damage to the 
epithelial cells or tight junctions could be responsible for the translocation of bacterial 
products. Indeed, CD4 depletion may be necessary, but neither sufficient nor predictive of 
progression to clinical immunodeficiency and other factors in the complex interplay between 
the virus and the host’s immune response may be critical. It is tempting to speculate that the 
relative proportions of the various CD4+ T cells subsets and imbalances caused by 
preferential depletion of some subsets and preservation of others are more important factors 
for progression to clinical immunodeficiency and AIDS than the absolute CD4+ T cell counts 
in the gut (Kanwar et al. 2010). 
1.2.4 Mucosal immune responses to HIV-1 
During the early years of the HIV pandemic, the virus was considered primarily a gut 
pathogen, having been identified as the aetiologic agent of the AIDS-associated enteropathy 
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syndrome, characterised by diarrhoea and significant weight loss (Kotler et al. 1984). 
Subsequently, the dramatic and disproportionate mucosal CD4+ T cell depletion documented 
in acute HIV and SIV infections reinforced this view and generated an interest in host-virus 
interaction at the level of the mucosal immune system (Heise et al. 1993; Heise et al. 1994; 
Veazey et al. 1998); in that context, CTL and humoral mucosal immune responses to HIV-1 
have recently attracted considerable interest. 
Current evidence suggest that HIV-specific CD8+ T cell responses in blood are essential in 
restraining the unchallenged replication of the virus during the acute phase of the infection 
and that their appearance coincides with a precipitous drop in plasma viral load (Koup et al. 
1994; Price et al. 1997). Eventually, however, this immune mechanism fails to control viral 
replication and the vast majority of patients depend on antiretroviral treatment to control 
disease progression and prevent the emergence of clinical immunodeficiency. The role of 
mucosal immune responses in preventing HIV-1 transmission or, in the case of established 
infection, in contributing to the control of viral replication is less well characterised. Li et al 
demonstrated in two different infection models (SIV infection in macaques and lymphocytic 
choriomeningitis in mice) the importance of sufficiently high effector-to-target (E:T) ratios at 
the mucosal inoculation points in preventing systemic dissemination and concluded that a 
sufficiently early and robust HIV-specific mucosal CTL response may prevent transmission 
(Li et al. 2009). The importance of mucosal CD8+ responses in controlling viral replication in 
chronically infected individuals was recently demonstrated in two studies, where gag-specific 
rectal responses and polyfunctionality were associated with higher CD4 counts and lower 
plasma viraemia (Critchfield et al. 2007; Critchfield et al. 2008). Furthermore, Ferre et al 
showed that gag-specific rectal responses are more polyfunctional in elite controllers 
compared to non-controllers and individuals on ART (Ferre et al. 2009). A further recent 
study confirmed that HIV positive elite controllers maintain strong polyfunctional CD8+ T 
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cell responses, whilst showing a low systemic immune activation profile (Owen et al. 2010). 
This data collectively supports the notion that mucosal CTL responses may contribute to 
viraemic control in established infection. 
Despite the fact that HIV is unable to enter and infect B cells, the impact of the virus on the 
mucosal inductive sites is dramatic, with loss of germinal centres in the Peyer’s patches and over 
80 percent of lymphoid follicles containing apoptotic lymphocytes (Levesque et al. 2009). 
Several lines of evidence suggest a role for mucosal antibody responses in preventing viral 
transmission. Highly exposed, persistently seronegative (HEPS) individuals have been found to 
have HIV-specific IgA antibodies in mucosal secretions (Mazzoli et al. 1997; Kaul et al. 2001), 
which, in some cases, demonstrated in vitro neutralizing activity as well as inhibition of 
transmission through an epithelial monolayer (Devito et al. 2000a; Devito et al. 2000b; 
Mestecky 2006). However, not all HEPS individuals demonstrate high levels of IgA antibodies 
(Dorrell et al. 2000; Skurnick et al. 2002) (Mestecky et al. 2004) and other yet unidentified 
factors may be important for the protection from viral transmission in this group. 
1.3 Quality assurance in flow cytometry–based methods to assess T cell 
responses in blood and mucosa 
The field of HIV vaccine research is currently very active, with many new candidate 
immunogens being tested in clinical trials. Adenovirus vectors have been shown to induce 
systemic and mucosal T cell gag responses in rhesus macaques (Sun et al. 2009). Similarly 
various modified vaccinia virus Ankara (MVA)-based vaccines have induced rectal IgA 
responses in non-human primates (Manrique et al. 2008), in addition to CD4 and CD8 
responses in mucosal lymph nodes and rectal biopsies (Burgers et al. 2009a; Engram et al. 
2009). It is not surprising, therefore, that there is considerable interest in the development of 
robust and precise protocols to analyse mucosal T-cell responses in the setting of ongoing 
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clinical trials. To monitor mucosal responses, gut tissue may be sampled at baseline and then 
again at a predetermined timepoint following vaccination. The use of polychromatic flow 
cytometry (PFC) allows the comparison of the magnitude and phenotype of vaccine-induced 
T-cell responses in PBMC and mucosal mononuclear cells (MMC). However, the application 
and standardisation of such protocols is challenging due to the complexity of acquiring and 
processing mucosal tissue and the comparatively low yields of mucosal mononuclear cells. 
Validated PFC protocols for blood samples have previously been described (Horton et al. 
2007) and the use of published guidelines on the operation of flow cytometers, design of 
monoclonal antibody panels and adherence to standard operating procedures (SOP) has made 
it possible to generate high quality data (Lamoreaux et al. 2006; Perfetto et al. 2006a). 
Similar extensively validated PFC-based protocols for analysis of mucosal T cell responses 
are generally lacking. Such methods can be applied to the current pipeline of vaccine 
products, which are largely aimed at inducing T cell responses. 
In addition to including quality control checks to monitor assay performance, inter-operator and 
inter assay variability also need to be monitored. Inter-assay variation is generally determined 
in real-time using statistical process control (Westgard et al. 1981; Westgard et al. 1983). In 
short, the quality control protocol described by Westgard et al involves repeated measurements 
of the experimental parameter of interest under stable conditions. These repeated measurements 
characterise the random errors of the procedure, for which a normal distribution is assumed. A 
control chart is then generated for each parameter of interest with parameter values on the y-
axis and time points on the x-axis. This type of chart is generally referred to as “Shewhart 
chart” or “Levey-Jennings chart” (Figure 1.4); horizontal lines are drawn for the mean and 
upper and lower limits, defined as multiples of the standard deviation (SD). Many different sets 
of control rules can be used to stop an assay if atypical variance is identified. For a well-
controlled assay, analytical values will range between +/- 1SD of the mean. In practice, the 
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stopping rules used to reject an experiment are: a. values greater than 2+ SD or 2-SD of the 
mean (random error) and b. 4 consecutive values greater than 1+ SD or 1-SD of the mean 
(systematic error). Figure 1.4 shows a representative example of Levey-Jennings charts. 
 
Figure 1.4. Application of Westgard Rules and Levey-Jennings control charts for quality 
assurance 
This figure shows Levey-Jennings plots for viable CD3+ percentages of total CD3+ cells (left) as well 
as CD4+ and CD8+ T cell percentages of total CD3+ cells (middle and right respectively). The black 
dotted line denoted the mean value of the concentrations (y-axis); blue dotted lines denote +/_ 1 
Standard Deviation (SD), whereas the red dotted lines +/- 2 SD. The various time points (10 in total) 
are shown across the x-axis. For a well-controlled assay, analytical values will range between the 
1+SD and 1-SD of the mean. Stopping rules used to reject an experiment (Westgard et al., 1981) were 
analytical values greater than 2+ SD or 2-SD of the mean (random error) and 4 consecutive values 
greater than +1 SD or less than -1SD of the mean (systematic error). 
1.4 Hypothesis and aims 
Measurement of HIV vaccine-induced specific T-cell responses, largely limited to T cells in the 
blood, may not be representative of responses occurring at the gastrointestinal mucosal 
surfaces. Furthermore, vaccine-induced mucosal T cell responses may be more important for 
control of primary HIV-1 infection than their counterparts in the blood, since transmission 
across mucosal surfaces accounts for the vast majority of cases worldwide. 
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Therefore, measurement of those responses would provide a more comprehensive assessment of 
immunity or potential correlates of protection. In that context, we will pursue the following aims: 
1. To develop a qualified assay for measurement of HIV-specific T-cell immune 
responses for the assessment of vaccine immunogenicity in preventative HIV 
vaccine trials. We will aim to standardise the methods for obtaining and processing 
mucosal samples and develop Standard Operating Procedures (SOPs) incorporating 
the use of viability dyes, dump channels to eliminate debris, dead cells and 
contaminating non-relevant populations, as well as a defined gating strategy. Intra- 
and inter-operator variability will be studied and the application of Westgard 
stopping rules will allow for real time monitoring of assay performance. 
2a. To assess and compare the magnitude and quality of CD8+ T cell responses after 
stimulation with the cognate HIV-1 peptides gag and nef in the blood vs. gut of HIV 
positive donors. Subsequently, we will aim to compare single responses between 
patients with detectable vs. undetectable plasma viraemia to study the effect of 
continuous antigenic exposure on the CD8+ T cell specific recall responses. Finally, 
we will aim to compare mucosal recall responses between different sites in the 
gastrointestinal tract, such as small bowel and colon. We will study the following 
immune functions: degranulation (as assessed by the surface mobilisation of 
CD107), as well as intracellular production of IFNγ, IL-2 and TNFα. 
2b. To study CD8+ T cell responses in the above groups and sites (as described in 2a) at 
the single cell level, focusing on the profile of polyfunctional cells in the blood and 
gut. This will be achieved by the application of the Boolean combination gating 
strategy, which will allow the study of all fifteen possible combinations of the 4 
single functions in the responding cell population. 
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3. To characterise the distribution of naïve (CD45RO-CD27+), central memory 
(CD45RO+CD27+), effector memory (CD45RO+CD27-) and terminally 
differentiated (CD45RO-CD27-) subpopulations in the CD4+ and CD8+ T cells in the 
blood vs. the gut of the above-described (2a and 2b) groups of donors and to further 
assess the cytotoxic potential of these cells by studying the intracellular expression 
of granzyme B and perforin. We will further aim to look for correlations between the 
frequency of expression of these cytolytic enzymes in the CD4/ CD8 populations 
and the surface expression of CD107 (degranulation marker) after stimulation with 
cognate HIV-1 peptides. Determining the cytotoxic potential of these cells and their 
ability to generate long term memory responses to HIV-1 (i.e. by assessing the 
frequency of central memory CD8+ and CD4+ T cells) would provide important 
background information for more efficient design of mucosal HIV-1 vaccines. 
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Chapter 2 Materials and Methods 
2.1 Patient recruitment and clinical sampling 
Ethics approval for the parallel blood and mucosal studies was obtained from the 
Hammersmith and Queen Charlotte's & Chelsea Research Ethics Committee (REC reference 
number: 06/Q0406/123). Research and Development approval for patient recruitment from 
the Endoscopy Unit and HIV Clinics at Chelsea and Westminster Hospital was obtained from 
the Chelsea and Westminster NHS Foundation Trust. Potential blood and gut tissue donors 
were sought among patients undergoing gastrointestinal endoscopy (oesophago-gastro-
duodenoscopy, flexible sigmoidoscopy or colonoscopy) as part of their clinical care, in the 
Endoscopy Unit of Chelsea and Westminster Hospital. The following samples were obtained 
from participating donors: 
1 Up to 60 ml of blood were drawn into 10ml sodium heparin tubes (BD, Plymouth, 
UK); venesection was undertaken by NHS clinical staff fully trained in the 
procedure. 
2 Up to 10 biopsy samples were taken from the second part of the duodenum if the 
participating donor was undergoing an oesophago-gastro-duodenoscopy. Where a 
flexible sigmoidoscopy or a colonoscopy were carried out, biopsies were taken from 
the sigmoid colon at 25-30cm from the anal verge. All endoscopic procedures were 
performed or directly supervised by experienced operators holding full JAG (Joint 
Advisory Group on Gastrointestinal Endoscopy) accreditation for the procedure 
undertaken. 
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2.2 Plasma HIV-1 viral load and lymphocyte subset quantification 
HIV-1 plasma viral load was determined by PCR, using branched DNA amplification 
technology (Bayer Healthcare, Tarrytown, NY, USA), at the Clinical Virology Department, 
St Mary’s Hospital, Imperial College Healthcare NHS Trust; the limit of detection for the 
above assay is 50 copies/ml. The CD4 counts, as well as the quantification of various other 
lymphocyte subsets was performed by the Clinical Immunology Department at Chelsea and 
Westminster Hospital using four-colour flow cytometry and staining whole (EDTA) blood 
with monoclonal antibodies against one of two panels of surface markers (CD3, CD4, CD8 
and CD45, or CD3, CD56, CD19 and CD45); data were acquired using a Cytomics FC500 
cytometer (Beckman Coulter Inc., High Wycombe, UK) 
2.3 Isolation of peripheral blood mononuclear cells (PBMC) and plasma 
separation 
PBMC were isolated using density gradient centrifugation. Blood was collected from HIV 
positive volunteers and healthy controls into 10ml sodium heparin tubes (BD, Plymouth. 
UK). This was carefully layered over 15ml of Histopaque (Sigma-Aldrich, Ayrshire, UK) in a 
50ml conical tube (Sarstedt, Nümbrecht, Germany) and centrifuged (400rpm, 40min, brake 
off). Two 1ml aliquots of plasma were stored at -80oC for future assays. PBMC were isolated 
from the plasma/Histopaque interface, washed twice with Hanks’ Balanced Salt Solution 
(HBSS, Sigma) and resuspended in R10 medium [RPMI-1640 (Sigma) with 10% FCS, 2mM 
L-glutamine, 1M HEPES Buffer, 100 IU/ml penicillin and 0.1 mg/ml streptomycin, all from 
Sigma] for counting. Viable cell counts were determined using an automated viable cell 
counter (Vi-cell, Beckman-Coulter, Fullerton, CA USA). Of the total number of PBMC 
isolated, 15x106 cells were resuspended in R10 in 24-well plates (BD, New Jersey, USA) and 
rested overnight at 37o C. The rest were divided in 1 mL aliquots (10x106/mL) in freezing 
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medium [90% foetal calf serum (FCS) and 10% dimethyl sulfoxide (DMSO)], placed at -
80°C for 18h and then transferred to vapour phase liquid nitrogen. 
2.4 Isolation of Mucosal Mononuclear Cells from human gastrointestinal 
mucosa 
Gut biopsies were obtained from volunteers undergoing an endoscopic procedure with the use 
of disposable biopsy forceps (EndoJaw Model No: FB-242U, Olympus, Japan). The biopsies 
were placed in sterile 50 ml polypropylene tubes containing 15ml of MR15 medium; this was 
prepared by adding L-glutamine (2mM final concentration), 10% FCS (Sigma), piperacillin 
(Sigma, final concentration 0.5mg/ml), tazobactam (Sigma, final concentration 0.02mg/ml) 
and amphotericin B (Sigma, final concentration 1.25mg/ml) to RPMI 1640 medium. The 
tubes were placed on ice and transferred to the laboratory where cell isolation was performed. 
The biopsies were centrifuged in the 50ml tubes at 400g for 10mins at 18oC. The biopsy 
pellet was then resuspended in 25ml of Collagense-II S digestion medium (CII-S), prepared 
by dissolving 50 mg of Collagenase II-S (Sigma) in 100ml of MR15 medium (final 
concentration of collagenase II-S of 0.5mg/ml). The tubes were sealed with parafilm and 
incubated in a shaking water bath (Julabo, USA) at 37oC and 220 rpm. Following incubation, 
the tissue suspension was mechanically disrupted by forcing it through a 16-gauge blunt-
ended needle (Miltenyi Biotechnology, Gladbach, Germany) attached to the Luer Lock end of 
a 60 mL syringe (Terumo, Leuven, Belgium). This process was repeated five times, 
following which the disrupted cell suspension was passed slowly through a 70µm nylon cell 
strainer (BD Falcon, MA, USA). The collected free cells were immediately washed and 
resuspended in 15ml of MR15 (to minimize exposure of the cell surface molecules to the 
collagenase solution), whereas the remaining tissue fragments were collected from the cell 
strainer and subjected to a second round of incubation with Collagense-II S and mechanical 
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disruption via passage through the needle (as described above). After a third cycle of 
collagenase incubation and mechanical disruption, all tubes containing free cell suspensions 
were pulled together, washed and resuspended in R10 medium; subsequently, they were 
counted and rested overnight in a 24 well-plate (maximum of 5x 106 cells per well) at 37oC. 
2.5 PBMC and MMC stimulation with viral peptides for detection of 
intracellular cytokines 
After overnight rest, PBMC and MMC were washed and recounted. The cells were 
subsequently placed into 96-well U-bottomed plates (0.5-1.5x106 cells per well) and 
stimulated with FEC, gag or nef peptides (15-mers overlapping by 11 amino acids, final 
concentration 2µg/ml; gag and nef clade B peptides were obtained from the NIH AIDS 
reagent repository). In addition, cells were stimulated with mock (DMSO, final concentration 
0.45%, negative control) and staphylococcal enterotoxin B (SEB, final concentration 2µg/ml, 
positive control). Monoclonal antibody against CD107 conjugated with FITC (BD 
Pharmingen, clone H4A3, cat. No 555800), as well as Brefeldin A (Sigma, 10µg/ml final 
concentration) and GolgiStop (BD cat. No 554724, supplied as x1200 solution) were added to 
the cultures (Betts et al. 2003). Cells were incubated for six hours at 37oC in a humidified 
incubator with 5% CO2 in air. Following incubation, cells were stored in the dark at 4oC for a 
maximum of 16 hours until staining. 
For quality assurance, cryopreserved PBMCs from the same irreversibly anonymised healthy 
volunteer were stimulated stained and analyzed along with the patient samples with each 
individual experiment. Data generated from this donor were plotted onto Levey-Jennings 
graphs to observe trends over time.  
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2.6 Surface and intracellular cytokine staining with the mucosal stimulation panel 
2.6.1 Viability staining 
The 96-well plates with the rested PBMCs and MMCs were washed twice with prewarmed 
PBS (Sigma D8537), after which they were incubated in the dark, at room temperature and 
for 20min with 100 µL of violet amine reactive dye (VIVID, Invitrogen L34955) already 
reconstituted in DMSO as per manufacturer’s instructions and further diluted 1:1600 in PBS 
(Perfetto et al. 2006b). The cells were then washed with FACSWash (prepared by adding 
0.5% BSA and 2.5% sodium azide in PBS) before surface staining. 
2.6.2 Surface staining 
50µL of the surface antibody mix in PBS (CD4, CD8, TCRγδ, CD14, and CD19, Table 2.1) were 
added to the cells for a 20 min incubation (in the dark, at room temperature). Besides organic 
fluorochromes used to conjugate monoclonal antibodies, quantum dot semiconductor nanocrystals 
were used as conjugates for the CD3 and CD4 antibodies (Chattopadhyay et al. 2006). 
Table 2.1. Mucosal stimulation antibody panel 
Antibody Conjugate Clone Vendor 50ul/test 
CD107α FITC H4A3 BD 555800 2.5 
VIVID PACIFIC BLUE N/A Invitrogen L34955  
CD8 Pacific Orange 3B5 Invitrogen MHCD0830 2.5 
CD4 605 QDot S3.5 Invitrogen Q10008 0.5 
Gamma delta PE 11F2 BD 333141 1.25 
CD14 PACIFIC BLUE M5E2 BD 558121 0.25 
CD19 PACIFIC BLUE SJ25-C1 Invitrogen MHCD1928 0.625 
IFNγ PeCy7 4S.B3 BD 557844 0.375 
CD3 655 QDot S4.1 Invitrogen Q10008 0.5 
TNFα A700 MAb11 BD 557996 0.5 
IL-2 APC MQ1-17H12 BD 554567 1.5 
 
Purple= CD107 intra culture staining   Red= surface staining 
Green= viability dye (VIVID)    Blue= intracellular staining 
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2.6.3 Intracellular cytokine staining 
Following surface staining, the cells were incubated with 100µL of cold BD 
Cytofix/Cytoperm fixation/permeabilisation solution (BD 554714) at 4oC for no longer than 
20min. After being washed twice with BD Perm/Wash buffer (BD 554714), the cells were 
incubated with 50µL of the intracellular antibody mix (IFNγ, CD3, TNFα and IL-2, as 
described in Table 2.1) in the dark for 30min at room temperature; they were then washed 
once with BD Perm/Wash buffer and stored at 4oC until acquisition (within 16 hours). 
2.6.4 Gating strategy for the analysis of CD8+ T cell responses in the blood and mucosa 
The gating strategy implemented for the detection of CD8+ T cell responses is shown in 
Figure 2.1. All acquired events were initially displayed in a Forward Scatter-Area (FSC-A) 
against Side Scatter-Area (SSC-A) plot. A time gate was subsequently applied (Time of 
acquisition vs. CD4 QDot) to ensure optimal and consistent acquisition rates of single 
samples and exclude artifacts caused by disruption of the fluidics (i.e. due to cell aggregates 
etc.). Following that, a FSC-A against FSC-H (Forward Scatter-Height) gate was used to 
define a population including singly recorded events only (singlets), thus excluding doublets 
and other irrelevant recordings. 
The next step was to exclude non-viable events, as well as monocytes and B cells using a 
Pacific Blue-labeled “Dump” channel; this included cells staining positively for CD14, CD19 
or/and ViVID (Perfetto et al. 2006b). The lymphocyte population was then selected from a 
FSC-A against SSC-A gate, based on the size and granularity of the cells of interest. 
The next gate excluded all CD3- (non-T cell) events. It is well established that stimulation 
with peptide antigens and super-antigens results in down regulation of the T-cell receptor 
(TCR) on the cell surface (Cai et al. 1997; Niedergang et al. 1997). These stimulated T cells 
would be characterised as CD3- and as such would be excluded from the final analysis, 
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resulting in considerable underestimation of the CD8+ T cell responses (as the down-
regulated activated cells would likely express one or more cytokines). To overcome this 
problem, a “down-regulated” CD3 gate was implemented to include the CD3+, CD3dim as well 
as the CD3- IFNγ+ populations (Figure 2.1. A). The downregulated CD8+ (Xiao et al. 2007) 
and CD4+ T cell gates were defined from the CD3+ gate after excluding double positive cells 
(Figure 2.1. B). The single positive cytokine gates used for the Boolean gating analysis were 
then defined using these T cell subset gates (Fig. 2.1. C). 
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Figure 2.1. Overview of the gating strategy used for detection of degranulation and intracellular 
cytokine production by CD8+ and CD4+ T cells. 
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Representative gating scheme applied for the analysis of polyfunctional responses of PBMC 
stimulated with staphylococcal enterotoxin B (SEB) in an HIV positive donor. 
Panel A shows (from left to right) a Forward Scatter-Area (FSC-A) vs. Side Scatter-Area (SSC-A) 
gate, a Time vs. CD4 QDot gate and FSC-A vs. FSC-Height (doublet exclusion gate); the next 3 gates 
are a FSC-A vs. CD14/CD19/ViVID (viable CD3+ T cell gate), a further FSC-A vs. SSC-A lymphocyte 
gate and a CD3 vs. IFNγ (downregulated CD3+ T cell) gate. 
Panel B shows (from left to right) a CD8 vs. IFNγ plot with 2 separate gates: a downregulated CD8+ 
T cell gate and a CD4+ T cell gate; the next plot shows the final CD4 gate (after exclusion of 
contaminating CD8+ T cells, 2nd plot in panel B). The final CD8+ gate is defined by excluding 
contaminating CD4 cells in a CD4 vs. IFNγ plot (3rd plot from left in panel B). 
Panel C shows all 6 possible combinations of the 4 functions studied in the CD8+ T cell population, i.e. 
(from left to right) TNFα vs. IFNγ, IL-2 vs. IFNγ, CD107 vs. IFNγ, IL-2 vs. TNFα, CD107 vs. TNFα and 
CD107 vs. IL-2. All the above cytokine gates originate from the CD8+ T cell gate (3rd plot in panel B). 
 
Since polychromatic flow cytometry (PFC) enables the measurement of multiple parameters at 
the single cell level, characterisation of different types of multifunctional cells is possible based 
on the number and types of parameters expressed. By applying the Boolean gating strategy, all 15 
possible combinations of four functions can be determined from the single cytokine gates. Table 
2.2 provides an example of all possible combination gates for IFNγ, IL-2, TNFa and CD107. 
Table 2.2. The Boolean gating strategy is used to define the fifteen possible combination gates for 
the four functions studied (IFNg, IL-2, TNFa and CD107) 




















2.7 The mucosal ex-vivo phenotype panel 
2.7.1 Surface and intracellular staining with the mucosal ex-vivo phenotype panel 
For the ex vivo phenotypic panel, overnight rested PBMC and MMC were washed and 
stained with ViVID (as described in 2.6.1) and subsequently incubated with the surface 
antidody mix (CD8, CD4, TCRγδ, CD14, CD19, CD56, CD3, CD16, CD27 and CD45RO, 
see Table 2.3) 
Table 2.3. Mucosal phenotypic ex vivo panel 
Antibody Conjugate Clone Vendor 50ul/test 
VIVID PACIFIC BLUE N/A Invitrogen L34955   
CD8 Pacific Orange 3B5 Invitrogen MHCD0830 2.5 
CD4 605 QDot S3.5 Invitrogen Q10008 0.5 
Gamma delta APC B1 BD 555718 1.25 
CD14 PACIFIC BLUE M5E2 BD 558121 0.25 
CD19 PACIFIC BLUE SJ25-C1 Invitrogen MHCD1928 0.625 
CD56 PeCy7 B159 BD 557747 2 
CD3 655 QDot S4.1 Invitrogen Q10008 0.5 
CD16 A700 3G8 Invitrogen MHCD1629 0.6 
CD27 APC H7 M-T271 560222 3 
CD45RO PeTxRd UCHL1 PN-IM2712U 5 
Granzyme B FITC GB11 BD 558132 10 
Perforin PE B-D48 DIACLONE 854.952.010 3 
 
Green= viability dye (VIVID) 
Red= surface staining 
Blue= intracellular staining 
 
Following incubation with BD Cytofix/cytoperm (see 2.6.3), the cells were stained with the 
intracellular panel (granzyme B, perforin, see Table 2.3) for 30min in 4oC and then washed 
and resuspepended in BD Perm/Wash buffer, pending acquisition. 
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For fluorescent compensation in both panels, single stained antibody-capture beads were used 
(CompBeads, BD Biosciences), (Lamoreaux et al. 2006). 
The acquisition was performed using a custom made BD LSR II Cytometer (BD H47200046) 
and FACS DIVA software version 6.1.1 (BD Biosciences). FlowJo Version 8.8.4 Software 
(TreeStar, Oregon, USA) was used for the analysis of flow cytomerty data. 
2.7.2 Gating strategy for immunophenotyping of T cell subsets and detection of 
intracellular granzyme B and perforin 
The gating strategy implemented for the surface phenotyping and detection of intracellular 
granzyme B and perforin is shown in Figures 2.2 and 2.3. All acquired events were initially 
displayed in two time gates (Time of acquisition vs. CD3 QDot and Time of acquisition vs. 
CD4 QDot) to ensure optimal and consistent acquisition rates of single samples and exclude 
artifacts caused by disruption of the fluidics and from the aggregation of nano-crystal used as 
fluorescent conjugates for CD3 and CD4 monoclonal antibodies. Following that, a FSC-A vs. 
FSC-H (Forward Scatter-Height) plot was used to define a gate including exclusively singly 
recorded events (singlets), thus excluding doublets and other recordings. Subsequently, a 
generous lymphocyte gate was applied in a FSC-A vs. FSC-H plot to include the cell 
populations of interest. 
The next step was to exclude non-viable events, as well as monocytes and B cells, using a 
Pacific Blue-labeled “Dump” channel which included CD14, CD19 and ViVID (Perfetto et 
al. 2006b). In the CD3 vs. ViVID plot, two gates were generated: a viable CD3+ cell gate and 
a viable CD3- cell gate. The former would give rise to the CD4+, CD8+ and gamma-delta 
gates, whereas the CD3- would contain mostly NK cells. 
In the next Figure (2.3), the CD4+, CD8+ and gamma-delta populations are further labeled for 
the surface memory markers CD45RO and CD27; based on the expression of those markers, 
CD4+ and CD8+ cells are further divided into the following groups: naïve cells, which have a 
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CD45RO-CD27+ phenotype, central memory cells, which express both markers 
(CD45RO+CD27+), effector memory cells, which have the memory phenotype 
CD45RO+CD27- and terminally differentiated cells, which are negative for both memory 
markers (CD45RO-CD27-). 
 
















































































































































































































































Figure 2.2. Overview of the gating strategy used for the detection of memory phenotypes and 
intracellular granzyme B and perforin. 
Representative gating scheme applied for the analysis of PBMC in an HIV positive donor. The first 
row shows (from left to right) a Time vs. CD3 QDot gate, a Time vs. CD4 QDot gate, a Forward 
Scatter-Area (FSC-A) vs. Forward Scatter-Height (FSC-H) gate (doublet exclusion gate) and a FSC-
A vs. Side Scatter-Area (SSC-A) gate. 
In the second row, there is a CD3 vs. ViVID gate, for the selection of viable CD3+ and viable CD3- 
cell populations. 
In the third row, there are three graphs gating on cell populations of interest, which are as follows 
(from left to right): CD4+ cell gate, CD8+ cell gate and gamma-delta cell gate. They all originate 
from the viable CD3+ cell gate. 
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Figure .3. Overview of the gating strategy used for the detection of memory phenotypes 
intracellular granzyme B and perforin. 
The two subpopulations of interest were further analysed for the expression of surface memory 
markers (CD45RO and CD27), as well as the intracellular expression of granzyme B and perforin. 
Each row of graphs represents a single subpopulation (CD4+ and CD8+ T cells). In the first column, 
each population is divided into four subgroups, based of the expression of CD45RO and CD27 as 
follows: CD45RO+CD27+ (central memory), CD45RO+CD27- (effector memory), CD45RO-CD27+ 
(naive) CD45RO-CD27- (terminally differentiated). In the second and third columns, the granzyme B 
and perforin populations are defined in CD4 and CD8 cells. Granzyme B verses CD27 and perforin 
verses CD27 plots are used to precisely define the cytolytic enzyme positive populations, since almost 
all CD27 positive cells are both gB- and perforin-. The fourth and fifth columns consist of overlaid 
graphs showing the distribution of granzyme B (green) and perforin (red) in the different memory 
subpopulations. 
 
The optimal concentrations of the conjugated monoclonal antibodies used in the two panels 
were determined after titration experiments. A representative overlay graph from such a 
titration experiment for the CD16 antibody conjugated with the Alexa 700 fluorochrome is 
shown in Figure 2.4. The mean fluorescent intensities (MFI) for the different concentrations 


















Figure 2.4. CD16 Alexa 700 titration experiment. 
The graph is an overlay of six individual histograms [five different dilutions of the CD16 antibody 
stock, represented by the solid coloured lines, as well as an unstained sample (black line)]. In the 
highest concentration of the antibody, there is significant non-specific staining of the negative cell 
population (red and dark blue lines), whereas in the lowest concentration (turquoise line) there is a 
shift of the “positive” peak of the histogram to the left, indicating reduced mean fluorescent intensity 
(MFI). The optimal concentration for the antibody is the lowest one with a high MFI for the positive 
population and minimal non-specific staining (in this example the 1:40 dilution, represented by a 
solid orange line) 
 
Table 2.4. Mean fluorescent intensity (MFI) values for different concentrations of the CD16 
antibody 
SAMPLE MFI 
1:5 dilution 115 
1:10 dilution 97 
1:20 dilution 82.9 
1:40 dilution 76.9 




2.8 Software and Statistical analysis 
For flow cytomerty analysis, data were exported from FlowJo into Microsoft Excel 2008 for 
Mac and then imported into Prism (GraphPad Prism 5.0 for MAC OS X, San Diego, USA). 
For the display of polychromatic flow cytometry data, data from Microsoft Excel were 
imported into PESTLE (version 1.6.1, provided by Mario Roederer, Vaccine Research 
Centre, NIAID, NIH) ; this software was used to format and recode data, which were 
subsequently imported into SPICE (Simplified Presentation of Incredibly Complex 
Evaluations, version 4.2.2, provided by Mario Roederer, Vaccine Research Centre, NIAID, 
NIH). The magnitude of the response to the negative control was subtracted for each 
individual cytokine or function measured. This often generates negative values, which cannot 
easily be considered for representational analysis; to overcome this problem all negative 
values (after subtraction of the negative control response) were arbitrary set to zero. Based on 
the background responses in the cohort of control individuals, the threshold for considering 
an individual response as positive was set to 0.1%. Differences between patients or patient 
groups were tested for statistical significance using the Mann Whitney U test (for 
comparisons between two sets of nonparametric unpaired observations) or the Kruskal Wallis 
test (when multiple sets of nonparametric unpaired observations were compared). Differences 
between two sets of paired nonparametric data were tested using the Wilcoxon matched pairs 
test. The threshold for statistical significance for all comparisons was set at a p value of less 
than 0.05. Where multiple comparisons were performed on the same set of subjects, the 
Bonferroni correction was applied and a nominal significance level (p value) of 0.05/k was 
applied, where k was the number of independent comparisons performed in that group of 
subjects. The Spearman rho test was used to study possible correlation between two sets 
nonparametric data; correlations were statistically significant when p values signified a 95% 
probability of rejection of the null hypothesis. 
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Chapter 3 Qualification of a flow cytometry-based method to 
characterise CD8+ and CD4+ T cell responses to HIV-1 
peptides in peripheral blood and mucosal mononuclear 
cells for use in vaccine clinical trials 
3.1 Introduction 
Recent evidence suggests that HIV-1 specific immune responses may be compartmentalised 
between blood and mucosal tissues (Rerks-Ngarm et al. 2009). There is considerable interest 
in the identification and characterization of the gastrointestinal recall immune responses to 
HIV-1 peptides, since they may correlate better with clinical status than responses observed 
in peripheral blood (Critchfield et al. 2008; Ferre et al. 2009). The measurement and 
assessment of antigen-specific immune responses in the gut is more challenging compared to 
peripheral blood, due to the complexities in obtaining and processing mucosal tissue and the 
proportionally low yields of mucosal mononuclear cells (MMC). The use of polychromatic 
flow cytometry (PFC) makes it possible to analyse complex data from relatively small 
numbers of cells. Unlike the use of the technique in the analysis of blood samples, where 
extensive validation and strict adherence to published standard operating procedures (SOPs) 
made it possible to generate high quality data (Lamoreaux et al. 2006; Perfetto et al. 2006a; 
Yokomizo et al. 2007), there are no such validated protocols for the analysis of gut samples. 
We sought to establish an accurate PFC-based method to evaluate T cell recall responses in 
the gut-associated lymphoid tissue (GALT), which would be suitable for assessment of 
immunogenicity in HIV-1 clinical vaccine trials. 
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3.2 Patient characteristics 
For the purpose of validating the methods described here, blood and gastrointestinal mucosal 
tissue was obtained from 24 control individuals and 34 HIV positive donors. 
The characteristics of the 24 controls participating in this study (including the clinical 
indication for the endoscopic procedure undertaken) are summarised in Table 3.1. The median 
age for the group was 39.5 years [interquartile ranges (IQR) 29-43]. There were 14 female and 
10 male donors. 15 patients had a colonoscopy, 3 had a flexible sigmoidoscopy and 6 had an 
oesophago-gastroduodenoscopy (OGD). All controls had normal gastrointestinal mucosa 
macroscopically (as assessed by the endoscopist at the time of the procedure). As part of 
patients’ clinical care, obtaining biopsies is considered common practice; however, biopsies are 
not obtained from all patients undergoing gastrointestinal endoscopy unless there is an 
appropriate indication. In general, biopsies will be taken to evaluate abnormal focal mucosal 
lesions (colonic polyps, ulcers etc), or abnormal mucosal appearance (indistinct vascular 
pattern, granulation tissue etc), which may be indicative of an inflammatory or other process. 
Biopsies also ought to be obtained from macroscopically normal mucosa (random biopsies), if 
there is clinical suspicion of an underlying condition commonly associated with 
macroscopically normal mucosa. Typical examples of such conditions are coeliac disease 
suspected in someone presenting with microcytic anaemia and microscopic colitis in someone 
presenting with unexplained diarrhoea; both these conditions are usually associated with 
normal appearance of the duodenal or colonic mucosa respectively. In the present study, the 24 
controls consisted exclusively of patients with macroscopically normal mucosa; of those 
patients, random biopsies were taken in 15 and were all reported as normal. 
The characteristics of the 34 HIV sero-positive donors are summarized in Table 3.2. The 
median age was 42 years [interquartile ranges (IQR) 34-47]. There were 2 female and 32 
male donors. 6 patients had a colonoscopy, 4 had a flexible sigmoidoscopy, 18 had an 
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oesophago-gastroduodenoscopy (OGD), 3 had both an OGD and colonoscopy and 3 had a 
combination of OGD and flexible sigmoidoscopy. In the group of HIV positive donors, one 
individual (M535) had clinically and histologically infectious proctitis; however, the research 
biopsy samples were obtained from a more proximal area of macroscopically normal mucosa. 
 
Table 3.1. Clinical characteristics of control donors (n=24) 
All patients had macroscopically normal mucosa, as assessed by the endoscopist. All available 









G345 M 43 Dyspepsia OGD Normal 
H400 F 50 Abdominal pain Colonoscopy Normal 
G162 F 37 Diarrhoea Colonoscopy Normal 
G363 F 24 CIBH1 Flexible 
sigmoidoscopy 
Normal 
P660 M 40 CIBH Colonoscopy Normal 
H655 M 28 Diarrhoea and bleeding 
PR2  
Colonoscopy Normal 
L200 F 23 Dyspepsia and weight 
loss 
OGD Normal 
B656 F 49 GORD3 OGD N/A 
H520 F 39 HNPCC4, polyp 
surveillance 
Colonoscopy N/A 
O160 M 45 Bleeding PR Colonoscopy N/A 
G125 F 43 Diarrhoea Colonoscopy Normal 
B630 F 28 Nausea and vomiting OGD Normal 
H630 F 44 Polyp surveillance Colonoscopy N/A 
S323 M 46 Abdominal pain Colonoscopy N/A 
P650 F 29 CIBH Colonoscopy Normal 
P200 M 36 Bleeding PR Flexible 
sigmoidoscopy 
N/A 
L516 M 21 Bleeding PR Colonoscopy N/A 
H220 M 42 Diarrhoea Flexible 
sigmoidoscopy 
Normal 









B412 F 36 Dyspepsia OGD Normal 
F236 M 31 Diarrhoea Colonoscopy Normal 
D120 F 41 Bleeding PR Colonoscopy N/A 
B516 F 40 Diarrhoea Colonoscopy Normal 
D125 M 40 Diarrhoea Colonoscopy Normal 
 
1. Change in bowel habit 
2. Per rectum 
3. Gastro-oesophageal reflux disease 
4. Hereditary non-polyposis colorectal cancer 
 
Table 3.2. Clinical characteristics of the HIV positive donors (n=34) 
All patients had macroscopically normal mucosa, as assessed by the endoscopist. All available 
clinical biopsies with the exception of one (17 out of 35 individuals) were also reported as normal. 
Donor M535 had infectious proctitis involving the distal rectum; however, research biopsies were 










B250 M 28 GORD OGD N/A 
P230 M 36 GORD OGD N/A 
R300 F 34 NUD1 OGD N/A 
V260 M 28 Dyspepsia OGD N/A 
H300 M 46 Dysphagia OGD Normal 
W625 M 41 Diarrhoea Flexible sigmoidoscopy Normal 
M210 M 42 Polyp surveillance Colonoscopy N/A 
M535 M 43 Diarrhoea and bleeding PR Colonoscopy 
Infectious 
proctitis 
P510 F 50 Dyspepsia OGD N/A 
W630 M 41 Diarrhoea Flexible sigmoidoscopy Normal 
C425 M 47 Dyspepsia OGD N/A 










P300 M 30 Epigastric pain OGD N/A 
V520 M 35 Epigastric pain OGD N/A 
H526 M 48 Dyspepsia OGD N/A 
F425 M 50 Iron deficiency anaemia OGD Normal 
G320 M 49 Polyp surveillance Colonoscopy N/A 
R500 M 49 Dyspepsia OGD N/A 
G650 M 28 Dyspepsia OGD N/A 
T525 M 42 Dyspepsia OGD N/A 
F630 M 23 Spontaneous pneumomediastinum OGD
2 Normal 






C230 M 43 Dyspepsia OGD N/A 
G400 M 33 Nausea OGD N/A 
P456 M 47 Barrett’s oesophagus OGD Normal 
O420 M 42 Diarrhoea 
OGD / Flexible 
sigmoidoscopy Normal 
S652 M 44 Diarrhoea OGD / Colonoscopy Normal 
C600 M 31 PR bleeding Colonoscopy N/A 
M420 M 47 Diarrhoea 
OGD / Flexible 
sigmoidoscopy Normal 
B530 M 45 Dyspepsia, diarrhoea 
OGD / Flexible 
sigmoidoscopy Normal 
C220 M 43 Dyspepsia, Diarrhoea ODG / Colonoscopy Normal 
W623 M 39 Anaemia, diarrhoea ODG / Colonoscopy Normal 
A452 M 29 Diarrhoea 
Flexible 
sigmoidoscopy Normal 
J520 B M 50 Diarrhoea Colonoscopy Normal 
 
1. Non-ulcer dyspepsia 
2. Inflammatory Bowel Disease 
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3.3 Cell yields and viability from peripheral blood and gastrointestinal 
biopsies 
After cell isolation and overnight rest, the median MMC yields for duodenum and colon were 
8.5 and 9.8 million cells per donor respectively (Table 3.3). The interquartile ranges were 5-
14 million cells for duodenum and 6.15-13 million for colonic tissue; this wide variation in 
the cell yields between donors can be explained as follows: although the aim was to obtain 10 
biopsies per donor for the purpose of isolating MMCs, in reality this number may vary, as 
biopsies can be lost within the working channel of the endoscope; individual biopsies differ 
in volume, depending on the size of the forceps used, the angle between the forceps and the 
mucosal surface etc, to mention only a few of the variables. With that in mind, it is not 
possible to calculate precisely the number of isolated viable MMCs per biopsy obtained; 
assuming that the number of biopsies per patient was 10, then approximately 1 million of 
viable MMCs were isolated per biopsy taken. 
 
Table 3.3. Mucosal cell yields in duodenum and colon in the study participants. 
The table shows the absolute numbers of viable mucosal mononuclear cells (millions) isolated from 
the duodenum (N=30) and colon (N=35) after overnight rest. There is no statistically significant 
difference between the cell yields from those 2 sites (p=0.679 using the Mann-Whitney test) 
 
 Duodenum   N=30 Colon   N=35 
25th centile 5 6.15 
Median 8.5 9.8 
75th centile 14 13 
 
The cell viabilities for PBMCs and MMCs in all donors are shown in Table 3.4. The 
viabilities of the mucosal cells are significantly lower compared to the PBMCs (68. 8 percent 
and 94.4 percent respectively); furthermore, the gut viabilities are far more variable between 
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different donors. Table 3.5 shows that the viabilities in the duodenum and colon do not differ 
significantly in the 2 groups of donors (p=0.96 using the unpaired t test). 
 
Table 3.4. Cell viabilities in blood and mucosal tissue in all donors. 
The viabilities of isolated PBMCs are significantly higher than those of MMCs (p<0.0001). 
 




Mean viability 94.64 
Standard deviation 1.8 
Standard error 0.36 
GUT 
Mean viability 68.8 
Standard deviation 8.07 
Standard error 1.05 
 
Table 3.5. Comparison of cell viabilities between duodenum and colon. 
 Duodenum (N=30) Colon (N=36) 
ALL 
DONORS 
Mean viability 69.30 67.44 
Standard deviation 7.24 8.34 
Standard error 1.32 1.39 
 
3.4 Application of time, singlet and viability gating strategies to reduce 
CD8+ T cell background staining in PBMC & MMC 
The ex-vivo processing of mucosal tissue and the isolation of MMC may result in activation 
of some cells in a non-specific manner, leading to cytokine production and degranulation 
(Perfetto et al. 2006b). In addition, cellular aggregates and dead cells can bind monoclonal 
antibodies non-specifically, thus significantly influencing the magnitude of cytokine 
responses (Perfetto et al. 2006b). Disruption of the fluidics during acquisition may result in 
artifacts and high acquisition speed (i.e. increased number of cells passing through the 
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interrogation point of the cytometer over a period of time) may result in increased frequency 
of “doublets” (cells generating duplicate signals). Any of these factors could affect the 
specificity of the apparent T cell response to cognate peptides, resulting in inaccurate 
characterisation of the responding cell population. To overcome these problems, a number of 
“quality control” gates were included in the gating strategy described in Chapter 2: a “Time” 
gate, a “singlets” gate and a “viability”/monocyte and B-cell exclusion gate (Figure 2.1). 
These gates will be hereafter collectively referred to as “filter gates”. We hypothesised that 
the application of “filter gating” would significantly reduce the nonspecific “background” 
staining for CD8+ T cells in both compartments (blood and gut). To test this hypothesis, “raw 
“ flow cytometry data obtained from the group of 24 controls and 34 HIV positive patients 
were analysed using FlowJo software both with and without the application of filter gates. 
Background values for all 4 parameters in CD8+ T cells, both with and without the application 
of filter gates, are shown in Table 3.6 A (controls) and 3.6 B (HIV positive patients). In general, 
background values were higher in the gut, with the exception of TNFα. When the backgrounds 
were compared for PBMC and MMC in both controls and HIV positive donors (Figure 3.1-
3.2), the reduction noted with application of filter gating was statistically significant for all 
comparisons (p< 0.0001 using the Wilcoxon matched pairs test). 
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Table 3.6. Application of quality control gating on mock responses in PBMC and MMC in CD8+ 
T cells in A: controls and B: HIV positive donors 
Background (mock) responses in blood and gut with and without application of the filter gating strategy 
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Figure 3.1. Reduction of CD8+ T cell background values A in the blood and B in the gut (N=24) 
with the application of the filter gating scheme in the group of control patients. 
The circles represent background values for CD8+ T cells for the four parameters (IFNγ, IL-2, TNFα 
and CD107. Solid circles represent backgrounds recorded after applying the above-described QC 
gating strategy (“filter gating”), whereas in the groups of hollow circles, no such gating was applied 
in the analysis. The solid horizontal lines represent median values within each group. Comparison 
between the two groups of observations for each parameter and compartment show statistically 
significant reduction in the background values with filter gating (p<0.05 for all comparisons, using 
the Wilcoxon matched pairs test). 
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Figure 3.2. Reduction of CD8+ T cell background values in A the blood (N=34) and B gut (N=40) 
with the application of the quality control gating scheme in the HIV positive group  
The circles represent background values for CD8+ T cells, for the four parameters (IFNγ, IL 2, TNFα 
or CD107) measured. Solid circles represent backgrounds recorded after applying the above-
described QC gating strategy (“filter gating”), whereas in the groups of hollow circles, no such 
gating was applied in the analysis. The solid horizontal lines represent median values within each 
group. Comparison between the two groups of observations for each parameter and compartment 
show statistically significant reduction in the background values with filter gating (p<0.05 for all 
comparisons, using the Wilcoxon matched pairs test). The number of observations in higher for 
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Figure 3.3 shows an example of the significant reduction in non-specific background 
responses with the application of filter gating in the blood and gut. 
 
STANDARD GATING FILTER GATING
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Figure 3.3. Representative plots showing the reduction in background responses with the 
application of the above described filter gating strategy 
The first 2 columns from the left show the negative control responses in the blood from the same 
donor, with and without the application of the filter gating strategy in the data analysis, whereas the 
3rd and 4th column from the left show similar data from a single donor in the gut. The 4 rows, from top 
to bottom, show IFNγ, IL-2, TNFα and CD107 responses respectively. As evident, there is significant 
reduction in background non-specific responses in both compartments and in all 4 functions studied 
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3.5 Quality assurance in HIV-1 recall and antigen-specific assays 
Inter-operator variability for the study of degranulation and intracellular cytokine expression 
in MMC was determined by a series of experiments in which three different operators 
independently performed cell isolation, stimulation, staining, acquisition and flow cytometric 
analysis of mucosal samples obtained from 3 different control donors. Mucosal mononuclear 
cells were stimulated with staphylococcal enterotoxin B (SEB) to ensure that degranulation 
and cytokine expression would be detected in all samples assessed. The inter-operator 
Coefficient of variation (CV) for CD107, IFNγ and TNFα ranged from 2.4% to 22.4% and 
was particularly good for patient 3 (Table 3.7). The inter-operator CV for IL-2 (27-42%) was 
higher than that seen for CD107, IFNγ and TNFα in all three patients; this may be because of 
the much lower levels of IL-2 expressed following SEB stimulation compared to the other 
immune parameters studied. As it was not possible to obtain sufficient numbers of MMC 
from one individual patient to assess reproducibility for antigen specific responses 
longitudinally, human buffy coat samples obtained from the same anonymised HIV negative 
donor with known antigen specific FEC immune responses were used for this set of 
experiments. Inter-operator variability was determined by three different operators on three 
different days who evaluated FEC responses in stored aliquots of frozen PBMC isolated from 
the above donor. The inter-operator CV for FEC induced immune responses ranged from 8-
20% (Table 3.7). The intra-operator CV ranged from 3-44% with FEC induced IL-2 cytokine 
response having the greatest variation. 
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Table 3.7. Coefficient of variation for inter-operator and intra-operator SEB and FEC-specific 
immune responses in mucosal mononuclear and buffy coat samples. 
SEB mucosal mononuclear cells 




Patient 1 18 19 22 42 
Patient 2 2 15 9 31 
Patient 3 7 4 4 27 
FEC Buffy coat 




Day 1 14 16 20 10 
Day 2 16 16 18 20 





Operator 1 5 3 23 24 
Operator 2 15 14 12 34 
Operator 3 26 28 12 44 
 
In order to assure assay precision, a single buffy coat sample with known robust CD8+ T cell 
responses to FEC was used. Cryoperserved aliquots from this buffy were treated in exactly 
the same manner as the freshly isolated PBMCs from donors for the fist 20 experiments 
performed. The first 10 of these experiments were used to define the mean values for the 
following parameters: CD3+ cell percentages of viable lymphocytes, CD8+ and CD4+ cell 
percentages of total CD3+ cells and CD8+ T cell memory responses to FEC (percentage of 
total CD8+ cells responding with IFNγ, IL-2, TNFα or degranulation). Since the FEC 
peptides used as antigen specific positive control preferentially elicited CD8+ responses, 
CD4+ T cell responses to SEB were used to assure quality of the immune stimulation assay 
for these cells. Data from the last 10 experiments were used to assess the assay variance; 
analytical values greater than 2± SD of the mean or 4 consecutive values greater than 1+ SD 
or 1-SD of the mean were employed as indicators for atypical assay variance (Westgard et al. 
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1981; Westgard 2003). Use of this set of statistical assay stopping rules indicated satisfactory 
assay precision (Figure 3.4). 
 
Figure 3.4. Application of Westgard Rules and Levey-Jennings control charts for quality 
assurance of the CD8+ and CD4+ T cell assays. 
 
Panel A shows Levey-Jennings plots for viable CD3+ percentages of total CD3+ cells (left) as well as 
CD4+ and CD8+ T cell percentages of total CD3+ cells (middle and right respectively). 
Panel B shows similar graphs for FEC-specific CD8+ T-cell responses over time using frozen PBMC 
aliquots from the same donor. 
In panel C, there are Levey-Jennings charts for the CD8+ and CD4+ T cell responses to SEB. The 
mean & SD derived from 10 measurements were plotted to determine the degree of variation. 
To determine inter-assay variation, subsequent values from the next 10 experiments were recorded 
and a set of statistically based stopping rules (Westgard rules) applied to evaluate the presence of 
atypical variance. For a well-controlled assay, analytical values will range between the 1+SD and 1-
SD of the mean. Stopping rules used to reject an experiment were as follows: analytical values 
greater than 2+ SD or 2-SD of the mean (random error) or 4 consecutive values greater than +1 SD 
or less than -1SD of the mean (systematic error). 
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3.6 Establishment of reference intervals for HIV-1 antigen-specific 
immune responses in CD8+ T cells 
There is considerable heterogeneity within ART treated HIV positive patients in the 
magnitude of memory CD8+ T cell responses to cognate HIV peptides. A significant 
proportion of individuals do not elicit detectable HIV recall responses, hence accurate 
definition of negative and positive thresholds is imperative when immunogenicity of 
candidate vaccines is to be assessed in clinical trials. A reference range for negative HIV-1 
antigen specific immune responses in PBMC and MMC subsets was established for each of 
the 4 parameters studied here, using samples from the group of controls. We elected to define 
the threshold for a positive HIV specific response as greater than the 95th centile value 
observed in the controls group. Response values for the four parameters (IFNγ, TNFα, IL-2 
and CD107) were derived from the 24 control individuals by subtracting apparent mock-
elicited responses from either gag or nef responses for both PBMC and MMC. The cut off 
values for a positive cytokine response varied according to stimulus and site of immune 
response (Table 3.8). The threshold values for positivity for gag and nef in blood 
approximated 0.1% for a number of cytokines; there was, however, a lower degree of non-
specific staining for gag- induced IFNγ response (with a 95th centile value of 0.03%.), as well 
as for nef-induced IFNγ, TNFa and CD107 responses (with 95th centile values of 0.05%, 
0.04% and 0.06% respectively). Cut off values were generally higher in MMC than in PBMC 
and differences for individual cytokines between blood and gut were significant; for example, 
the gag- and nef- induced IL-2 response positivity threshold was two and three times higher 
respectively in the mucosal samples compared to blood. The data presented here suggest that 
there is no simple fit for all cytokines, stimuli and compartments and that the definition of 
thresholds for positivity is essential for each individual readout. 
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Table 3.8. Reference interveals for CD8+ T cell recall responses to HIV-1 peptides in the controls 
population. 
The far right column shows the 5th-95th centile intervals of recall responses in the controls group for a 
specific cytokine, stimulus (gag or nef) and compartment (blood or gut). These reference intervals 
represent responses obtained after subtracting the apparent response to negative control (mock). 
 























3.7 Difference in the magnitude of HIV-1 recall responses in parallel blood 
and gut samples 
The individual thresholds for each cytokine and compartment (Table 3.8) were subsequently 
used to characterise recall responses to gag and nef as positive or negative in the group of 
HIV sero-positive individuals. Individual donors with both duodenal and colonic samples 
were excluded from comparison of responses between blood and gut compartments. A 
positive response was empirically defined as one that fulfilled the following criteria: a) it was 
at least twice the magnitude of the mock control (Shacklett et al. 2003b; Janetzki et al. 2005; 
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Sun et al. 2008) and b) it was greater than the 95th centile of the responses observed in the 
low risk HIV group (for a particular HIV peptide in blood or gut, Table 3.8). 
Tables 3.9 and 3.10 summarise the responses in the above group of donors (n=27) for gag and 
nef respectively. Overall, a response to gag and nef was detected in 25 and 24 out of the 27 
HIV positive patients (over 90 percent). IL-2 responses to either gag or nef peptide pools 
were generally absent in both compartments. Multiple single responses (at least 3) were 
observed in higher frequency in the gut with gag as stimulus, whereas they are more often 
seen in the blood with nef. Comparison of complex responses between blood and the mucosal 
samples showed that immune responses for gag and nef peptide pools in some patients were 
clearly compartmentalised; furthermore, this compartmentalization is more pronounced with 
nef responses compared to gag. In the blood, the majority of positive responses to gag 
consisted of two functions (mostly IFNγ and CD107), whereas the nef responses were 
dominated by three single responses (IFNγ, TNFα and CD107). Individuals with four single 
CD8+ T cell functions were seen in response to gag, but not nef. In the gut, the majority of 
responses to both gag and nef consisted of all four single functions; more gag –stimulated 
mucosal CD8+ cells responded with four functions (three individuals) compared to nef (one 
individual). 
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Table 3.9. Complex immune CD8+ T cell responses to the gag peptide pool in HIV positive 
individuals in the blood vs. the gut. 
CD8+ T cell responses to gag are demonstrated here. Each row represents responses of a single donor 
in blood and gut. There are 8 columns representing all 4 functions studied (IFNγ, IL-2, TNFα and 
CD107) in the blood (4 columns to the left) or gut (4 columns to the right). A positive response for a 
specific function is depicted by the plus sign, whereas the minus sign denotes a negative response. 
Furthermore, the positive responses in blood and gut have been highlighted red and blue respectively 
to facilitate comparisons between compartments. 
 
Subject GAG 
 BLOOD GUT 
 IFNγ IL-2 TNFα CD107 IFNγ IL-2 TNFα CD107 
R300 + - - + + - + + 
V260 - - - - - - + + 
B520 + - - + + - + + 
P230 - - - + - + - + 
M210 - - - - + - + + 
W625 + - + + - - - + 
H300 - - - - - - - - 
M535 + - - + + - + + 
P510 + - - + - - - - 
W630 + - - + + - + + 
B630 (P) + - - + + - - - 
P300 + - - - + - + + 
C425 - - - - + - - - 
V520 + + - - + + - - 
H526 + - + + + + + + 
F425 + + + + + + + + 
G320 + - - + + - + - 
R500 + + - + + - - + 
G650 + - + + + - + + 
T525 - - - - - - + + 
F630 + - + + - - - - 
A536 + - - + + - + + 
C230 + - + + + + + + 
G400 + + + + + - + + 
P456 - - - - + - - - 
A452 + - + + + - + + 
J520 B - - - - - - - - 
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Table 3.10. Complex immune CD8+ T cell responses to the nef peptide pool in HIV positive 
individuals in the blood vs. the gut. 
CD8+ T cell responses to nef are demonstrated here. Each row represents responses of a single donor 
in blood and gut. There are 8 columns representing all 4 functions studied (IFNγ, IL-2, TNFα and 
CD107) in the blood (4 columns to the left) or gut (4 columns to the right). A positive response for a 
specific function is depicted by the plus sign, whereas the minus sign denotes a negative response. 
Furthermore, the positive responses in blood and gut have been highlighted red and blue respectively 
to facilitate comparisons between compartments. 
 
Subject NEF 
 BLOOD GUT 
 IFNγ IL-2 TNFα CD107 IFNγ IL-2 TNFα CD107 
R300 + - - + + - + + 
V260 - - - - + - + + 
B250 + - + + + - + + 
P230 - - - - - - - - 
M210 - - - - + - - - 
W625 + - + + - - - - 
H300 + - + + + - + + 
M535 + - - - + - + + 
P510 - - - - - - - - 
W630 + - + + + - - - 
B630 P + - + + + - + + 
P300 + - + - + - + + 
C425 + - + + + - + + 
V520 + + - + + + + + 
H526 + - + + + - + + 
F425 + - - - - - - - 
G320 + - - + - - - - 
R500 + - + + + - + + 
G650 - - - - - - + + 
T525 - - - - - - + + 
F630 + - + + - - - - 
A536 + - + + + - + + 
C230 + - + + + - + + 
G400 + - + + + - + + 
P456 - - - - - - - - 
A452 + - + + + - + + 
J520 B - - - - + - - - 
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3.8 The magnitude of gag-specific IFNγ and CD107 responses closely 
correlates with the complexity of the single CD8+ T cell responses 
The individual thresholds for each cytokine and compartment (Table 3.8.) were subsequently 
taken into consideration in order to study possible correlations between the individual 
responses. As seen in Tables 3.9 and 3.10, IL-2 responses to gag and nef in the group of sero-
positive individuals were generally absent; for this reason, only the CD107, IFNγ and TNFα 
responses were studied for possible correlations. The clinical characteristics of the individuals 
(CD4 cell counts, plasma viral loads, antiretroviral treatment status etc) were not considered 
at this point, as the aim was to establish possible mechanistic correlations between individual 
parameters and not address potential correlates of protection. 
As is shown in Figure 3.5, all of the controls (n=25) have very low magnitude CD107, IFNγ 
and TNFα responses to gag, in both the blood and gut compartments; these responses are 
predominately monofunctional. The 95th percentiles of those responses (Table 3.8) are 
generally lower than 0.11 for all 3 functions in the blood and less than 0.28 in the gut. In the 
HIV positive population, a range of responses is noted (from negative to triple positive, 
Figure 3.5); a positive IFNγ response is associated with concurrent CD107 and TNFα 
responses. Also, there is a tendency for the responses to be more complex (i.e. consisting of 
multiple single functions) as the magnitude of the IFNγ response increases. 
In the case of nef-stimulated cells (Figure 3.5), the correlation between magnitude of IFNγ 
response and complexity of the overall single responses appears to apply as well. The higher 
magnitude IFNγ responses are associated with CD107 and TNFα responses; in keeping with 
that observation, low magnitude IFNγ nef responses in blood and gut of HIV positive 
individuals are predominately monofunctional. 
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Figure 3.5. D graphs showing the IFNγ, CD107 and TNFα responses in the CD8+ T cell 
populations following stimulation with gag and nef. 
The numerical values on each axis represent percentages of total CD8 cells that respond by 
expressing the relevant function/cytokine. The red bars represent HIV positive donors and the black 
bars represent controls. 
 
3.9 Application of filter gating in the analysis of CD4+ T cell immune 
responses in blood and gut mucosa 
Subsequently, CD4+ T responses were studied in the groups of controls (Table 3.1) and HIV 
positive individuals (Table 3. 2) for the purpose of establishing reference intervals and 
positive response thresholds. In a manner similar to the study of CD8+ T cells, the impact of 
the application of quality control gating on CD4+ T cell background responses was studied. 
In the group of controls, application of filter gates significantly reduced the background for 
IFNγ and CD107, whereas they did not have an impact on the IL-2 and TNFα backgrounds 
(Table 3.11, Figure 3.6). In the HIV positive donor group, the TNFα and CD107 backgrounds 
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in the blood, as well as the backgrounds for all four functions in the gut were significantly 
reduced with implementation of the filter gating strategy (Table 3.11, Figure 3.7). In general, 
the quality control gating strategy was more important in reducing nonspecific background 
responses in the mucosa, compared to the blood. IL-2 was the only cytokine not significantly 
affected by the application of filter gating, whereas non-specific CD107 background was 
considerably reduced (Table 3.11). 
 
Table 3.11. Application of quality control gating on mock responses in PBMC and MMC in CD4+ 
T cells. A: controls group and B: HIV positive donors 
Background (mock) responses in blood and gut with and without application of the filter gating strategy 




























25% Percentile 0 0 0.02 0.02 0 0 0. 0 
Median 0 0.01 0.03 0.03 0 0 0 0 
75% Percentile 0.02 0.03 0.05 0.08 0.01 0.01 0 0 
MMC 
25% Percentile 0 0 0 0.02 0 0 0.0 0.05 
Median 0 0.06 0.05 0.07 0 0 0.0 0.08 




























25% Percentile 0 0 0.01 0.02 0 0 0 0 
Median 0.01 0.01 0.03 0.04 0 0.01 0 0 
75% Percentile 0.03 0.04 0.07 0.09 0.01 0.03 0 0.03 
MMC 
25% Percentile 0 0 0.0 0 0.0 0 0 0 
Median 0 0.05 0.0 0.07 0.0 0.06 0 0.11 



















Figure 3.6. Reduction of CD4+ T cell background values A in the blood and B in the gut (N=24) 
with the application of the quality control gating scheme in the group of control donors. 
The circles represent background values for CD4+ T cells, for the four parameters (IFNγ, IL-2, TNFα 
and CD107. Solid circles represent backgrounds recorded after applying the above-described QC 
gating strategy, whereas in the groups of hollow circles, no such gating was applied in the analysis. 
The solid horizontal lines represent median values within each group. The p values indicate that filter 
gating results in statistically significant reduction in the IFNγ and CD107 backgrounds in both blood 













































































































Figure 3.7. Reduction of CD4+ T cell background values A in the blood (N=34) and B in the gut 
(N=40) with the application of the quality control gating scheme in the HIV positive donor group. 
The circles represent background values for CD4+ T cells, for the four parameters (IFNγ, IL-2, TNFα 
and CD107) measured. The solid circles represent backgrounds recorded after applying the above-
described QC gating strategy, whereas in the groups of hollow circles, no such gating was applied in 
the analysis. The solid horizontal lines represent median values within each group. The p values 
indicate that filter gating results in statistically significant reduction in the TNFα and CD107 
backgrounds in blood as well as in all cytokine backgrounds in the gut (p<0.05, with the use of the 




















































































3.10 Establishment of reference intervals for HIV-1 antigen-specific 
immune responses in CD4+ T cells 
CD4+ T cell responses to HIV-1 peptides are less well studied compared to CD8+ responses; 
this is especially true for mucosal CD4+ T cell responses. However, there are reports of CD4+ 
T cell memory responses to gag in HIV controllers in blood (Vingert et al.). 
In order to define positive CD4+ T cell recall responses, the control group of donors was 
studied. In keeping with the criteria for positivity used to characterise CD8+ responses, we 
calculated the 95th centile of the CD4+ T cell responses to gag and nef for each individual 
cytokine and compartment, after subtracting the apparent negative control response (mock). 
As shown in Table 3.12, the cut off values for a positive response vary between 0.06 and 0.23 
percent. Mucosal thresholds are generally higher than those seen in blood, reflecting the 
higher nonspecific backgrounds seen in gut T cell responses. IL-2 and CD107 responses in 
general have higher thresholds for positivity across compartments and stimulation conditions, 
in keeping with similar patterns in CD8+ T cell responses (Table 3.12). 
Table 3.12. Reference intervals for CD4+ T cell recall responses to HIV-1 peptides in the control population. 
The far right column shows the 5th-95th centile intervals of recall responses in the control population for 
a specific cytokine, stimulus (gag or nef) and compartment (blood or gut). These reference intervals 
represent responses obtained after subtracting the apparent response to the negative control (mock). 
 
























3.11 CD4+ T cell antigen specific immune responses to gag and nef in 
parallel blood and gut samples 
The cut off values for CD4+ T cell positive responses (Table 3.12) were used to characterise 
complex immune responses across compartments and stimulation conditions. As in the case of 
CD8+ T cell responses, a positive response should fulfil the following criteria: a) it should be at 
least twice the magnitude of the mock response and b) it should be greater than the 95th centile 
of the responses observed in the control group (for a particular HIV peptide in blood or gut). 
Tables 3.13 and 3.14 summarise the responses to gag and nef in the group of HIV positive 
donors. Overall, an immune response to gag and nef in the blood was detected in 31 percent and 
14 percent of HIV positive donors respectively. The majority of the responding donors (over 80 
percent) had responses consisting of one or two functions, with the most common pattern being 
monofunctional IFNγ responses. Intracellular IL-2 responses to gag and nef peptide pools in the 
blood were uncommon and nonexistent respectively. Multiple single responses to gag and nef (at 
least 3 functions) were observed in 6 and 3 percent respectively in blood. 
The pattern of mucosal responses was similar to the blood, with responses seen in 30 and 12 
percent to gag and nef respectively. In keeping with the blood data, the responses in the 
mucosal compartment were also dominated by 1 or 2 functions. Furthermore, Tables 3.13 and 
3.14 demonstrate lack of concordance between blood and gut responses to either gag or nef. 
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Table 3.13. Complex immune CD4+ T cell responses to the gag peptide pool in HIV positive 
individuals in the blood vs. the gut. 
CD4+ T cell responses to gag are demonstrated here. Each row represents responses of a single donor 
in blood and gut. There are 8 columns representing all 4 functions studied (IFNγ, IL-2, TNFα and 
CD107) in the blood (4 columns to the left) or gut (4 columns to the right). A positive response for a 
specific function is depicted by the plus sign, whereas the minus sign denotes a negative response. 
Furthermore, the positive responses in blood and gut have been highlighted red and blue respectively 
to facilitate comparisons between compartments. 
 
Subject GAG 
 BLOOD GUT 
 IFNγ  IL-2 TNFα  CD107 IFNγ  IL-2 TNFα  CD107 
R300 + + + + + - - - 
B250 - - - - - - - - 
P230 - - - - - - - - 
G320 + - - - - - - - 
P456 - - - - - + - - 
B630P - - - - - - - - 
P300 - - - - + + + - 
H300 - - - - - - - - 
C425 + + + - - - - - 
F630 - - - - - - - - 
H526 + - + - + + + - 
W630 - - - - - - - - 
P510 - - - - - - - - 
J520A - - - - - - - - 
A536 - - - - - - - + 
G400 - - - - - - - - 
M535 - - - - - - - - 
M210 - - - - + - - - 
R500 + - - - - - - - 
W625 - - - - - - - - 
V260 - - - - - - - - 
V520 + - - - - - - - 
G650 + - - - - - - - 
F245 + - - - - - - - 
T525 - - - - - - - - 
C230 - - - - - - - - 




Table 3.14. Complex immune CD4+ T cell responses to the nef peptide pool in HIV positive 
individuals in the blood vs. the gut. 
CD4+ T cell responses to nef are demonstrated here. Each row represents responses of a single donor 
in blood and gut. There are 8 columns representing all 4 functions studied (IFNγ, IL-2, TNFα and 
CD107) in the blood (4 columns to the left) or gut (4 columns to the right). A positive response for a 
specific function is depicted by the plus sign, whereas the minus sign denotes a negative response. 
Furthermore, the positive responses in blood and gut have been highlighted red and blue respectively 
to facilitate comparisons between compartments. 
 
Subject NEF 
 BLOOD GUT 
 IFNγ  IL-2 TNFα  CD107 IFNγ  IL-2 TNFα  CD107 
R300 - - - - - - - - 
B250 - - - - - - - - 
P230 - - - - - - - - 
G320 - - - - - - - - 
P456 - - - - - - - - 
B630P - - - - - - - - 
P300 - - - - + - + + 
H300 - - - - - - - - 
C425 - - - - - - - - 
F630 - - - - - - - - 
H526 - - - - - - + - 
W630 - - - - - - - - 
P510 - - - - - - - - 
J520B - - - - - - - - 
A536 - - - - + - - + 
G400 - - - - - - - - 
M535 - - - - - - - - 
M210 - - - - - - - - 
R500 + - - - - - - - 
W625 - - - - - - - - 
V260 - - - - - - - - 
V520 + - + + - - - - 
G650 - - - - - - + - 
F245 + - + - - - - - 
T525 - - - - - - - - 
C230 - - - - - - - - 
A452 - - - - - - - - 
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3.12 Magnitude and complexity of CD4+ T cell responses in blood and gut of 
HIV positive donors 
The magnitude and complexity of CD4+ T cell responses to gag and nef in the blood and 
mucosa of controls and HIV positive donors are shown in Figure 3.8. All IFNγ, TNFα and 
CD107 responses in the control group are of very low magnitude (values represented by the 
black bars are clustered around zero). In the group of HIV positive donors, the magnitude of 
the responses observed is also very low, with over 95 and 98 percent of gag and nef responses 
being less than 0.5 percent. There is only one donor whose recorded IFNγ and TNFα 
responses to gag are over 1 percent in the mucosal compartment. Comparison between CD8+ 
and CD4+ T cell responses in the group of HIV positive donors (Figures 3.5 and 3.8) shows 






Figure 3.8. D graphs showing the IFNγ, CD107 and TNFα responses in the CD4+ T cell 
populations following stimulation with gag and nef. 
The numerical values on each axis represent percentages of total CD4+ T cells that respond by 
expressing the relevant function/cytokine. The red bars represent HIV positive donors and the black 
bars control individuals 
Gag Blood Gag Gut 
Nef Blood Nef Gut 
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3.13 Discussion 
Validation of assays to measure HIV antigen specific immune responses is essential for 
assessment of vaccine immunogenicity in clinical trials. Here we describe a modified 
protocol for obtaining mucosal tissue, isolating MMC and analysing the CD8+ and CD4+ T 
cell responses to HIV-1 peptide antigens; blood T cell responses to the same peptides can 
also be assessed with application of this protocol. The use of well designed antibody panels 
and agreed gating strategies, as well as strict adherence to Standard Operating Procedures 
(SOPs) resulted in a significant reduction in background staining in PBMC and MMC and 
acceptable inter operator CV. Incorporation of a buffy coat panel to detect antigen specific 
immune responses resulted in real time quality assurance of flow cytometric assays, giving 
greater confidence in the validity of the results obtained. Reference intervals for immune 
biomarkers and magnitude of HIV specific immune responses varied with individual cytokine 
tested and with the site (blood or gut). Multiple single HIV antigen specific CD8+ T cell 
responses in blood and mucosal tissues were not concordant in individual study participants. 
Cell yields obtained from mucosal samples in this study were similar to those previously 
reported and allowed us to acquire a minimum of 100,000 lymphocyte events for analysis. 
Some investigators have suggested that at least a million events may be necessary to ensure 
accurate measurement of a polyfunctional T cell immune response and sufficient numbers of 
events in all Boolean combination gates for robust statistical analysis (Seder et al. 2008). 
Polyclonal expansion of mucosal mononuclear cells using bi-specific antibodies could be 
used to increase cell counts, since data suggests that the functional profile of mucosal T cells 
generated in this manner is similar to non-expanded cells (Shacklett et al. 2003b). 
Implementation of quality control procedures adopted for analysis of blood samples such as 
the incorporation of viability dyes (Perfetto et al. 2006b), dump channels to eliminate debris, 
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non-viable and contaminating cells, as well as application of a defined gating strategy led to a 
significant reduction in non specific background staining in both PBMC and MMC mock 
control samples. The additional use of specific gating templates and double checking of all 
data obtained by a senior scientist helped to minimize inter-operator variability for the 
measurement of CD107, IFNγ and TNFα immune responses in MMC. The CV for detection 
of IL-2 was, however, higher than other immune markers tested, possibly due to the low 
levels of this cytokine; this is of concern, given the importance of this cytokine as a potential 
marker of immune protection (Sekaly 2008). 
The use of a process control (PBMCs isolated from an individual with known pre-existing 
antigen specific immune to markers analyzed in this study) allowed for real-time detection of 
systematic and random variance by means of application of statistical stopping rules 
(Westgard 1981). A limitation of our approach is that our quality control sample is unable to 
check for variance in extraction and isolation of mucosal mononuclear cell populations; 
however it does provide quality assurance in flow cytometric instrumentation set up, sample 
acquisition and data analysis. The use of more process controls with different magnitude of 
antigen specific immune response would lead to application of more vigorous statistical 
stopping rules resulting in increased sensitivity and specificity of this procedure to detect 
systematic and random bias in measurement (Westgard 2003). Although this quality control 
method gives a reliable indicator of assay precision in the absence of an externally verified 
gold standard, determination of a true value of an antigen specific immune response (marker 
of accuracy) is not possible. Collaboration between academia and industry is needed to 
establish reference cell preparations for determination of antigen specific immune responses 
similar to initiatives already in place in diagnostic laboratories for calculation of CD4+ T cell 
counts. 
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The development of reference intervals for HIV antigen specific immune responses in a 
population of controls enabled us to set validation criteria for specificity. The HIV-1 status of 
control study participants was not formally tested, since the estimated prevalence of HIV-1 
infection in individuals aged 16-49 who seek general medical care in our institution is 0.3%. 
It is very unlikely that we inadvertently enrolled HIV-1 sero-positive individuals into our 
control cohort and the appearance of HIV antigen specific immune response in some 
individuals may represent a cross reactivity between HIV peptide pool and self- or other 
proteins. In this study more emphasis was placed on the validation of assay specificity rather 
than sensitivity given the importance of measuring genuine HIV specific immune responses 
in vaccine trials. Data presented show that reference intervals for HIV specific immune 
responses vary according to site of immune response and individual immune biomarker. 
Significant differences between Western laboratory reference ranges and those found in 
Africa have been recently described (Kibaya et al. 2008); it may, therefore, be necessary to 
establish region-specific reference intervals for HIV antigen specific immune responses for 
vaccine trials conducted in different parts of the world. 
Positive immune responses can be defined empirically or statistically and studies of 
individual cytokine responses using ELISPOT technology show that both approaches work 
well (Cox et al. 2005).We defined a positive immune response as one in which the magnitude 
of a cytokine response in the peptide stimulation sample was at least twice the background 
value. The reference intervals and mock background values varied for each cytokine assessed 
and incorporation of these parameters into the definition of a positive immune response 
meant that each immune biomarker had its own unique threshold value. In this study, 
multiple single CD8+ T cell responses were characterised by the expression of IFNγ, CD107 
and TNFα. Our data show absence of IL-2 particularly in MMC; the CVs for this cytokine 
were high partly driven by very low levels of secretion (data not shown). The majority of 
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HIV study participants had chronic infection and were on antiretroviral therapy; this may 
have contributed to the lack of IL-2 specific immune responses observed. A significant 
proportion of HIV study participants had single or no immune responses and this could well 
influence calculation of sample sizes required to adequately power immunology studies of 
this nature in future HIV vaccine trials. We did not find a close correlation in this small study 
between the presence of multiple single CD8+ HIV T cell antigen specific immune responses 
in blood and gastrointestinal tract for individual patients, confirming previous reports that 
immune responses to HIV may be compartmentalised (Guadalupe et al. 2006; Critchfield et 
al. 2007; Ferre et al. 2009). Indeed, one hypothesis which may explain the protection from 
HIV-1 transmission demonstrated in the group of vacinees in the recent RV144 trial is that it 
may have been mediated by development of local mucosal immune responses, in the absence 
of parallel blood responses (Rerks-Ngarm et al. 2009; Berkhout et al. 2009). 
In conclusion, we outline a protocol to analyse CD8+ and CD4+ T cell HIV antigen specific 
immune responses in gastrointestinal mucosal tissue samples in a robust and meaningful 
manner. Application of this or similar protocols will be essential for accurate assessment of 
the immunogenicity of candidate HIV-1 vaccines. 
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Chapter 4 Characterisation of CD8+ T cell recall responses to 
HIV-1 peptides in peripheral blood and mucosal 
mononuclear cells 
4.1 Introduction 
The study of mucosal immune responses to HIV has attracted considerable interest in recent 
years. Studies of mucosal immune responses, however, have been largely limited to the 
mucosa of the rectum due to easier access to tissue from this site (Critchfield et al. 2007; 
Critchfield et al. 2008). Overall, the frequencies of HIV-specific CD8+ T cells in the blood 
and gut appear to be comparable (approximately 1% of the total CD8+ T cells) (Shacklett et 
al. 2003a). It appears that the majority of CD8+ T cells in chronically infected individuals 
unable to control viral replication are monofunctional, responding to peptide stimulation by 
either degranulation or IFNγ production only (i.e. surface mobilisation of CD107). A recent 
study of rectal CD8+ in HIV-1 elite controllers showed that this group of individuals 
demonstrated stronger and more polyfunctional responses compared to individuals receiving 
suppressive ART (Ferre et al. 2009). Furthermore, rectal responses in the group of controllers 
were generally of higher magnitude and complexity than those observed in the blood. A 
further recent study confirmed that HIV positive elite controllers maintain strong 
polyfunctional CD8+ T cell responses, whilst showing a low systemic immune activation 
profile (Owen et al., 2010). 
There are significant differences between the immune system in the blood and gut mucosa, 
which are outlined elsewhere (Introduction, 1.2). One of the major differences is in the 
proportions of memory CD8+ and CD4+ T cells, which are considerably higher in the mucosal 
immune system. Furthermore, in terms of overall size, the mucosal immune system contains 
approximately ten times more lymphocytes than the blood. With that in mind, it is conceivable 
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that immunological events taking place in the gut mucosa are at least as important at those in 
the blood in determining the nature of the host-pathogen interaction in HIV-1 infection. 
Therefore, it is rather surprising that the large number of clinical trials of candidate HIV 
vaccines rely on single (or even multiple) readouts obtained from blood CD8+ T cells, thus 
completely ignoring the role of the mucosal immune system in defences against HIV. 
Although several key immunological events taking place in the gut mucosa need to be further 
characterised, it would appear as though a successful HIV-1 vaccine should be able to elicit 
polyfunctional T cell responses in the gut mucosa. This is supported by the fact that vaccine-
induced CD8+ SIV-specific mucosal responses reduced the peak viraemia upon subsequent 
challenge of the vaccinated macaques, in contrast to blood CD8+ T cell responses which were 
of no value as correlates of protection (Belyakov et al. 2006). 
The above data support the hypothesis that the T cell immune responses against HIV may 
differ between the blood and gut. This dichotomy could partly be explained by the 
differences in the degree of CD4+ T-cell depletion in blood and gut early in the course of the 
infection, as well differences in the degree of CD4 reconstitution in those compartments 
following suppressive ART. Comparison of the magnitude of blood vs. gut recall responses 
should also take into account differences in representation of the memory T cell population 
pool between the 2 compartments (Brenchley et al. 2006a). 
Whilst there is a significant body of literature studying CD8+ T cell mucosal responses in 
HIV-1 infection, very few studies describing mucosal CD4+ T cell responses have been 
published. A number of studies have shown a positive correlation between viraemic control 
and degree of polyfunctionality in blood CD4+ T cells (Boaz et al. 2002; Emu et al. 2005; 
Harari et al. 2005). CD4+ T cells are important in providing “help” to CD8+ T cells in 
eliciting antigen-specific responses. A recent study of rectal CD4+ T cells found a positive 
correlation between the frequency of polyfunctional CD4+ T cells and the magnitude of HIV-
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antigen-specific CD8+ T cell responses, supporting the above notion (Ferre et al.). In the same 
study, the frequency of polyfunctional CD4+ T cells was found to be higher in the group of 
HIV controllers compared to non-controllers or individuals on ART. 
We hypothesised that blood and gut recall immune responses to cognate HIV-1 peptides are 
different in magnitude and quality, which would imply that gut responses ought to be 
assessed separately in order to accurately evaluate candidate HIV-1 vaccines. We further 
hypothesised that those responses may differ according to the level or degree of immune 
reconstitution, length of treatment, viral load and CD4+ T cell nadir, as well as between 
different mucosal sites (small bowel vs. colon). In this context, we would pursuit the 
following aims: 
● To characterise the magnitude and quality of CD8+ T cell recall responses to gag and 
nef in blood and gut. 
● To compare those between groups of HIV positive donors based on CD4+ T cell 
count, degree of immune reconstitution, viral load, length of treatment and CD4+ T 
cell nadir counts 
● To compare the magnitude and quality of CD8+ T cell responses between different 
mucosal sites 
4.2 Patient characteristics 
Demographic data from the controls and HIV positive donors participating in this study can 
be found in Tables 3.1 and 3.2 of the previous Chapter. The data are summarized in Tables 
4.1 and A-1 (Appendix). The three groups of donors (controls, treated and untreated HIV 
positive patients) do not differ significantly in age distribution. Male patients dominate in the 
HIV positive groups (as previously described), whereas only 41 percent in the group of 
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controls are males. The median CD4 counts are 553cells/µl and 429cells/µl for treated and 
untreated patients respectively and did not differ significantly between those groups. 
Similarly, the CD4+ T cell frequencies did not differ between treated and untreated HIV 
positive donors, but they were significantly lower compared to the control group. CD4 cell 
nadir values were significantly lower in treated vs. untreated HIV positive patients 
(143cells/µl and 356 cells/µl respectively, p=0.0002 for the comparison); similarly, plasma 
viral loads were significantly lower in the treated patient group. The treated positive patients 
in our study have had a diagnosis of HIV infection for 9 years (median value), as opposed to 




Table 4.1. Summary of the clinical characteristics of the controls (n=24), HIV positive donors on 
antiretroviral treatment (ART, n=21) and untreated HIV positive donors (n=14) 
The numbers of CD4 T cells per µl were determined using 4-colour flow cytometry and staining whole 
(EDTA) blood. The CD4 frequencies reported here are percentages of total CD3 cells and were 
determined by flow cytometry in mock-stimulated samples. Where applicable, statistics (median 
values and IQRs) for each parameter were compared between groups (using the Mann-Whitney or 
Kruskal-Wallis tests, as appropriate); when statistically significant differences were found between 
groups, median and IQR values are shown in bold numbers. Plasma viral load was arbitrarily set to 
zero in all individuals with viraemia below the limit of detection of the commercially available PCR 








Age: Median (IQR) 40 (30.7-44) 44 (35-47.5) 38.5 (32.5-43) 
Sex: Male: n (%) 10 (41%) 19 (90%) 14 (100%) 
CD4 cells/µl: Median 
(IQR) 
N/A 553 (353-687) 429 (380-559) 
CD4 %: Median (IQR) 69.1 (61.9-72.2) 48.8 (31.5-62) 46.3 (29-56) 
CD4 nadir cells /µl: 
Median (IQR) 
N/A 143 (42-294) 356 (328-497) 
Viral Load: Median 
(IQR) 
N/A 0 (0-0)* 8,142 (1,632-57,616) 
Years since HIV-1 
diagnosis: Median 
(IQR) 
N/A 9 (5-13.75) 2.5 (1.75-6.5) 
Years on ART: Median 
(IQR) 
N/A 6 (1-12) N/A 
Years after diagnosis 
before ART: Median 
(IQR) 
N/A 1 (0-4) N/A 
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4.3 Detection of single cytokine responses and degranulation by 
intracellular Flow Cytometry 
4.3.1 Analysis of single responses of CD8+ T cells to FEC in the blood vs. the gut 
Representative graphs of CD8+ T cell responses to positive controls (FEC and SEB) in the 
blood and gut of an HIV positive donor are shown in Figure 4.1. In this individual, there are 
positive responses to FEC in both the blood and gut mucosal compartments. The blood 
responses are of higher magnitude compared to the gut. Within each compartment, the 
responding CD8+ T cells are expressing far greater levels of intracellular IFNγ, TNFα and 
surface CD107 compared to IL-2; a similar pattern is observed when SEB (non-antigen 
















































































































































Figure 4.1. Representative plots of single cytokine responses to the positive controls FEC and SEB 
in the blood and gut of an HIV positive donor (T525). 
The upper 2 rows show responses in the blood and the lower 2 rows similar responses in the gut. The 
1st and 3rd row show responses to FEC, while the 2nd and 4th row show SEB responses. The 4 columns 
(from left to right) show IFNγ, IL-2, TNFα and CD107 single responses respectively. 
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Comparison of blood and MMC samples isolated from controls and HIV-1 patients showed 
no significant differences in expression of IFNγ, TNFα and CD1O7 in response to 
stimulation with FEC (Figure 4.2). IL-2 responses in general were of very low magnitude and 
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Figure 4.2. CD8+ T cell single cytokine responses to FEC in blood vs. gut in A the control group 
(n=24) and B the HIV positive group (n=34). 
The values on the y-axis represent percentages of the total CD8+ T cell population, which respond to 
the stimulus with expression of any of the 4 functions studied. The whiskers denote the whole of the 
distribution (0-100 centile) of a cytokine response (IFNγ, IL-2, TNFα and CD107, from left to right) 
and the boxes represent the IQRs. The red box and whiskers graphs represent blood responses 
whereas the grey ones represent similar responses in the gut. P values are shown for the comparisons 
of cell frequencies (for all 4 cytokines) between the blood and the gut. Where the comparisons show 
statistically significant differences, the p values are in bold numbers (Wilcoxon matched pairs test) 
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4.3.2 Analysis of single responses of CD8+ T cells to gag and nef peptide pools in the 
blood vs. the gut 
Single cytokine (IFNγ, IL-2 and TNFα) production and degranulation (surface detection of 
CD107) were measured in the CD8+ T cell population of the blood and gut in HIV positive 
donors after stimulation with gag and nef peptide pools. All responses reported here were 
background-subtracted (i.e. the value of the mock response in each sample has been 
subtracted from the corresponding antigen-specific peptide response for each donor and 
compartment). In the event these values were negative (i.e. the absolute value of a 
background response was higher than of the corresponding HIV peptide response), the net 
peptide response was arbitrarily set to zero, since a negative value would not be biologically 
meaningful. Since IFNγ and CD107 were the dominant responses in antigen-specific CD8+ T 
cells and the ones showing more variation between compartments, representative dot plots of 
those in blood and colon of an HIV positive donor after stimulation with gag and nef are 
shown in Figure 4.3. The negative control responses in both compartments are shown as well. 
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Figure 4.3. IFNγ and CD107 expression by CD8+ T cells in blood and colon of an HIV positive 
donor after stimulation with gag and nef. 
The upper row shows negative control responses (mock), whereas the middle and lower rows show 
responses to gag and nef respectively. The two left columns represent IFNγ responses (blood and gut) 
and the two on the right of the figure show CD107 responses (blood and gut). The frequencies of the 
positive populations are shown next to the relevant gates. In this example, the mucosal IFNγ and 
CD107 immune responses are much higher than those seen in the blood. 
 
The main CD8+ T cells responses to gag and nef stimulation in gut and blood are IFNγ and 
CD107 degranulation in both compartments (Figure 4.4 A and B). There is a more moderate 
production of TNFα and very small amounts of IL-2 produced. The range of distribution of 
positive responses in the gut is considerably wider compared to the blood for all four 
functions, particularly IFNγ and CD107 as reflected in the IQRs (Table 4.2). Immune 
responses to HIV peptides are significantly higher in MMC samples compared to PBMC 
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Figure 4.4. CD8+ T cell single cytokine responses to A gag and B nef in blood vs. gut in HIV 
positive donors (n=34). 
The values on the y-axis represent percentages of the total CD8+ T cell population, which respond to 
the stimulus with expression of any of the 4 functions studied. The whiskers denote the whole of the 
distribution (0-100th centile) of a cytokine response (IFNγ, IL-2, TNFα and CD107, from left to right) 
and the boxes represent the IQR. The red box and whiskers graphs represent blood responses 
whereas the grey ones represent similar responses in the gut. P values are shown for the comparisons 
of cell frequencies (for all 4 cytokines) between the blood and the gut. Where the comparisons show 
statistically significant differences, the p values are in bold numbers (Wilcoxon matched pairs test). 
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Table 4.2. Magnitude of CD8+ T cell responses to gag and nef in blood and gut compartments in 
the HIV positive population. 
IFNγ, IL-2, TNFα and CD107 responses to gag and nef are shown in both compartments. The bold 
numbers represent median values, whereas the numbers in brackets are interquartile ranges (IQRs). 
 
gag 
CD8+ T cell responses: BLOOD GUT 
IFNγ response: median (IQR) 0.26 (0.15-0.72) 0.71 (0.15-2.41) 
IL-2 response: median (IQR) 0.06 (0.04-0.15) 0.13 (0.05-0.26) 
TNFα response: median (IQR) 0.09 (0.02-0.24) 0.2 (0.02-0.49) 
CD107 response: median (IQR) 0.31 (0.12-0.62) 0.79 (0.23-3.04) 
nef 
IFNγ response: median (IQR) 0.24 (0.09-0.78) 0.64 (0.20-2.34) 
IL-2 response: median (IQR) 0.08 (0.04-0.14) 0.12 (0.05-0.26) 
TNFα response: median (IQR) 0.1 (0.03-0.32) 0.37 (0.03-0.86) 
CD107 response: median (IQR) 0.27 (0.06-0.79) 1.00 (0.25-3.00) 
 
4.3.3 Analysis of single cytokine responses in donors with detectable vs. undetectable 
plasma viraemia in blood and gut 
The extent to which antigenic burden drives CD8+ T cell maturation and determines the 
magnitude and quality of antigen-specific CTL responses in HIV is controversial (Gea-
Banacloche et al. 2000; Betts et al. 2001; Champagne et al. 2001; Tussey et al. 2003; Hess et 
al. 2004; Jansen et al. 2006; Streeck et al. 2008). To address this issue, CD8+ T cell responses 
were compared between the groups of HIV positive donors with undetectable vs. detectable 
plasma viraemia (i.e. plasma viral load<50 and >50 copies per ml). Among the HIV positive 
donor group (n=34) there were sixteen individuals with detectable viraemia and eighteen with 
undetectable viral load; blood and gut responses between those two groups were compared. 
Analysis of single responses to gag and nef in both compartments showed that the main 
responses were IFNγ and CD107 degranulation (Figure 4.5). Furthermore, comparison 
between the groups with detectable vs. undetectable viraemia showed no differences in the 
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blood between those groups; in the gut, however, the IFNγ, TNFα and CD107 nef responses, 
as well as the CD107 gag response were significantly higher in group of donors with 
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Figure 4.5. Single cytokine gag responses in blood A and gut B and nef responses in blood C and 
gut D in HIV positive donors with undetectable (n=18) vs. detectable (n=16) viraemia. 
The values on the y-axis represent percentages of the total CD8+ T cell population responding to the 
stimulus with expression of any of the 4 functions studied. The whiskers denote the whole of the 
distribution (0-100th centile) of a cytokine response (IFNγ, IL-2, TNFα and CD107, from left to right) 
and the boxes represent the IQR. The red box and whiskers graphs represent responses in the group 
with viral load (VL)<50 copies/ml, whereas the grey ones represent similar responses in the group of 
donors with detectable viraemia (VL>50 copies/ml). P values are shown for the comparisons of cell 
frequencies (for all 4 cytokines) between the two groups. Where the comparisons show statistically 
significant differences, p values are in bold numbers (Mann-Whitney U test). 
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4.3.4 Analysis of single CD8+ T cell responses in the duodenum vs. the colon in HIV 
positive donors 
The small intestine and the colon are two anatomically and physiologically different parts of 
the human gastrointestinal tract. Briefly, the small intestinal mucosa consists of villae and is 
responsible for the absorption of nutrients; the colonic mucosa lacks these structures and its 
main role is the absorption of water and electrolytes. Besides those differences, the small 
intestinal lumen is to a large extent sterile, in contrast to the colonic lumen where a large 
number of commensal bacteria reside. We hypothesised that antigen-specific immune 
responses in those two mucosal sites may be different, given the distinct properties of the 
mucosal immune system in the small bowel and colon. Mucosal responses to gag and nef 
were variable in the group of HIV positive donors studied and in many cases undetectable; 
therefore, in order to compare the small intestinal and colonic responses, a group of donors 
who provided samples from both sites on the same day was selected. This group consists of 
eight patients, whose demographic characteristics are summarized in Table 5.3. 
 
Table 4.3. Demographic characteristics of HIV positive donors with parallel duodenal and 
colonic samples. 
Soundex code Viral load 
(copies/ml) 
CD4 count Anriretroviral 
treatment 
O420 <50 625 YES 
S652 11,610 611 YES 
C600 808 390 NO 
M420 <50 704 YES 
B530 153,145 335 NO 
C220 299,228 356 NO 
W623 11,884 732 NO 
J522 359,834 550 NO 
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Representative plots with all four responses to gag and nef in the duodenum and colon of one 
donor are shown in Figure 4.6; in this individual, there are significant differences in the size 
of the IFNγ, CD107 and TNFα responses to gag and nef between the two mucosal sites, 
whereas there is little or no production of IL-2 in any of the gut compartments. 










































































































































Figure 4.6. Representative plots of single cytokine responses to gag and nef in the duodenum vs. 
the colon of a single HIV positive donor (S652). 
The 4 rows (from upper to lower) show IFNγ, IL-2, TNFα and CD107 single responses respectively. 
The 1st and 2nd columns (from left) show responses to gag, whereas the 3rd and 4th show nef responses 
in duodenum and colon of the same patient. 
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The duodenal CD8+ T cells respond to FEC predominately by degranulating and producing 
IFNγ, with smaller amounts of IL-2 and very little TNFα. The colonic CD8+ T cells generally 
produce IFNγ, TNFα and degranulate in response to FEC, whereas the production of IL-2 is 
much less. IFNγ, TNFα and CD107 single FEC responses are significantly higher in the 





































Figure 4.7. CD8+ T cell single cytokine responses to FEC in duodenum vs. colon of the HIV 
positive group of donors with parallel mucosal samples (n=8). 
The values on the y-axis represent percentages of the total CD8+ T cell population responding to the 
stimulus with expression of any of the 4 functions studied. The whiskers denote the whole of the 
distribution (0-100th centile) of a cytokine response (IFNγ, IL-2, TNFα and CD107, from left to right) 
and the boxes represent the IQR. The red box and whiskers graphs represent duodenal responses 
whereas the grey ones represent similar responses in the colon. P values are shown for the 
comparisons of cell frequencies (for all 4 cytokines) between duodenum and colon. Where the 
comparisons show statistically significant differences, the p values are in bold numbers (Wilcoxon 
matched pairs test). 
 
HIV peptide recall responses were predominately seen with IFNγ and CD107 degranulation 
and to a lesser extent TNFα (Figure 4.8). The duodenal responses to gag were higher in 
magnitude compared to the colonic for every single parameter. The differences, however, 
reached statistically significant levels only for IFNγ and CD107 (Figure 4.8 A, p=0.007 for 
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both comparisons). The differences between duodenum and colon were less pronounced after 
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Figure 4.8. CD8+ T cell single cytokine responses to A gag and B nef in duodenum vs. colon of the 
HIV positive group of donors with parallel mucosal samples (n=8). 
The values on the y-axis represent percentages of the total CD8+ T cell population responding to the 
stimulus with expression of any of the 4 functions studied. The whiskers denote the whole of the 
distribution (0-100th centile) of a cytokine response (IFNγ, IL-2, TNFα and CD107, from left to right) 
and the boxes represent the IQR. The red box and whiskers graphs represent duodenal responses 
whereas the grey ones represent similar responses in the colon. P values are shown for the comparisons 
of cell frequencies (for all 4 cytokines) between duodenum and colon. Where the comparisons show 
statistically significant differences, the p values are in bold numbers (Wilcoxon matched pairs test). 
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4.4 Analysis of polyfunctional CD8+ T cell responses 
An emerging concept from multiple studies of CD8+ T cell responses in viral and parasitic 
infection models, including HIV-1, is that rather than the magnitude of the single responses, 
the combination of functions at the single cell level (i.e. the “quality” of the T cell response) 
may be a better correlate of disease control (Gea-Banacloche et al. 2000; Betts et al. 2001; 
Betts et al. 2006; Critchfield et al. 2007; Seder et al. 2008). 
In order to study the quality of CD8+ T cell response in the blood and gut compartments, the 
Boolean gating strategy was adopted in the analysis of the results (Table 2.2, Materials and 
Methods) and specialised software was used for presentation of complex data (SPICE: 
Simplified Presentation of Incredibly Complex Evaluations, version 5.1, provided by Mario 
Roederer, Vaccine Research Centre, NIAID, NIH). Comparisons of whole responses between 
groups (permutations tests) are shown in the graphs; for those tests, p<0.05 is set as the cut-
off for statistically significant differences. A further set of p values is provided by the 
software for individual comparisons between the fifteen possible Boolean combinations in 
different groups. For these multiple comparisons, application of the Bonferroni correction 
would entail that a nominal significance level of 0.05/15=0.0033 should be used as indicative 
of true statistical difference in any of the fifteen sub-groups of the total responding cells. 
A representative example of analysis and presentation of polyfunctional CD8+ T cell 
































































































Figure 4.9. Magnitude and quality of duodenal CD8+ T cell responses in a representative HIV 
positive donor. 
The Boolean gating strategy was used for the analysis of the magnitude and the quality of the CD8+ T 
cell responses to gag, nef and FEC in the mucosal compartment. There are fifteen possible 
combinations of the four functions studied (IFNγ, IL-2, TNFα, and CD107). The CD8+ T cell 
responses shown here are from the colon of a representative HIV positive donor. 
A. The solid bars represent all fifteen possible combinations of the four functions expressed at the 
single cell level. The y-axis scale indicates absolute percentages of the total responding cells that 
correspond to a particular combination of functions. For example, the IFNγ+IL-2-TNFα-CD107+ 
response to nef (seventh yellow bar from the left) corresponds to 60 on the y-axis, indicating that 60 
percent of all the responding cells are “double-positive” for this cytokine combination and negative 
for IL-2 and TNFα. 
B. The three pie charts represent total CD8+ T cell responses to gag, nef and FEC (from left to right 
respectively) and are colour-coded according to the number of functions expressed at the single cell 
level. For example, in the third pie chart from the left (total CD8+ T cell response to FEC) 
approximately 50 percent of the response consists of monofunctional cells (yellow slice, further 
subdivided with the solid black lines into 4 “monofunctional” subsets, i.e. IFNγ+IL-2-TNFα-CD107-, 
IFNγ-IL-2+TNFα-CD107-, IFNγ-IL-2-TNFα+CD107- and IFNγ-IL-2-TNFα-CD107+). The colour coding 
of the 15 functions (when represented in the pie charts) is depicted at the bottom of the bar chart (1 
quadruple combination: red; 4 triple combinations: blue; 6 double combinations: green and 4 single 
functions: yellow) and corresponds to the pie chart colour coding. It should be emphasised that pie 
charts represent only responding cells, which are a very small percentage of the total CD8+ T cell 
population and that the IFNγ-IL-2-TNFα-CD107- (over 99 percent of CD8+ T cells in most cases) is 
not shown. 
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4.4.1 CD8+ T cell polyfunctional responses to SEB and FEC in the blood and gut of 
HIV positive donors 
Analysis of polyfunctional responses of CD8+ T cells to SEB in the blood and gut of HIV 
positive donors showed that the majority of the responding cells express three and two 
functions, followed by one function and four functions (Figure 4.10) 
As seen in the bar chart, the most common combination of three functions is the IFNγ+IL-2-
TNFα+CD107+; the most frequently seen “double” combination is the IFNγ+IL-2-TNFα-
CD107+, whereas the commonest single response is the IFNγ-IL-2-TNFα-CD107+. Six out of 
the fifteen Boolean combination functions differ significantly between blood and gut, being 
more frequent in the latter compartment. They are as follows: IFNγ+IL-2+TNFα+CD107+, 
IFNγ-IL-2+TNFα+CD107+, IFNγ-IL2+TNFα-CD107-, IFNγ-IL-2-TNFα+CD107+, IFNγ-IL-2-
TNFα+CD107- and IFNγ-IL2-TNFα-CD107+. As evident by the comparison of the pie charts, 
the proportion of cells responding with four functions is higher in the gut compared to the 
blood, whereas the proportions of cells responding with three, two and one function are very 
similar between compartments. The overall response is significantly more polyfunctional in 
the gut (p=0.0011, permutation test). 
Analysis the blood and mucosal CD8+ T cell responses to FEC (Figure 4.11) shows dominant 
monofunctional responses, especially in the gut, where they exceed 50 percent of the total 
response (with IFNγ-IL2-TNFα-CD107+ being the most common monofunctional subset). 
The second commonest group is the triple responses (with IFNγ+IL2-TNFα+CD107+ being 
the most abundant), followed by the double responding cells (mainly IFNγ+IL2-TNFα-
CD107+). There is a statistically significant difference in the quality of the total response, 
which is more polyfunctional in the blood (p=0.007). When the Boolean combinations are 
compared between compartments, only the monofunctional CD107 response appears to be 
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Figure 4.10. Quality of CD8+ T cell responses to SEB in blood vs. gut of HIV positive donors 
(n=34). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would need to be 





























































































Figure 4.11. Quality of CD8+ T cell responses to FEC in the blood vs. the gut of HIV positive 
donors (n=34). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 
to define statistically significant differences (Bonferroni correction). 
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4.4.2 Analysis of polyfunctional responses of CD8+ T cells to gag and nef in the blood 
and gut of HIV positive donors 
Comparison of CD8+ T cell gag responses in blood and gut showed similar profiles in both 
compartments (Figure 4.12). Approximately three quarters of the total responding cells are 
monofunctional (mainly IFNγ-IL2-TNFα-CD107+, and IFNγ+IL2-TNFα-CD107-), followed by 
cells expressing two functions (primarily IFNγ+IL2-TNFα-CD107+) and fewer with three 
functions (almost exclusively IFNγ+IL2-TNFα+CD107+). The total response between 
compartments did not differ significantly (p=0.24). When the Boolean combinations were 
studied, only the monofunctional CD107 response appeared to be significantly more 
prevalent in the gut (p<0.0033). 
Similarly, in the case of stimulation with nef (Figure 4.13), the most common responses were 
single, double and triple (in order of frequency), with the most common Boolean 
combinations being IFNγ-IL2-TNFα-CD107+, IFNγ+IL2-TNFα-CD107+ and IFNγ+IL2-
TNFα+CD107+. The overall quality of the response in the blood and gut appeared to be 
comparable (p=0.16); when Boolean combinations were compared, only the monofunctional 

























































































Figure 4.12. Quality of CD8+ T cell responses to gag in the blood vs. the gut of HIV positive donors 
(n=34). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 


























































































Figure 4.13. Quality of CD8+ T cell responses to nef in the blood vs. the gut of HIV positive donors 
(n=34). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination, whereas the 
horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 
to define statistically significant differences (Bonferroni correction). 
When the quality of the gag vs. the nef CD8+ T cell responses in blood and in the mucosal 




4.4.3 Analysis of CD8+ T cell polyfunctional responses to gag and nef in donors with 
undetectable and detectable plasma viraemia in blood and gut 
The quality of CD8+ T cell responses to gag (Figure 4.14) and nef (Figure 4.15) was studied 
in the blood and gut of the subgroup of eighteen HIV positive donors with undetectable 
plasma viral load (VL<50copies/ml). Approximately three quarters of the cells responding to 
either gag or nef were positive for one function (mostly CD107), followed by double positive 
cells (mostly for IFNγ and CD107) and triple positive populations (mainly for IFNγ, TNFα 
and CD107). CD8+ T cells positive for all four functions comprised only a small percentage 
of the total response and were almost exclusively detected in the gut mucosa. Comparison of 
the quality of CD8+ T cell response between blood and gut for both of these stimuli did not 
show any significant differences (p values 0.412 and 0.16 for gag and nef stimulation 
respectively). Furthermore, comparisons of Boolean combinations between blood and gut 
failed to show any statistically significant differences in the response for either gag or nef. 
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Figure 4.14. Quality of CD8+ T cell responses to gag in the blood vs. the gut of HIV positive donors 
with undetectable plasma viral load (n=18). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 
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Figure 4.15. Quality of CD8+ T cell responses to nef in the blood vs. the gut of HIV positive donors 
with undetectable vireamia (n=18). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 
to define statistically significant differences (Bonferroni correction). 
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Subsequently, the blood and gut CD8+T cell responses to gag and nef were compared in the 
group of HIV positive donors with detectable plasma viral load (VL>50 copies/ml, Figures 
4.16 and 4.17). When gag was used as a stimulus, the overall combinations of the blood and 
gut responses were similar (p=0.36 for the comparison); both responses were dominated by 
monofunctional CD107 and IFNγ-producing cells, followed by bi-functional IFNγ+CD107+ 
cells and to a lesser extent CD8+T cells expressing three functions (IFNγ+TNFα+CD107+). 
When the Boolean combinations were compared between compartments, there were three 
subpopulations of responding CD8+T cells with significantly more frequent representation in 
the gut: IFNγ-IL2-TNFα-CD107+, IFNγ+IL2-TNFα-CD107- and IFNγ+IL2-TNFα-CD107+ (p 
values <0.0033 for all three comparisons). 
Similarly, after stimulation with nef in the group of individuals with detectable viraemia 
(Figure 4.17), the combination of responses in the blood was similar to the gut (p=0.449); the 
multiple comparisons for all fifteen Boolean combinations between compartments show 
significantly more IFNγ-IL2-TNFα-CD107+ and IFNγ+IL2-TNFα-CD107- monofunctional 
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Figure 4.16. Quality of CD8+ T cell responses to gag in the blood vs. the gut of HIV positive donors 
with detectable plasma viral load (n=16). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 
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Figure 4.17. Quality of CD8+ T cell responses to nef in the blood vs. the gut of HIV positive donors 
with detectable plasma viral load (n=16). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in blood and gut respectively. The y-axis scale indicates the absolute 
percentage (of the total responding cells) that corresponds to a particular combination of functions; 
each blue or red bar represents the interquartile range (IQR) for that combination in blood and gut 
respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between the 2 compartments (Wilcoxon matched pairs test). The right lower table shows p 
values when the total responses in the two compartments (blood and gut) are compared (permutation 
test). P values indicative of statistically significant differences (p<0.05) are highlighted red. However, 
for the comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied 
to define statistically significant differences (Bonferroni correction). 
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When the “flavour” of the CD8+ T cell response to gag in the blood was compared between 
donors with detectable vs. undetectable viraemia (Figure 4.18), the overall response was 
significantly more polyfunctional in the group of donors with undetectable plasma viral loads 
(p=0.0012). Over 50 percent of the responding CD8+ T cells were monofunctional (mainly 
the IFNγ+IL2-TNFα-CD107- and IFNγ-IL2-TNFα-CD107+ subsets), followed by “double 
positive” (mainly IFNγ+IL2-TNFα-CD107+) and “triple positive” (almost exclusively 
IFNγ+IL2-TNFα+CD107+) CD8+ T cells. No single Boolean combination showed significant 
difference in the frequency it was encountered between the two groups when multiple 
comparisons correction was applied. 
Similarly, when CD8+ T cell gag responses in the gut were compared between viraemic and 
aviraemic donors (Figure 4.19), the responses in the undetectable viraemia group were more 
polyfunctional (p=0.0011 for the comparison). The single IFNγ+IL2-TNFα-CD107- and IFNγ-
IL2-TNFα-CD107+ responses were significantly overrepresented in the viraemic group, where 
there was also a trend towards more frequent IFNγ+IL2-TNFα-CD107+ double responses 
(although this did not reach statistically significant levels). As shown in the pie charts (Figure 
4.19), CD8+ T cells in which all four functions were detected were exclusively seen in the 
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Figure 4.18. Quality of CD8+ T cell responses to gag in the blood of HIV positive donors with 
detectable (n=16) vs. undetectable plasma viral load (n=18) 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in viraemic and aviraemic donors respectively. The y-axis scale 
indicates the absolute percentage (of the total responding cells) that corresponds to a particular 
combination of functions; each blue or red bar represents the interquartile range (IQR) for that 
combination in the viraemic and aviraemic groups respectively, whereas the horizontal solid black 
bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between viraemic and aviraemic donors (Student’s t test). The right lower table shows p 
values when the total responses in the two groups of donors are compared (permutation test). P 
values indicative of statistically significant differences (p<0.05) are highlighted red. However, for the 
comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied to 
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Figure 4.19. Quality of CD8+ T cell responses to gag in the gut of HIV positive donors with 
detectable (n=16) vs. undetectable viraemia (n=18) 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in viraemic and aviraemic donors respectively. The y-axis scale 
indicates the absolute percentage (of the total responding cells) that corresponds to a particular 
combination of functions; each blue or red bar represents the interquartile range (IQR) for that 
combination in the viraemic and aviraemic groups respectively, whereas the horizontal solid black 
bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between viraemic and aviraemic donors (Student’s t test). The right lower table shows p 
values when the total responses in the two groups of donors are compared (permutation test). P 
values indicative of statistically significant differences (p<0.05) are highlighted red. However, for the 
comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied to 
define statistically significant differences (Bonferroni correction). 
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The overall blood CD8+ T cell responses to nef appear to differ significantly in quality 
between the groups with detectable vs. undetectable viral load (Figure 4.20). Similarly to the 
gag responses (Figure 4.18) over 50 percent of the responding CD8+ T cells were 
monofunctional (mainly the IFNγ+IL2-TNFα-CD107- and IFNγ-IL2-TNFα-CD107+ subsets), 
followed by “double positive” (mainly IFNγ+IL2-TNFα-CD107+) and “triple positive” 
(almost exclusively IFNγ+IL2-TNFα+CD107+) CD8+ T cells. No statistically significant 
differences were noted when the individual Boolean combinations were compared; 
polyfunctional cells with four positive functions were only seen in the population of HIV 
positive donors with undetectable plasma viral load. 
Finally, stimulation of gut CD8+ T cells with nef resulted in more polyfunctional responses in 
the aviraemic donor group (Figure 4.21). Once again, monofunctional cells comprised over 
50 percent of the total response in both groups. Double responses were more frequently seen 
in the viraemic group (mainly the IFNγ+IL2-TNFα-CD107+ combination), but CD8+T cells 
with three functions were proportionally higher in the group without detectable viraemia. 
Cells responding with all four functions were exclusively seen in the group of donors with 
undetectable plasma viral load. When the individual Boolean combinations were compared, 
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Figure 4.20. Quality of CD8+ T cell responses to nef in the blood of HIV positive donors with 
detectable (n=16) vs. undetectable viraemia (n=18) 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in donors with detectable and undetectable viral load respectively. 
The y-axis scale indicates the absolute percentage (of the total responding cells) that corresponds to a 
particular combination of functions; each blue or red bar represents the interquartile range (IQR) for 
that combination in the viraemic and aviraemic groups respectively, whereas the horizontal solid 
black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between viraemic and aviraemic donors (Student’s t test). The right lower table shows p 
values when the total responses in the two groups of donors are compared (permutation test). P 
values indicative of statistically significant differences (p<0.05) are highlighted red. However, for the 
comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied to 
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Figure 4.21. Quality of CD8+ T cell responses to nef in the gut of HIV positive donors with 
detectable (n=16) vs. undetectable viraemia (n=18) 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level in donors with detectable and undetectable viral load respectively. 
The y-axis scale indicates the absolute percentage (of the total responding cells) that corresponds to a 
particular combination of functions; each blue or red bar represents the interquartile range (IQR) for 
that combination in the viraemic and aviraemic groups respectively, whereas the horizontal solid 
black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared between viraemic and aviraemic donors (Student’s t test). The right lower table shows p 
values when the total responses in the two groups of donors are compared (permutation test). P 
values indicative of statistically significant differences (p<0.05) are highlighted red. However, for the 
comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied to 
define statistically significant differences (Bonferroni correction). 
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4.4.4 Analysis of CD8+ T cell polyfunctional responses in subgroups of donors naïve 
to antiretroviral treatment 
Among the HIV positive donors recruited for the study of recall responses, there were 
fourteen individuals naïve to antiretroviral treatment (ART) (Table A-1, Appendix). We 
attempted to correlate the quality of CD8+ T cell responses to gag and nef in these donors 
with the blood CD4 count, the plasma viral load (VL) and the length of HIV diagnosis. We 
used 400 cells/µL as a cut-off value to divide the group into 6 donors with low and 8 donors 
with high CD4 count. This cut-off value is close to 350 cells/µL which is currently 
considered the threshold below which antiretroviral treatment should be commenced 
(Gazzard 2008). The cut-off value for VL was 10,000 copies/ml, which divided the ART-
naïve donors into 8 with low and 6 with high plasma VL. Finally, the group was divided into 
7 donors with a short duration of infection (time from diagnosis ≤ 2 years) and 7 donors with 
long duration of infection (time from diagnosis > 2 years). 
Comparison of gag responses between the subsets of ART-naïve donors (as defined above) 
showed these to be of similar quality irrespective of CD4 count, viral load or length of the 
infection (Figure 4.22); all gag responses were predominately monofunctional, followed by 
cells expressing two and three functions. When nef responses were studied, there was a trend 
towards more polyfunctional responses in donors with lower CD4 counts, lower viral loads 
and longer duration of the infection; those demographic characteristics were associated with a 
dominant responding cell population expressing two functions, as well as a significant 
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Figure 4.22. Quality of CD8+ T cell responses to gag and nef in subgroups of ART-naive HIV 
positive donors in the blood. 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the number of functions simultaneously expressed at the single cell level. The 1st row 
shows comparisons between 2 groups divided on the basis of blood CD4 counts; in the 2nd row, 
donors are divided based on the level of plasma viraemia, whereas in the 3rd row the two groups 
consist of patients with short and long duration of infection. The 1st and 2nd columns from the left 
show responses to gag, whereas the last two show responses to nef. N values show the numbers of 
donors in each group. 
 
When similar correlations were made in the mucosal compartment (Figure 4.23), gag 
responses had a tendency towards more triple positive CD8+ T cells in the group with lower 
CD4 counts, higher viral loads and shorter duration of the infection; the same demographic 
characteristics were also predictive of more polyfunctional nef responses; in the case of nef, a 
small fraction of cells positive for all four functions was exclusively seen in these three 






































Figure 4.23. Quality of CD8+ T cell responses to gag and nef in subgroups of ART-naive HIV 
positive donors in the mucosal compartment. 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the number of functions simultaneously expressed at the single cell level. The 1st row 
shows comparisons between 2 groups divided on the basis of blood CD4 counts; in the 2nd row, 
donors are divided based on the level of plasma viraemia, whereas in the 3rd row the two groups 
consist of patients with short and long duration of infection. The 1st and 2nd columns from the left 
show total responses to gag, whereas the last two show responses to nef. N values show the numbers 
of donors in each group. 
 
4.4.5 Analysis of CD8+ T cell polyfunctional responses in subgroups of donors on 
antiretroviral treatment 
Subsequently, the group of patients on ART was studied for possible correlations between 
CD4 counts, degree of immune reconstitution or duration of ART with the quality of the 
CD8+ T cell responses in the blood and gastrointestinal mucosa. Out of the 21 donors on ART 
(Table A-1, Appendix), 2 were excluded from the analysis as they were failing to suppress 
viraemia despite treatment (R300 and S652). The remaining 19 donors were divided into 12 
patients with high CD4 counts (>500cells/µl) and 7 with low counts (<500cells/µl). A second 
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classification was based on the degree of immune reconstitution after suppressive ART; this 
was determined for each patient by subtracting the nadir CD4 count from the most recent 
measurement whilst on treatment; these patients were then divided into those whose CD4 
count increased by over 300cells/µl with suppressive ART (n=9) and those who had a less 
than 300cells/µl increment with treatment (n=7). A third classification was based on the 
duration of ART (7 donors were treated for less than 2 years, whereas 11 have had ART for a 
longer period of time). 
The quality of the overall CD8+ T cell response to gag and nef in the blood was compared in 
the above subgroups of ART-treated donors (Figure 4.24). When gag responses were 
analysed, there was a significant trend towards more complex polyfunctional responses with 
better level (i.e. CD4>500cells/µl) and degree of immune reconstitution (i.e. increase in CD4 
count of over 300cells/µl with ART). Over three quarters of responding cells in the group 
with CD4<500cells/µl were monofunctional, followed by less than 10 percent double positive 
and very few triple positive cells. In contrast, responses in the group of patients with CD4 
count>500cells/µL, whilst still mostly monofunctional (over 30 percent), consisted of 30 
percent triple positive cells, 25 percent double positives and a small proportion of cells 
positive for all four functions. Similarly, patients who had a less than 300 cells/µL increase in 
CD4 count with suppressive ART had a dominant monofunctional response, followed by 25 
percent triple positive and 20 percent double positive cells, whereas in the group with better 
reconstitution the responses tended to be more enriched in double and triple positive cells; 
finally, a small percentage of cells positive for all cytokines and degranulation was found 
exclusively in the group with better degree of CD4 immune reconstitution. When the group 
of treated patients was divided based on duration of ART, patients treated for less than 2 
years had predominantly triple positive gag responses, as opposed to patients with longer 
duration of treatment (mostly monofunctional). Interestingly, no such trends (i.e. better 
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quality of response with better reconstitution and shorter duration of ART) were identified in 
the analysis of nef responses, which were mostly concordant across all subgroups compared. 
Of note, small percentage of quadruple-positive nef responding cells were exclusively seen in 
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Figure 4.24. Quality of CD8+ T cell responses to gag and nef in the blood compartment in 
subgroups of HIV positive donors on antiretroviral treatment. 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the number of functions simultaneously expressed at the single cell level. The 1st row 
shows comparisons between 2 groups divided on the basis of blood CD4 counts; in the 2nd row, 
donors are divided based on the degree of immune reconstitution after suppressive ART (see text), 
whereas in the 3rd row the two groups consist of patients with short and long duration of 
antiretroviral treatment. The 1st and 2nd columns from the left show total responses to gag, whereas 
the last two show responses to nef. N values depict the numbers of donors in each group. 
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When mucosal responses to gag and nef were analysed in HIV positive donors on ART in the 
subgroups defined above, those were found to be almost exclusively monofunctional, with 
only very small proportions of double and triple positive responding cells (Figure 4.25). This 
is in sharp contrast to the blood responses in patients on ART (Figure 4.24), which show 
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Figure 4.25. Quality of CD8+ T cell responses to gag and nef in the mucosal compartment in 
subgroups of HIV positive donors on antiretroviral treatment. 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the number of functions simultaneously expressed at the single cell level. The 1st row 
shows comparisons between 2 groups divided on the basis of blood CD4 counts; in the 2nd row, 
donors are divided based on the degree of immune reconstitution after suppressive ART (see text), 
whereas in the 3rd row the two groups consist of patients with short and long duration of 
antiretroviral treatment. The 1st and 2nd column from the left show total responses to gag, whereas the 
last two show responses to nef. N values show the numbers of donors in each group. 
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4.4.6 Analysis of polyfunctional responses of CD8+ T cells in the duodenum vs. the 
colon of HIV positive donors 
Study of the group of HIV positive individuals who provided parallel duodenal and colonic 
samples showed that the magnitude of the single responses to FEC, gag and nef may differ 
significantly in those two compartments (4.3.4, Figures 4.7-4.8). In this section, the overall 
quality of the CD8+ T cell response in those two distinct gut compartments is studied and 
analysed for possible differences. 
Approximately three quarters of the FEC-specific CD8+ responding cells in the duodenum are 
monofunctional (mainly positive for IFNγ or CD107), followed by cells expressing two 
functions (IFNγ and CD107) (Figure 4.26). There is also a small fraction of responding cells 
expressing three functions (IFNγ, TNFα and CD107). In the colon, 50 percent of the 
responses are monofunctional (mostly IFNγ or CD107), followed by cells expressing three 
and two functions (approximately 20 percent of the total response for each category). In 
contrast to the duodenal response, there is a small proportion of antigen-specific CD8+ T cells 
which expresses all four functions in response to FEC stimulation. Comparison of the 
individual Boolean combinations between the duodenum and colon shows that the 
subpopulations of IFNγ+IL2+TNFα+CD107+, IFNγ+IL2-TNFα+CD107+, IFNγ+IL2-TNFα-
CD107+, IFNγ+IL2-TNFα+CD107-, IFNγ-IL2-TNFα-CD107+ and IFNγ+IL2-TNFα-CD107- are 
more frequently seen in the colon; however, the differences in the above populations do not 






























































































Figure 4.26. Quality of CD8+ T cell responses to FEC in the duodenum vs. the colon in HIV positive 
donors (n=8). 
The solid blue and red bars represent all 15 possible combinations of the 4 functions expressed at the 
single cell level in the duodenum and colon respectively. The y-axis scale indicates absolute 
percentages (of the total responding cells); each blue or red bar represents the interquartile range 
(IQR) for a Boolean combination, whereas the horizontal solid black bars denote median values. 
The colour-coded pie charts represent the total responding cells and the 4 different coloured slices 
correspond to the fraction of responding cells expressing four, three, two or one functions 
simultaneously. 
The right top table shows p values when the 15 combination functions are compared between the 2 
compartments (Wilcoxon matched pairs test). The right lower table shows p values when the total 
responses in the 2 compartments (blood and gut) are compared with each other (permutation test). 
P values indicative of statistically significant differences (p<0.05) in both tables are highlighted red. 
 
The differences between duodenum and colon in the quality of the CD8+ response to FEC were 
also studied for each individual donor (Figure 4.27). In the group of eight patients with samples 
from both sites, six had more polyfunctional responses in the colon (O420, S652, B530, C220, 
W623 and J5220); in the other two donors (C600 and M240), the flavour of the response was 
very similar in the two gut compartments. Of note, cells expressing all four functions are almost 
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Figure 4.27. Quality of CD8+ T cell responses to FEC in the duodenum vs. the colon of the HIV 
positive donors with samples from both sites (n=8). 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the numbers of functions simultaneously expressed at the single cell level. The eight pie 
charts in the upper row represent duodenal responses for the eight individual donors, whereas the 
corresponding pie charts in the lower row represent colonic responses. 
 
When the gag CD8+ T cell responses in the two gut compartments were analysed (Figure 
4.28), the overall flavour was similar (p=0.167 for the comparison). Although a few Boolean 
combinations were over-represented in the duodenum compared to the colon (IFNγ+IL2-
TNFα-CD107+, IFNγ-IL2-TNFα-CD107+ and IFNγ+IL2-TNFα-CD107-), those differences 
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Figure 4.28. Quality of CD8+ T cell responses to gag in the duodenum vs. the colon in HIV positive 
donors (n=8). 
The solid blue and red bars represent all 15 possible combinations of the 4 functions expressed at the 
single cell level in the duodenum and colon respectively. The y-axis scale indicates absolute 
percentages (of the total responding cells); each blue or red bar represents the interquartile range 
(IQR) for a Boolean combination, whereas the horizontal solid black bars denote median values. 
The colour-coded pie charts represent total responding cells and the 4 different coloured slices 
correspond to the fraction of responding cells expressing four, three, two or one functions 
simultaneously. 
The right top table shows p values when the 15 combination functions are compared between the 2 
compartments (Wilcoxon matched pairs test). The right lower table shows p values when the total 
responses in the 2 compartments (blood and gut) are compared with each other (permutation test). 
P values indicative of statistically significant differences (p<0.05) in both tables are highlighted red. 
 
Subsequently, the differences in the gag CD8+ T cell response between duodenum and colon 
were studied for each of the eight individual donors (Figure 4.29). The duodenal CD8+ 
response was more polyfunctional than the colonic in five of those individuals (S652, C600, 
B530, C220 and W623); in the other three donors (O420, M240 and J522) the opposite was 
true, with the colonic response being more complex and including a significant proportion of 
cells positive for three functions. 
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Figure 4.29. Quality of CD8+ T cell responses to gag in the duodenum vs. the colon of the HIV 
positive donors with biopsies from both sites (n=8). 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the number of functions simultaneously expressed at the single cell level. The eight pie 
charts in the upper row represent duodenal responses for the eight individual donors, whereas the 
corresponding pie charts in the lower row represent colonic responses. 
 
Finally, the flavour of the response to nef in the duodenum and colon was analysed in the 
small cohort of individuals with samples from both mucosal sites (Figure 4.30). As evident 
from the pie charts, the duodenal nef response consists of a significantly larger proportion of 
cells with three and two functions compared to the colonic response. Also, exclusively in the 
duodenum, a small population of cells expressing all four functions can be identified. The 
difference in the total responses in the two compartments is statistically significant (p=0.023). 
Comparison of the Boolean combinations of functions between the duodenum and colon 
shows that, although there is a trend towards more frequent representation of the IFNγ+IL2-
TNFα-CD107+, IFNγ-IL2-TNFα-CD107+ and IFNγ+IL2-TNFα-CD107- subpopulations in the 




















































































Pie Category Test Results




Figure 4.30. Quality of CD8+ T cell responses to nef in the duodenum vs. the colon in HIV positive 
donors (n=8). 
The solid blue and red bars represent all 15 possible combinations of the 4 functions expressed at the 
single cell level in the duodenum and colon respectively. The y-axis scale indicates absolute 
percentages (of the total responding cells); each blue or red bar represents the interquartile range 
(IQR) for a Boolean combination in the HIV positive donor group, whereas the horizontal solid black 
bars denote median values. 
The colour-coded pie charts represent the total responding cells and the 4 different coloured slices 
correspond to the fraction of responding cells expressing four, three, two or one functions 
simultaneously. 
The right top table shows p values when the 15 combination functions are compared between the 2 
compartments (Wilcoxon matched pairs test). The right lower table shows p values when the total 
responses in the 2 compartments (blood and gut) are compared with each other (permutation test). 
P values indicative of statistically significant differences (p<0.05) in both tables are highlighted red. 
 
When the individual patients’ nef responses were compared between duodenum and colon 
(Figure 4.31), six donors had more polyfunctional duodenal responses (S652, C600, B530, 
C220, W623 and J522); in one individual (M240), the opposite was true, whereas in another 
one (O420) there were 100 percent monofunctional responses in both gut compartments. 
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Figure 4.31. Quality of CD8+ T cell responses to nef in the duodenum vs. the colon of the HIV 
positive donors with biopsies from both sites (n=8). 
The colour-coded pie charts represent the total responding cells and the 4 different colours 
correspond to the number of functions simultaneously expressed at the single cell level. The eight pie 
charts in the upper row represent duodenal responses of the eight individual donors, whereas the 
corresponding pie charts in the lower row represent colonic responses. 
148 
4.5 Discussion 
4.5.1 Summary of findings 
This study describes the magnitude and quality of the CD8+ T cell responses to gag and nef in 
the blood and gastrointestinal mucosa of HIV positive donors. Comparison of the responses 
between compartments indicates that those are significantly higher in the mucosa for all four 
functions analysed here (IFNγ, IL-2, TNFα and CD107). No differences where seen when 
gag responses were compared between the groups with detectable vs. undetectable plasma 
viraemia in either blood or mucosal compartments; however, nef responses were significantly 
higher in the mucosa of vireamic donors, whereas no differences were seen in the blood. In 
the small group of donors with parallel duodenal and colonic samples, FEC responses were 
significantly higher in the colonic mucosa; in contrast, gag and nef IFNγ and CD107 
responses were significantly higher in the duodenum. 
When the functional profile of CD8+ T cells was studied, FEC responses were significantly 
more polyfunctional in the blood, whereas no differences were seen for either gag or nef. 
Comparison of the responses between the groups with detectable vs. undetectable plasma 
viraemia showed consistently better quality of response in the group with undetectable 
circulating virus across both compartments (blood, gut) and stimuli (gag, nef). 
Correlation studies in the groups of ART naïve and treated donors, whilst statistically 
underpowered, showed a trend towards better preserved polyfunctional responses in the blood 
(but not the gut) in treated individuals with better immune reconstitution and shorter duration 
of treatment. Finally, comparison of the response profile between duodenum and colon in the 
group of donors with parallel samples showed the nef responses to be significantly more 
polyfunctional in the duodenum, whereas no statistical difference was observed in the gag 
and FEC responses. 
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4.5.2 Implications of study findings 
4.5.2.1 Recall immune responses in blood and gut 
The primary aim of our study was to compare the immune responses in the blood and 
mucosa; strong correlation between the CD8+ responses in blood and gut would justify the 
use of blood CD8+ T cells as surrogates for the study of mucosal immune responses. The 
advantage of this approach is that obtaining blood samples is relatively uncomplicated, less 
invasive and safer compared to mucosal sampling, especially when candidate immunogens 
are tested in large-scale vaccine trials. Analysis of single CD8+ T cell antigen specific 
immune responses to HIV peptides in blood and gut in the group of HIV positive donors 
showed statistically significant differences between compartments, with higher magnitude 
responses in the gut after stimulation with either gag of nef. This is in keeping with previous 
reports showing differences between blood and gut mucosal CD8+ memory responses 
(Guadalupe et al. 2006; Critchfield et al. 2007; Ferre et al. 2009). Furthermore, the responses 
did not seem to differ significantly between individuals with detectable viraemia and those 
with suppressed viral replication in the blood. This finding may add support to the notion that 
continuous exposure to antigen in the bloodstream (as in the case of individuals with 
detectable viraemia) is not the main factor driving the CD8+ T cell recall responses. In 
contrast to the above finding, lack of viral suppression seems to be associated with higher 
magnitude of CD8+ responses to nef in the gut mucosa and, to a lesser extent, higher gag 
responses in that compartment. It is debatable whether such responses provide any degree of 
control of viral replication in the gastrointestinal mucosa. Indeed, one of the outcomes of the 
RV144 study was that no superior control of viraemia was seen in the group of vaccinated 
individuals who acquired the infection compared to infected unvaccinated patients (Berkhout 
et al. 2009); the interpretation of this finding is hindered by the fact that the mucosal CD8+ T 
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cell responses to gag or nef were not examined in the study participants, either at baseline or 
post-vaccination. 
Polychromatic flow cytometry can characterise T cell subsets based on the expression of 
surface markers and the identification of multiple functions, such as intracellular production 
of cytokines and expression of cytotoxic enzymes (Chattopadhyay et al. 2005). It also allows 
the identification of cytokine patterns at the single cell level and hence the characterisation of 
the quality of the response. These complex response patterns and the presence of 
“polyfunctional “ CD8+ T cells have been identified as possible correlates of protection in 
HIV-1 infection (Betts et al. 2006), as well as in vaccine trials for other pathogens (Precopio 
et al. 2007). 
From the analysis of polyfunctional responses in blood and gut in the group of HIV positive 
donors, there was no difference in the flavour of the response (to either gag or nef) between 
compartments, despite significant differences in the magnitude of single responses. 
Interestingly, when the quality of CD8+ response was compared between viraemic individuals 
and those without detectable plasma viral load, the latter group consistently showed 
significantly more polyfunctional responses across compartments (for both gag and nef). This 
is to some degree surprising, since the study of single responses showed higher magnitude 
nef (and to a lesser extend gag) mucosal responses in the viraemic donors. In view of the fact 
that the frequency of polyfunctional responses is considered a correlate of immune 
protection, this discordance between “superior” quality and magnitude of single immune 
responses questions the validity of the currently used consensus read-outs in vaccine efficacy 
trials. Indeed, the IFNγ ELISPOT assay is currently used as the main screening tool in HIV-1 
vaccine trials, despite data showing weak correlation between the magnitude of the elicited 
IFNγ response and vaccine efficacy (Salmon-Ceron et al. ; Vasan et al. ; McElrath et al. 2008; 
Streeck et al. 2009). There are advantages in using ELISPOT as a screening tool, such as low 
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cost, extensive validation, very low limit of detection (Schmittel et al. 1997); however, given 
the shift of focus to mucosal responses and the additional advantages of PFC (i.e. the ability 
to assess response profiles of different cytokines at the single cell level), perhaps the role of 
ELISPOT in future candidate vaccine immunogenicity studies should be re-evaluated. 
The main responses observed in CD8+ T cell populations in this study were and IFNγ and 
CD107, whereas IL-2 responses were negligible, in keeping with similar reports. Critchfield, 
Lemongello et al as well as Critchfield, Young et al examined five different functions in rectal 
CD8+ T cells and observed strong IFNγ, CD107 and MIP-1b responses; the TNFα response 
was much less prominent and the IL-2 response virtually nonexistent (our panel did not include 
the chemokine MIP-1b). Betts et al also found that IFNγ, CD107 and MIP-1b responses in the 
blood were much higher than TNFα, whereas IL-2 responses were scarce and of low 
magnitude. In a recent study comparing blood and rectal mucosa in HIV controllers, Ferre et al 
observed more polyfunctional CD8+ responses in the rectal mucosa of controllers, but very low 
IL-2 production (Ferre et al. 2008). Although IL-2 is generally not considered an effector 
cytokine, there is evidence that it sustains superior “quality“ central memory CD8+ T cells in 
several disease models and as such is associated with better disease control (Makedonas et al. 
2006; Darrah et al. 2007). IL-2 production by memory CD8+ T cells in response to peptide 
stimulation has been associated with superior control of viral replication and “long-term non-
progressor” status (Potter et al. 2007; Emu et al. 2008; Pereyra et al. 2008). 
4.5.2.2 T cell immune responses in the duodenum and colon 
The gastrointestinal tract consists of diverse organs, such as the oral mucosa, the oesophagus, 
stomach, small bowel (further subdivided into duodenum, jejunum and ileum) and the colon. 
Biopsies obtained in this study were from the second part of the duodenum in donors 
undergoing an oesophago-gastro-duodenoscopy (OGD) and from the sigmoid colon 
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(approximately 25 cm from the anal verge) in those having a colonoscopy or a flexible 
sigmoidoscopy. These two areas differ significantly in many aspects; the small bowel mucosa 
consists of vast numbers of villae, which dramatically increase the surface area, thus 
facilitating absorption of nutrients; such structures are absent in the colon. Furthermore, the 
small bowel lumen with its contents is practically sterile, in contrast to the colon where there 
is an abundance of commensal bacteria in close proximity to the mucosa. Interestingly, 
studies of recall responses to HIV peptides in the duodenum have been largely absent; one 
study of a total of three HIV infected individuals reports the presence of duodenal cytotoxic 
lymphocytes specific for HIV-1 in one individual (Shacklett et al. 2000). 
In view of the above-described differences between those two mucosal sites, CD8+ T cells 
recall responses to gag and nef were studied separately in those and compared between sites. 
Given the variability in the magnitude of responses in HIV infected individuals, only parallel 
duodenal and colonic samples obtained from the same donor in the same day were compared. 
The size of this cohort (n=8) was small, since they had to be selected exclusively from 
individuals referred for two endoscopic procedures as part of their clinical care. These 
limitations notwithstanding, there were differences between duodenum and colon in the size 
of the single responses. Colonic CD8+ T cell memory responses to FEC were significantly 
higher for all four functions (IFNγ, IL-2, TNFα and CD107) compared to duodenal CD8+ 
responses. When the HIV-1 specific responses were studied, the IFNγ and CD107 responses 
to gag as well as the IFNγ response to nef were significantly higher in the duodenum. 
Comparison of the response quality between duodenum and colon for nef showed a 
significantly more polyfunctional response in the duodenum, whereas the data for gag 
showed marked differences in individual patients but overall similar response flavour in the 
two compartments. 
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Although larger scale comparison studies would be needed to establish different patterns of 
HIV-1 specific responses in the small and large bowel, the data presented here show that such 
differences exist and thus add a further layer of complexity in the assessment of mucosal 
responses, especially in the context of HIV vaccine trials. 
4.5.2.3 Immune correlates of control of viral replication 
Several correlates of immune protection for HIV-1 have been suggested, such as proliferative 
ability (Migueles et al. 2002; Horton et al. 2006) and polyfunctionality (Boaz et al. 2002; 
Betts et al. 2006; Almeida et al. 2007). Here we attempted to correlate several clinical and 
laboratory parameters in ART naïve as well as treated individuals with the functionality of 
CD8+ T cell response in either the blood or gut mucosa. The data presented here are 
preliminary and lack statistical power due to the small numbers of patients in each group. 
With these limitations in mind, data from patients treated with suppressive ART show more 
polyfunctional responses with better degree of immune reconstitution; responses also were 
better preserved (more polyfunctional) in the first 2 years of post commencement of ART. 
The same pilot data show no association of polyfunctionality with plasma viral load, CD4 
count and duration of treatment in the ART naïve group. Larger scale clinical trials would be 
needed to confirm these correlations and further study the role of antiretroviral treatment in 
maintaining and restoring the quality of CD8+ recall responses to HIV-1. 
4.5.3 Novel aspects, limitations of the study and future work 
In contrast to the rectum and colon, studies of duodenal CD8+ T cell recall responses to HIV-
1 have been largely absent. One such report describes the presence of duodenal cytotoxic 
lymphocytes specific for HIV-1 in one individual out of a total of three studied (Shacklett et 
al. 2000). Our study is the first to characterise in detail the gag and nef recall responses in a 
cohort of HIV positive donors using a qualified flow cytometry method. The responses to the 
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antigen-specific positive control FEC in the duodenal compartment are also described and 
compared to the blood. Study of small bowel recall responses is of particular importance in 
the study of mucosal defences against HIV; although the small bowel mucosal surfaces are 
not a point of entry of the virus, the total small bowel lymphoid tissue is several times larger 
than of the colon and serves as a reservoir for continuous viral replication. Knowledge of the 
quantity and quality of CD8+ responses in the small bowel would be the first step in 
understanding local antiviral immune defences as well as the mechanisms used by the virus to 
evade the immune system in that compartment. 
The present study addresses for the first time the differences in CD8+ T cell recall responses 
between small bowel and colon. Although limited by the small number of study participants 
providing parallel samples from both sites, the pilot data here show more robust and 
polyfunctional nef responses in the duodenum compared to the colon, whereas the opposite is 
true for the memory responses to FEC; gag responses appear to be of similar quality in the 
two compartments but of higher magnitude in the duodenum. Of interest, there are significant 
differences in response quality between duodenum and colon in several study participants, 
whereas responses are very similar in others. Understanding the mechanisms behind those 
differences (i.e. level of immune activation/exhaustion in each mucosal site, antigenic burden 
etc) will help in finding ways to preserve and potentiate these responses. 
Another novel aspect of this study is the analysis of the quality of blood and gut CD8+ T cell 
responses to nef. This protein is an important virulence factor for all lentiviruses and there are data 
to support its role in accelerating the progression of HIV infection (Piguet et al. 1999; Arien et al. 
2008). It is produced in large quantities at the early stages of infection (Cullen 1994) and is capable 
of downregulating cell surface CD4 (Garcia et al. 1992; Aiken et al. 1994), as well as MHC class I 
molecules (Schwartz et al. 1996; Piguet et al. 2001), thus facilitating evasion of cytotoxic T cell 
responses; these properties make nef theoretically an attractive target for HIV vaccines. 
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In the previous Chapter, we established a flow cytometry-based method for assessment of blood 
and mucosal immune responses. Furthermore, we established individual thresholds for each 
cytokine examined in each compartment. These stringent criteria were focused on the need to 
make a definitive distinction between a positive and negative response; this is an essential 
distinction in the context of assessing the immunogenicity of candidate vaccines in a population 
of healthy volunteers. The objective of this study (current Chapter), however, has shifted to the 
comparison of responses between compartments. Here, the HIV status of all donors is known and 
therefore, no responses were excluded based on the positivity thresholds established in Chapter 3. 
Still, positive HIV peptide responses had to be at least twice the magnitude of mock (negative 
background) and all cytokine response values in this Chapter were also background-subtracted; 
where the result of such subtraction was a negative number (i.e. mock response values higher 
than HIV peptide responses in an individual patient and compartment), that response value was 
arbitrarily set to zero. For the analysis of polyfunctional responses, the currently available 
software (SPICE) would not allow for different threshold values settings for different parameters. 
In keeping with the literature on polyfunctional responses using SPICE as a visualization tool, 
where threshold values extremely close to zero were used to offset the bias resulting from zeroing 
only negative background-subtracted responses (Precopio et al. 2007; Duvall et al. 2008), the 
threshold was set to 0% for the current study. 
Another limitation of the current study is in the classification of HIV positive individuals as 
viraemic or aviraemic on the basis of the presence or absence of detectable plasma viraemia. 
The plasma viral load was then used as a surrogate for the presence and degree of virus in the 
mucosal milieu. However, the Gut-Associated Lymphoid Tissue (GALT), which contains by 
far the largest pool of CD4+ T cells susceptible to HIV-1 infection, has emerged as a major 
viral reservoir, with persistent ongoing replication even in the face of apparently successful 
suppressive ART (Poles et al. 2006; Chun et al. 2008). Therefore, although it plausible that 
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the HIV-1 antigenic burden in the mucosa would to an extent reflect the presence or absence 
of actively replicating virus in the plasma, this association may not always follow a specific 
pattern. Perhaps in future studies semi quantitative methods of assessing the “mucosal viral 
load”, such as immunohistochemistry (IHC) for p24 or other HIV-1 antigens, would provide 
a more accurate picture of the degree of exposure (continuous or intermittent) of the gut 
immune system to replicating HIV-1. 
As stated elsewhere in the present Chapter, the correlations between several immunological 
or demographic parameters with the quality of CD8+ T cell responses to gag and nef are only 
preliminary observations, which will need to be confirmed in larger scale clinical trials. 
Similarly, the differences in immune responses between duodenum and colon would also 
need to be further studied in larger cohorts of donors. 
4.5.4 Conclusions 
This study has described the comparison of CD8+ T cell recall immune responses to HIV-1 
peptides in the blood and gastrointestinal mucosa. In addition, comparisons of such responses 
between different sites of the mucosal immune system were presented here. Limited pilot 
data on correlation between immunological parameters and response quality are also shown 
in this study. Blood and gut responses are not always concordant and assessment of the 
former has been shown to be an inadequate surrogate for the study of the mucosal immune 
system. Furthermore, significant differences exist between small bowel and colonic 
responses, thus making the characterisation of mucosal antiviral responses more complex. 
Another important finding is the discrepancies between quality and magnitude of responses 
observed in several comparisons across compartments and stimuli, underlying the fact that 
assessment of single cytokine responses may prove to be of limited usefulness in identifying 
correlates of immune protection 
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The gastrointestinal immune system plays a vital role in the antiviral defences against HIV, 
since it contains a significantly larger number of immune cells compared to the blood and 
also constitutes the first line of defence against viral transmission. Undoubtedly, attempts to 
assess the immunogenicity of candidate mucosal vaccines will continue and probably 
intensify in the foreseeable future. The present study emphasizes the need for mucosal 
sampling in order to accurately assess candidate vaccines ; it also suggests that currently used 
single cytokine read-outs (such as IFNγ ELISPOT) may be of limited value and that 
polychromatic flow cytometry may have an important role in this context. 
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Chapter 5 Surface phenotypes and expression of cytolytic 
enzymes in blood and mucosa in HIV-1 infection 
5.1 Introduction 
The previous chapter discussed antigen specific CD8+ T cell responses to HIV-1 in the blood 
and gut. CD8+ T cells eliminate virus-infected cells through recognition of peptide antigens 
presented in the context of major histocompatibility complex (MHC)-1 by the T cell receptor 
(TCR). Cytotoxic lymphocytes (CTLs) and innate immune cells share a common pathway 
that mediates target cell lysis, namely the secretory granule-mediated cell death pathway 
(described in 1.1.4.1), of which major components are the cytolytic enzymes granzyme B and 
perforin. This pathway involves the formation of an immunological synapse between effector 
and target cells, with resulting release of lytic enzymes into the cytoplasm and initiation of 
apoptotic signals (Voskoboinik et al.). 
Historically, the “gold standard“ for assessment of a cell’s cytotoxic potential has been the 
chromium (51Cr) release assay (Brunner et al. 1968); alternative methods based on the release 
of fluorescent dyes from target cells have been more recently described (Sheehy et al. 2001). 
The surface expression of CD107 upon antigenic stimulation (studied in the previous chapter) 
provides an alternative to MHC-1 tetramer staining in defining antigen-specific memory 
populations (Betts et al. 2003). However, the ability of CTLs to degranulate cannot be used as 
a surrogate marker of cytotoxicity, as it does not provide any information about the contents 
of those granules. This notion is supported by the following observations: although all 
lymphocytes express CD107 intracellularly, only a minority of them contain pre-formed 
perforin in their cytoplasm (Betts et al. 2003). Even though antigen-specific cells transiently 
expressing CD107a on their surface after peptide stimulation were found to have little or no 
perforin in the cytoplasm, it is still impossible to draw conclusions regarding the pre formed  
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or de novo perforin contents of those cells in the resting state (Betts et al. 2003). Furthermore, 
considerable heterogeneity within the antigen specific population for CMV pp65 protein was 
described in humans, with most of these cells staining negative for perforin and positive for 
granzyme B (Sandberg et al. 2001). In this study, intracellular perforin, IFNγ, TNFα and IL-2 
expression were found to be largely segregated; they are also closely related to the expression 
of memory markers on the surface of CD8+ T cells, with perforin expressing cells generally 
confined (but not entirely limited) to the CD27- CD45RO- (terminally differentiated) 
population. The recent suggestion of a separate mechanism (other than cytotoxic granule 
exocytosis) by which newly-synthesized perforin reaches the immunological synapse after 
stimulation of antigen-specific cells argues against an association between surface CD107 
expression and cytolytic enzyme contents in resting CTLs (Makedonas et al. 2009). Finally, 
the importance of early engagement and efficient activation of the secretory granule pathway 
in controlling viral replication was demonstrated in a vaccination trial of rhesus macaques 
with either heterologous prime-boost vaccinations (combinations of DNA, adenovirus and 
poxvirus recombinants) or live-attenuated SIV (Rollman et al. 2007); the latter strategy which 
is accepted as more efficient in controlling early viraemia in macaques (Daniel et al. 1992; 
Koff et al. 2006) was associated with high levels of expression of CD107 and granzyme B 
release, but little IFNγ. In contrast, nearly all primates receiving prime boost vaccination 
expressed IFNγ in all antigen specific CD8+ T cells. These results suggest that vaccine 
mediated protection may not always correlate with levels of IFNγ expression and that 
assessment of the killing capacity of CTLs could be essential in assessing T cell-based 
vaccine efficacy. It is therefore important to study different components of the secretory 
granule pathway as potential correlates of immune protection in HIV-1 infection and to 
determine if there is an association between secretory granule proteins and IFNγ expression 
after stimulation, since this cytokine is commonly used at the “gold standard” readout in 
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vaccine efficacy studies in humans and non-human primates (NHP)(Maecker et al. 2001; 
Dale et al. 2004). 
We therefore hypothesised that the magnitude of CD107 and IFNγ CD8+ recall responses to 
gag and nef would be proportional to the frequency of effector memory CD8+ T cells in the 
blood and mucosa of HIV infected individuals; furthermore, we hypothesised that the above 
recall responses would correlate with the frequency of expression of granzyme B and perforin 
in the CD8+ T cell population, since those are mainly secreted by effector memory antigen-
specific CTLs upon antigenic encounter. In this context, the aims of this study are as follows: 
● To characterise the memory phenotypes of CD8+ T cells in blood and gut in the 
groups of controls and HIV positive donors, as well as compare those between HIV 
positive donors with undetectable and detectable plasma viraemia. 
● To characterise the intracellular distribution of granzyme B and perforin in the above 
groups of donors. 
● To compare memory subsets and cytolytic enzyme levels in the mucosa of small 
bowel vs. colon. 
● To correlate the magnitude of CD107 and IFNγ recall responses to gag and nef with 
the frequencies of memory subsets in blood and gut, in the group of HIV positive 
donors in whom both these sets of parameters were studied. In the same group of 
donors, we will seek possible correlations between the magnitude of those recall 
responses to gag and nef and the ex vivo expression of granzyme B and perforin. 
5.2 Patient characteristics 
38 controls and 46 HIV positive donors provided samples for this study. All of those samples 
were used for the surface phenotyping part of the study (5.3.1). For the analysis of memory 
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subsets and intracellular expression of granzyme B and perforin in blood and gut (5.4.1), a 
fraction of those samples were used; specifically, 16 control individuals (1 to 16, Table A-2, 
Appendix) and 37 HIV positive donors (1 to 37, Table A-3, Appendix) provided blood and 
gut samples for this part of the study. For the comparison of memory phenotypes and 
granzyme B and perforin expression in the duodenum and colon (5.5.1), 8 parallel pairs of 
samples from both mucosal sites were used (Table 4.3). Finally, 26 patients who provided 
samples both for the study of recall responses (Chapter 4) as well as for memory phenotyping 
and granzyme B/perforin expression were used for the study of potential correlations between 
those sets of parameters (Table A-4). 
The demographic characteristics of the 38 control donors participating in this study and the 
clinical indications for endoscopy are summarized in Table 5.1. The median age was 40 years 
for the control group (IQR: 30.75-44). There were 21 female and 17 male donors. 22 patients 
had a colonoscopy, 13 had an OGD and 3 had a flexible sigmoidoscopy. The group of control 
donors consisted exclusively of patients with macroscopically normal mucosa; of those 
patients, diagnostic biopsies were taken in 24 and were all reported as normal. 
The demographic characteristics of the 46 HIV positive donors are summarised in Table 5.1. 
The median age was 41.5 years (IQR 33.75-47). There were 6 female and 40 male donors. 7 
patients had a colonoscopy, 5 had a flexible sigmoidoscopy, 25 had an oesophago-
gastroduodenoscopy (OGD), 6 had both OGD and colonoscopy and 3 had a combination of 
OGD and flexible sigmoidoscopy. In the group of HIV positive donors, one individual 
(M535) had clinically and histologically infectious proctitis; however, the research biopsy 
samples were obtained from a more proximal area of macroscopically normal mucosa. 
The age distribution was similar in the groups of healthy controls, HIV positive donors on 
ART and HIV untreated patients. Female patients were underrepresented in both subgroups 
of HIV positive donors; this was due to the demographics of the patient population of the 
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HIV Unit at our institution. The CD4 counts were higher in the group of HIV patients 
receiving ART compared to the untreated donors (median values 544 vs. 408 cells/µL), 
whereas the CD4+ T cell frequencies were similar between those two groups and significantly 
lower than in the controls. As expected, the group of patients on ART had lower CD4 nadir 
values (177 vs. 351.5 cells/µL) and had a diagnosis of HIV-1 infection for a considerably 
longer time (median time from diagnosis to sampling: 7 years, compared with 2 years for the 
group of patients not on ART). 
 
Table 5.1. Summary of the clinical characteristics of the HIV positive (n=46) and control (n=38) 
groups 






Age: Median (IQR) 40 (30.75-44) 42 (34-47) 39 (33-43) 
Sex: Male: n (%) 17 (37%) 25 (80%) 15 (100%) 
CD4 cells/µl: Median 
(IQR) 
NO DATA 544 (399-625) 408 (356-550) 
CD4 %: Median (IQR) 68.7 (60.7-71.7) 48.8 (31.5-62) 46.3 (29-56) 
CD4 nadir cells /µl: 
Median (IQR) 
N/A 177 (66-294) 351.5 (312.5-482.3) 
Viral Load: Median (IQR) N/A 0 (0-0)* 8,143 (1,907-39,878) 
Years since HIV-1 
diagnosis: Median (IQR) 
N/A 7(4-13) 2 (1-6) 
Years on ART: Median 
(IQR) 
N/A 4(1-9.75) N/A 
Years after diagnosis 
before ART: Median 
(IQR) 
N/A 1 (0-4) N/A 
 
* The plasma viral load was arbitrarily set to zero in all individuals with viraemia below the limit of detection 
for the commercially available PCR assay used (<50 copies per ml). 
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5.3 Fluorescent surface immunophenotyping of T cell subsets in the blood 
and gut 
The relative frequencies of CD8+ and CD4+ T cells were studied in the groups of controls and 
HIV positive donors, in both compartments (blood and gut). The frequencies of the above 
populations were expressed as a percentage of viable CD3+ T cells. Surface 
immunophenotyping with these markers identified four subsets of CD3+ cells: CD4+CD8-, 
CD4-CD8+, CD4+CD8+ or “double positive“ (DP) cells and CD4-CD8- or “double negative” 
(DN) cells. In order to ensure that there was no contamination of the CD3+CD4-CD8- with 
gamma-delta+ T cells, an additional gamma-delta T cell exclusion gate was used for the 
immunophenotypic analysis of these cells. The gating strategy implemented is shown in 
Figure 5.1 (representative experiment). 
 
 



















































Figure 5.1. Gating strategy used for the surface immunophenotyping of CD3+ T cells in the blood 
and gut. 
The left gate is a “downregulated CD3+ T cell gate”; this is followed by a CD8 vs. gamma-delta gate, 
including only gamma-delta negative events; these events are then further divided into 4 
subpopulations, based on the expression of CD8 and CD4: a. CD8+CD4-, b. CD8+CD4+ double 
positive (DP), c. CD8-CD4+ and d. CD8-CD4- double negative (DN). The relative frequencies of these 
populations (as percentages of CD3+ cells) are also shown in the graph and, in this particular donor, 
they are as follows: CD8+ 52.8%, DP 0.28%, CD4+ 42.6% and DN 4.39%. 
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Comparison of the relative frequencies of T cell subsets in controls and HIV positives in the 
blood (Figure 5.2) shows that the CD4+ cells are significantly fewer with significantly more 
CD8+ T cells in the HIV positive group. The CD4+CD8+ populations are generally less than 1 
percent of the total CD3+ cells and do not differ significantly between the two groups of 
donors. The CD4-CD8- population is also present in both donor groups and is significantly 




























Figure 5.2. Relative frequencies of CD8+, double positive (DP), CD4+ and double negative (DN) 
cell populations in the blood of controls (n=38) and HIV positive donors (n=46). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the control group whereas the red ones represent similar 
frequencies in the HIV positive group. P values are shown for the comparisons of cell frequencies (for 
all 4 cell groups) between the controls and the HIV positive groups. Where the comparisons show 
statistically significant differences, the p values are in bold numbers (Mann-Whitney U test). 
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Subsequently, similar phenotypic data from the mucosal compartment were analysed. 
Relative frequencies of the CD8+, DP, CD4+ and DN subpopulations in the gut (after 




































Figure 5.3. CD3+ cell subpopulations in the gut: representative plots from a control and an HIV 
positive donor. 
The left plot depicts CD3+ gamma-delta- events from a control donor, further subdivided into 4 
populations based on the expression of CD8 and CD4: a. CD8+ CD4-, b. CD8+CD4+ double positive 
(DP), c. CD8-CD4+ and d. CD8-CD4- double negative (DN). The relative frequencies of these 
populations (as percentages of CD3+ cells) are also shown in the graph and are as follows: CD8+ 
62.2%%, DP 0.43%, CD4+ 7.14% and DN 30.6%. The plot on the right shows similar data from an 
HIV positive donor; here the relative frequencies of the 4 subpopulations are: CD8+ 4%%, DP 
0.57%, CD4+ 15.4% and DN 19.6% 
 
Comparison of the relative frequencies of CD3+ subsets in the mucosal tissue of controls and 
HIV positive patients (Figure 5.4) shows that the CD8+ T cells are significantly higher in the 
HIV group (p<0.0001). The CD4+CD8+ populations are generally less than 1 percent of the 
total CD3+ cells and do not differ significantly between the two groups of donors. There is a 
trend towards higher CD4+ T cell frequencies in the control population, which is not, 
however, statistically significant. Rather surprisingly, there is a significant proportion of 
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CD4-CD8- cells in the gut, which is much higher than that observed in the blood, in both 





























Figure 5.4. Relative frequencies of CD8+, double positive (DP), CD4+ and double negative (DN) 
cell populations in the gut of controls and HIV positive donors. 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the control group whereas the red ones represent similar 
frequencies in the HIV positive group. P values are shown for the comparisons of cell frequencies (for 
all 4 cell groups) between controls and HIV positive donors. Where the comparisons show 






Table 5.2 summarises the relative frequencies of subpopulations of CD3+ cells in the groups 
of controls and HIV positive donors in the blood and gut. 
 
Table 5.2. CD8, CD4 , “double positive” and “double negative” cell frequencies in blood and 
gut of controls and HIV positive donors. 
The median and interquartile range values are shown here. Median values in bold numbers denote 
statistically significant differences (p<0.05) between the groups of controls and HIV positive donors, 
when compared using the Mann-Whitney U test.  
 
 Controls HIV positive 
BLOOD 
CD8 %: Median (IQR)∗ 28.2 (25.5-37.2) 43.8 (36.65-53.7) 
CD4 %: Median (IQR) 68.7 (60.7-71.7) 48.8 (36-59) 
“Double positive” %: Median 
(IQR) 0.37 (0.22-0.69) 0.31 (0.16-0.53) 
“Double negative” %: Median 
(IQR) 2 (1.7-3.9) 3.9 (2.5-6.7) 
GUT 
CD8 %: Median (IQR) 26.2 (20.3- 37.2) 49.3 (38.4-58.5) 
CD4 %: Median (IQR) 23.4 (7-47.1) 14.2 (7.3-28.3) 
“Double positive” %: Median 
(IQR) 0.67 (0.35-1.8) 0.49 (0.33-1) 
“Double negative” %: Median 




5.4 Memory phenotypes and intracellular expression of granzyme B and 
perforin in CD8+ T cells in blood and gut 
The three main T lymphocyte subpopulations (CD8+, CD4+ and gamma-delta cells) were 
further divided based on the surface expression of CD45RO and CD27 into four memory 
phenotypes: CD45RO+CD27+ (central memory), CD45RO+CD27- (effector memory), 
CD45RO-CD27+(naive) and CD45RO-CD27- (terminally differentiated). All CD8+ T cells 
were also stained intracellularly for the cytolytic enzymes granzyme B and perforin 
The distribution and the relative frequencies of CD8+ T cell memory subsets in the blood and 
gut were compared between the control and the HIV positive groups. 
As shown for the blood compartment (Figure 5.5 A), the percentage of effector memory and 
terminally differentiated CD8+ T cells in the HIV positive group is significantly higher 
compared to the controls (p=0.03 and 0.002 respectively). In addition, there are significantly 
less naïve CD8+ T cells in the HIV group (p=0.005), whereas there is no significant 
difference in the percentages of the central memory cells. 
When CD8+ T cell memory subsets are compared in the gut (Figure 5.5 B), the central 
memory, naïve and terminally differentiated cells are proportionally similar. Contrary to what 
was observed in the blood, the effector memory population is significantly lower in the HIV 
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Figure 5.5. Comparison of memory subsets of CD8+ T cells in A the blood and B the gut of 
controls (n=16) vs. HIV positive donors (n=37). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the controls, whereas the red ones represent similar 
frequencies in the HIV positive group. P values are shown for the comparisons of cell frequencies (for 
all 4 cell populations) between controls and HIV positive donors. Where the comparisons show 
statistically significant differences, the p values are in bold numbers (Mann-Whitney U test). 
 
Subsequently, the intracellular expression of granzyme B and perforin in blood and gut CD8+ 
T cells was compared between the control and HIV positive groups (Figure 5.6). Cells 
expressing granzyme B and perforin were significantly more frequent in the HIV positive 
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population in the blood compartment (p<0.0001 and p=0.0003 respectively, Figure 5.6.A); 
also, there was a much wider distribution in the frequencies of cytolytic enzyme-positive 
CD8+ cells in the HIV positive group; this was evident when the IQRs were compared (9.1-
22% vs. 28.1-60% for granzyme B and 2.9-11.6% vs. 9.5-27.5% for perforin in the control 
and HIV positive populations respectively, Table 5.3). 
When gut CD8+ T cells were compared between controls and positive donors (Figure 5.6. B), 
the frequencies of CD8+ T cells expressing granzyme B and perforin were also significantly 
higher in the HIV population (p<0.0001 and p=0.0003 respectively). Similarly to the blood, 







































































Figure 5.6. Comparison of granzyme B and perforin expression on CD8+ T cells in A the blood 
and B the gut of controls (n=16) vs. HIV positive donors (n=37). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent the IQR. 
The yellow boxes show cell frequencies in the HIV control group whereas the red ones represent 
similar frequencies in the HIV positive group. P values are shown for the comparisons of cell 
frequencies between the two groups. Where the comparisons show statistically significant differences, 
p values are in bold numbers (Mann-Whitney U test) 
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The frequencies of all the above subpopulations of CD8+ T cells as a percentage of the total 
CD8+ population are summarised in Table 5.3. 
Table 5.3. Frequencies of memory subsets and granzyme B /perforin positive CD8+ T cells in the 
blood and gut of controls and HIV positive donors. 
The numerical values in this table represent percentages of total CD8+ T cells; median values and 
interquartile ranges (IQRs) are shown. Median values in bold numbers denote statistically significant 
differences (p<0.05) between the groups of controls and HIV positive donors, when compared using 
the Mann-Whitney U test. In the blood, the EM and TD CD8+ T cells are significantly more frequent 
in the group of positive patients; in the same group, naïve CD8+ cells are significantly less common. 
Both granzyme B and perforin are expressed significantly more in the HIV positives in blood, as well 
as in the gut compartment; the control group shows significantly higher percentages of CM cells in 
the gut than the group of positives. 
 
 BLOOD GUT 
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In order to address the impact of HIV viraemia on the distribution of CD8+ cell subsets and 
their expression of granzyme B and perforin, HIV positive patients were divided in two 
groups, based on the presence or absence of detectable plasma viral load; memory subsets of 
CD8+ T cells as well as the expression of cytolytic enzymes were then compared between 
groups. The presence or absence of detectable plasma viraemia was also used to divide HIV 
patients into those two groups for the study of mucosal CD8+ T cells. The use of plasma 
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viraemia as a surrogate for the “antigenic burden” in the mucosa is further addressed in the 
“Discussion” section of this Chapter. 
The relative proportions of memory subsets in blood CD8+ T cells did not differ significantly 
between HIV positive donors with detectable vs. undetectable viral load (Figure 5.7 A). When 
memory subsets were compared in the gut mucosa (Figure 5.7 B), the central memory cells 
were found to be significantly more frequent in the patients with detectable plasma viraemia; in 
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Figure 5.7. Comparison of memory subsets of CD8+ T cells in the blood A and gut B of HIV 
positive donors with undetectable (VL<50copies/ml, n=22) vs. detectable (VL>50 
copies/ml, n=15) viral load. 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent the IQR. 
The yellow boxes show cell frequencies in the group of donors with undetectable viraemia, whereas 
the red ones represent similar frequencies in the group with detectable viral loads. P values are 
shown for the comparisons of cell frequencies between the above two groups. Where the comparisons 
show statistically significant differences, the p values are in bold numbers (Mann-Whitney U test). 
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When the expression of granzyme B and perforin was compared between the two groups in the 
blood (Figure 5.8. A), no significant differences were found. However, a significantly higher 
proportion of mucosal CD8+ T cells of patients with detectable viraemia expressed granzyme 
B intracellularly, compared to those with undetectable viral load (p=0.0002), whereas the 


































































Figure 5.8. Comparison of granzyme B and perforin expression in CD8+ T cells in the blood A and 
gut B of HIV positive donors with undetectable (n=22) vs. detectable (n=15) viral load. 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the group of donors with undetectable viraemia, whereas 
the red ones represent similar frequencies in the group with detectable viral loads. P values are 
shown for the comparisons of cell frequencies between the above two groups. Where the comparisons 
show statistically significant differences, the p values are in bold numbers (Mann-Whitney U test) 
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5.5 Analysis of memory phenotypes of CD4+ T cells and expression of 
granzyme B and perforin in blood and gut 
The memory phenotypes of CD4+ T cells in the blood and gut, as well as the intracellular 
expression of granzyme B and perforin were analysed in the groups of controls and HIV 
positive donors. The percentages of central memory, effector memory and naïve CD4+ T cells 
did not differ significantly between the groups of controls and HIV positive patients in the 
blood (Figure 5.9.A). The frequency of terminally differentiated CD4+ T cells in the blood 
was generally very low (Table 5.4) and was statistically higher in the HIV positives (p=0.03). 
In the gut compartment (Figure 5.9. B), comparison between controls and positive donors 
showed no difference in the naïve and terminally differentiated CD4+ T cell populations. 
Similarly to what was observed in the gut CD8+ T cell memory subsets (Figure 5.5), the 
effector memory CD4+ subset was proportionally contracted in the HIV positive population 
(p=0.02). In contrast to effector memory cells, the central memory CD4+ cells were 
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Figure 5.9. Comparison of memory subsets of CD4+ T cells in the blood A and gut B of controls 
(n=16) vs. HIV positive donors (n=37). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the control group whereas the red ones represent similar 
frequencies in the HIV positive group. P values are shown for the comparisons of cell frequencies (for 
all 4 cell populations) between the control and the HIV positive groups. Where the comparisons show 
statistically significant differences, the p values are in bold numbers (Mann-Whitney U test) 
 
As expected, the frequencies of CD4+ T cells expressing granzyme B and perforin were 
significantly lower compared to CD8+ cells, especially in the gut, where the numbers of 
perforin expressing CD4+ cells were negligible. Comparison of the intracellular expression of 
granzyme B and perforin in the blood CD4+ cells between the control and positive groups 
(Figure 5.10 A) showed proportionally higher numbers of gut CD4+ cells expressing those 
enzymes (p=0.0001 and p=0.0002 for granzyme B and perforin respectively). As with CD8+ 
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cells (Figure 5.6), there was a much wider distribution in the frequencies of cytolytic enzyme-
positive CD4+ cells in the HIV positive group; this was also evident when the IQRs are 
compared (Table 5.4). 
When similar comparisons were made for mucosal CD4+ cells in the control and positive 
groups (Figure 5.10 B), in keeping with the blood data, granzyme B expressing cells were 
overrepresented in the HIV positive patients (p=0.0002). There was no statistical difference 
in the perforin expressing CD4+ T cells; furthermore, the absolute percentages of those cells 





































































Figure 5.10. Comparison of granzyme B and perforin expression in CD4+ T cells in the blood A and 
gut B of controls (n=16) vs. HIV positive donors (n=37). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the control group whereas the red ones represent similar 
frequencies in the HIV positive group. P values are shown for the comparisons of cell frequencies 
between the control and the HIV positive groups. Where the comparisons show statistically significant 
differences, the p values are in bold numbers (Mann-Whitney U test) 
 
The frequencies of CD4+ memory subsets and cells expressing granzyme B and perforin in 
blood and gut are summarized in Table 6.4 for both controls and HIV positive donors. 
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Table 5.4. Frequencies of memory subsets and granzyme B /perforin positive CD4+ T cells in the 
blood and gut of controls and HIV positive donors. 
The numerical values in this table represent percentages of total CD4+ T cells; median values and 
interquartile ranges (IQRs) are shown. Median values in bold numbers denote statistically significant 
differences (p<0.05) between the groups of controls and HIV positive donors, when compared using 
the Mann-Whitney U test. In the blood, all 4 memory subsets of CD4+ cells did not differ significantly 
between controls and positive patients. When the gastrointestinal mucosa was studied, the group of 
positive donors had higher proportions of CM and lower proportions of EM cells compared to the 
controls. Finally, cytolytic enzyme frequencies were much higher in positive patients in both 
compartments, except for perforin in the gut (negligible expression in mucosal CD4+ T cells). 
 
 BLOOD GUT 
 Controls HIV positive Controls HIV positive 





























































To address whether the presence or absence of detectable plasma viraemia has an impact on 
memory phenotypes and expression of cytolytic enzymes in the CD4+ T cells, the study donors 
were divided into two groups: those with detectable viral load (n=15) and those with viral load 
below the limit of detection (n=22). The relative proportions of central memory, effector 
memory, naïve and terminally differentiated subsets were similar irrespective of the presence or 
absence of virus in the blood (Figure 5.11.A). In the mucosal compartment, however, the 
presence of detectable viraemia appeared to be associated with significant increases in the 
central memory and naïve CD4+ T cell populations (p=0.01 for both comparisons), as well as a 
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Figure 5.11. Comparison of memory subsets of CD4+ T cells in the blood A and gut B of HIV 
positive donors with undetectable (n=22) vs. detectable (n=15) plasma viral load. 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the group of donors with undetectable viraemia, whereas 
the red ones represent similar frequencies in the group with detectable viral loads. P values are 
shown for the comparisons of cell frequencies between the above two groups. Where the comparisons 
show statistically significant differences, the p values are in bold numbers (Mann-Whitney U test) 
 
When the expression of granzyme B and perforin in the blood was studied in the CD4+ T 
cells of viraemic and aviraemic HIV positive donors (Figure 5.12.A), no significant 
differences were observed between the groups. 
However, the presence of detectable virus in the plasma seems to affect the percentages of 
gut mucosal CD4+ cells expressing granzyme B and perforin (Figure 5.12 B); they are both 
significantly increased in the group of donors with detectable plasma viral load (p<0.0001 




































































Figure 5.12. Comparison of granzyme B and perforin expression on CD4+ T cells in the blood A 
and gut B of HIV positive donors with undetectable (n=22) vs. detectable (n=15) 
viraemia. 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the group of donors with undetectable viraemia, whereas 
the red ones represent similar frequencies in the group with detectable viral loads. P values are 
shown for the comparisons of cell frequencies between the above two groups. Where the comparisons 
show statistically significant differences, the p values are in bold numbers (Mann-Whitney U test) 
5.6 Surface immunophenotyping and intracellular expression of granzyme 
B and perforin in CD8+ and CD4+ cells in small intestine and colon 
As previously discussed (4.3.4), there are important differences between the immune system 
in the small bowel and colon. It was also shown in the previous chapter that there are 
differences in the magnitude of the CD8+ T cell single cytokine recall responses to FEC, gag 
and nef between those mucosal sites. Moreover, the quality of the CD8+ responses was 
different between the duodenum and colon after cognate peptide stimulation. In view of those 
differences, we sought to establish whether the memory phenotypes of CD4+ and CD8+ T 
cells also differ between mucosal sites; furthermore, the expression of granzyme B and 
perforin by CD8+ and CD4+ cells was compared between the small and large intestine. 
Similar to the comparison of recall responses between duodenum and colon (Chapter 4), we 
used parallel duodenal and colonic samples obtained from the same donor on the same day; 
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those were individuals undergoing two endoscopic procedures as part of their clinical care 
(either OGD and flexible sigmoidoscopy or ODG and colonoscopy). Table 4.3 summarises 
the clinical characteristics of the donors who provided parallel samples. Flow cytometry plots 
from two donors of duodenal and colonic samples showing differences in the frequencies of 
memory subsets between the two mucosal sites are shown in Figure A-8 (Appendix). 
Comparison of CD8+ T cell memory subtypes between duodenum and colon showed no 
significant difference in the frequencies of central memory and terminally differentiated 
CD8+ cells between the two mucosal sites (Figure 5.13). The effector memory subset was 
underrepresented in the colonic mucosa compared to the duodenum (p=0.02); also, there was 
a trend towards higher naïve CD8+ T cell frequencies in the colon, which did not reach 
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Figure 5.13. Comparison of memory subsets of CD8+ T cells in the duodenum vs. the colon of HIV 
positive donors (n=9) . 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the duodenum whereas the red ones represent similar 
frequencies in the colon. P values are shown for the comparisons of cell frequencies (for all 4 cell 
populations) between the duodenum and the colon. Where the comparisons show statistically 
significant differences, the p values are in bold numbers (Wilcoxon matched pairs test). 
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The CD8+ T cell memory subset distribution between duodenum and colon in all nine donors 
who provided parallel samples from both sites is shown in Figure 5.14. The CD8+ memory 
subset frequencies were quite similar in duodenum and colon in five donors (O420, C600, 
M420, D100 and J530). There were, however, two donors with markedly different memory 
subset distribution between those sites (S652 and B530); in both these individuals, the 
significant majority of the CD8+ cells in the colon exhibited a terminally differentiated 
phenotype, whereas in the duodenum there were large proportions of central memory and 











Figure 5.14. Comparison of memory subsets of CD8+ T cells in the duodenum vs. the colon of HIV 
positive donors (n=9) . 
The colour-coded pie charts represent the total CD8+ T cell population in the duodenum (1st row) and 
the colon (2nd row) of the nine individuals who provided parallel duodenal and colonic samples. The 
different slices represent CD8+ T cell memory subsets in these compartments. 
 
When the granzyme B and perforin expression by CD8+ T cells were compared between 





































Figure 5.15. Comparison of granzyme B and perforin expression in CD8+ T cells in the duodenum 
vs. the colon of HIV positive donors (n=9) . 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the duodenum whereas the red ones represent similar 
frequencies in the colon. P values are shown for the comparisons of cell frequencies (for all 4 cell 
populations) between the duodenum and the colon. Where the comparisons show statistically 
significant differences, the p values are in bold numbers (Wilcoxon matched pairs test). 
 
Comparison between CD4+ T cell memory phenotypes in duodenum vs. colon (Figure 5.16) 
showed no significant differences in the frequencies of central memory, naïve and terminally 
differentiated CD4+ cells between duodenum and colon. There was an increased frequency of 
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Figure 5.16. Comparison of memory subsets of CD4+ T cells in the duodenum vs. the colon of HIV 
positive donors (n=9). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the duodenum whereas the red ones represent similar 
frequencies in the colon. P values are shown for the comparisons of cell frequencies (for all 4 cell 
populations) between the duodenum and the colon. Where the comparisons show statistically 
significant differences, the p values are in bold numbers (Wilcoxon matched pairs test). 
 
The CD4+ T cell memory subset distribution between duodenum and colon in all nine donors 
who provided parallel samples from these sites is shown in Figure 5.17. The CD4+ memory 
subset frequencies were quite similar in duodenum and colon in five donors (O420, C600, 
M420, D100 and J530). There were two donors with very different memory subset 
distribution between those sites (S652 and B530); in both these individuals, the significant 
majority of the CD4+ cells in the colon exhibited a terminally differentiated phenotype, 
whereas in the duodenum there were significant proportions of central memory and effector 
memory cells. Interestingly, the S652 and B530 study participants showing marked 
differences in CD4+ memory phenotype distribution between duodenum and colon were the 
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same ones showing differences in the CD8+ T cell memory subsets (Figure A-8, Appendix) 
and the patterns of those differences were very similar in both types of T cells (i.e. almost 











Figure 5.17. Comparison of memory subsets of CD4+ T cells in the duodenum vs. the colon of HIV 
positive donors (n=9). 
The colour-coded pie charts represent the total CD4+ T cell population in the duodenum (1st row) and 
the colon (2nd row) in the nine individuals who provided parallel duodenal and colonic samples. The 
slices represent the CD4+ memory subsets in these compartments 
 
When the expression of cytolytic enzymes in the CD4+ population was compared between 
duodenum and colon (Figure 5.18), there were significant differences, with both granzyme B 
and perforin expressed in much higher frequencies in duodenal CD4+ T cells (p=0.003 and 
0.03 respectively). These differences in cytolytic enzyme expression between compartments 






































Figure 5.18. Comparison of granzyme B and perforin expression in CD4+ T cells in the duodenum 
vs. the colon of HIV positive donors (n=9). 
The whiskers denote the whole of the distribution (0-100 percentile) and the boxes represent IQRs. 
The yellow boxes show cell frequencies in the duodenum whereas the red ones represent similar 
frequencies in the colon. P values are shown for the comparisons of cell frequencies (for all 4 cell 
populations) between the duodenum and the colon. Where the comparisons show statistically 
significant differences, the p values are in bold numbers (Wilcoxon matched pairs test). 
 
5.7 Study of correlations between peptide recall responses, memory 
phenotypes and cytolytic enzyme expression in blood and mucosal 
CD8+ and CD4+ T cells 
As stated in the beginning of this Chapter (5.1), one of the aims of this study was to look into 
possible correlations between HIV-1 cognate peptide immune responses and memory 
phenotypes in CD8+ T cells in blood and gut, as well as between recall immune responses and 
cytolytic enzyme contents. The donor population participating in this part of the study 
consists of 26 HIV positive donors whose blood and gut samples were used both for 
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assessment of recall responses as well as for ex vivo phenotyping for memory markers, 
granzyme B and perforin (Table A-4, Appendix). 
As shown in Chapter 4, the two main responses of memory CD8+ T cells to gag and nef were 
IFNγ and CD107, followed by smaller amounts of TNFα and negligible production of IL-2. 
Furthermore, the CD107 response to peptide stimulation was used as an alternative to MHC-1 
tetramer staining to define antigen-specific cells (Betts et al. 2003) and the single IFNγ 
response has often been the main or sole readout (using the ELISPOT assay) in HIV 
candidate vaccine trials. We, therefore, sought to determine possible correlations between the 
magnitude of IFNγ or CD107 responses (after peptide stimulation) and phenotypic memory 
markers of the same cells in resting state; possible correlations between IFNγ or CD107 
responses and cytolytic enzyme expression in ex vivo resting cells were also examined. 
5.7.1 Correlations of recall responses with memory phenotypes and in blood and 
mucosal CD8+ T cells 
We first looked for potential correlations between the magnitude of the IFNγ response to both 
gag and nef and the proportions of CM and EM CD8+ T cells in blood and gut. There was a 
statistically significant positive correlation between the IFNγ response to gag and the 
proportion of CM CD8+ T cells in blood (Figure 5.19 A, r=0.37, p=0.05). No correlation was 
observed between the IFNγ response to nef and CM CD8+ proportions. There was no 
correlation between the IFNγ response to either gag or nef and the proportion of EM CD8+ T 
cells in the blood. 
In the gut (Figure 5.19 B), there appeared to be a strong positive correlation between IFNγ 
magnitude (in response to either gag or nef) and the proportion of mucosal CM CD8+ T cells 
(r=0.59, p=0.001 for gag and r=0.57, p=0.002 for nef responses). In keeping with the findings 
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in the blood, there was no association between the magnitude of the IFNγ response and the 
frequency of EM CD8+ T cells in the mucosal compartment. 
Subsequently, possible correlations between the expression of CD107 (in response to 
stimulation with gag or nef) and proportions of CM and EM CD8+ T cells were studied 
(Figure 5.20 A and B). In both the blood (A) and gut (B) compartments, the findings are 
similar to those for the IFNγ correlations: there is a positive and statistically significant 
association between CD107 levels (in response to gag) and CM CD8+ T cells in blood 
(r=0.38, p=0.05); also, there is a strong positive correlation between CD107 (in response to 
both gag and nef) and CM proportions of mucosal CD8+ T cells (r=0.67, p=0.0001 for gag 










































































































Figure 5.19. Correlation between the magnitude of IFNγ recall responses and frequencies of central 
(CM) and effector memory (EM) CD8+ T cells in blood A and gut B 
Figure 5.19 A consists of four Spearman rho correlation graphs in blood CD8+ T cells in the HIV 
positive group (n=26). The x-axis shows the magnitude of the IFNγ response (percentage of total 
CD8+ T cells expressing IFNγ) after stimulation with gag (1st row) or nef (2nd row). The y-axis 
represents proportions of central memory (1st column) and effector memory (2nd column) cells out of 
total CD8+ T cells. Figure 5.19 B shows similar correlations for the mucosal compartment. Spearman 
correlation coefficients r as well as p values for each correlation are depicted on each graph; p 
values less than 0.05 for any given correlation are in bold numbers. 
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Figure 5.20. Correlation between the magnitude of CD107 recall responses and frequencies of 
central (CM) and effector memory (EM) CD8+ T cells in blood A and gut B 
Figure 5.20 A consists of four Spearman rho correlation graphs in blood CD8+ T cells of the HIV 
positive group (n=26). The x-axis shows the magnitude of the CD107 response (percentage of total 
CD8+ T cells expressing CD107) after stimulation with gag (1st row) or nef (2nd row). The y-axis 
represents proportions of central memory (1st column) or effector memory (2nd column) cells out of 
total CD8+ T cells. Figure 5.20 B shows similar correlations for the mucosal CD8+ T cells. Spearman 
correlation coefficients r as well as p values for each correlation are depicted on each graph; p 
values less than 0.05 for any given correlation are in bold numbers. 
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5.7.2 Correlations of recall responses with cytolytic enzyme expression in blood and 
mucosal CD8+ T cells 
In the same study cohort, we subsequently sought to determine possible associations between 
IFNγ or CD107 responses and granzyme B and perforin expression in CD8+ T cells. There 
was no significant correlation in the blood between the magnitude of IFNγ response (to either 
gag or nef) and granzyme B or perforin expression in CD8+ T cells (Figure 5.21 A). In 
contrast, there was a strong positive correlation between IFNγ (in response to both gag and 
nef) and granzyme B expression in mucosal CD8+ T cells (Figure 5.21 B, r=0.60 and p=0.001 
for gag, r=0.62, and p=0.0007 for nef responses); interestingly, no such association was 
found between IFNγ responses and perforin expression in gut CD8+ T cells. 
In a similar manner, when the magnitude of CD107 responses was studied for possible 
correlations with the above cytolytic enzyme levels, no such associations were found in the 
blood CD8+ T cells (Figure 5.22 A). In the mucosal compartment, however, strong positive 
correlation between CD107 magnitude (in response to both gag and nef) and granzyme B 
expression in CD8+ T cells was observed (Figure 5.22 B, r=0.66 and p=0.0002 for gag, 
r=0.59 and 0.001 for nef responses). No correlation was found between CD107 response 
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Figure 5.21. Correlation between the magnitude of IFNγ recall responses and frequency of 
granzyme (gB) and perforin expression in CD8+ T cells in blood A and gut B 
Figure 5.21 A consists of four Spearman rho correlation graphs in blood CD8+ T cells of the group of 
HIV positive donors (n=26). The x-axis shows the magnitude of IFNγ response (percentage of total 
CD8+ T cells expressing IFNγ) after stimulation with gag (1st row) or nef (2nd row). The y-axis 
represents the proportion CD8+ T cells expressing granzyme B (1st column) or perforin (2nd column) 
out of total CD8+ T cells. Figure 5.21 B shows similar correlations for the mucosal CD8+ T cells. 
Spearman correlation coefficients r as well as p values for each correlation are depicted on each 
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Figure 5.22. Correlation between the magnitude of CD107 recall responses and frequencies of 
granzyme (gB) and perforin expression in CD8+ T cells in blood A and gut B. 
Figure 5.22 A consists of four Spearman rho correlation graphs in blood CD8+ T cells of the group of 
HIV positive donors (n=26). The x-axis shows the magnitude of CD107 response (percentage of total 
CD8+ T cells expressing CD107) after stimulation with gag (1st row) or nef (2nd row). The y-axis 
represents the proportion CD8+ T cells expressing granzyme B (1st column) or perforin (2nd column) 
out of total CD8+ T cells. Figure 5.23 B shows similar correlations for the mucosal CD8+ T cells. 
Spearman correlation coefficients r as well as p values for each correlation are depicted on each 
graph; p values less than 0.05 for any given correlation are in bold numbers. 
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5.8 Discussion 
5.8.1 Summary of findings 
In the study of surface phenotypes of blood and mucosal T cells, rather unexpectedly a high 
percentage of CD3+CD8-CD4- T (“double negatives”, DN) cells were found in the mucosal 
compartment in both the control and HIV positive groups. 
In the blood CD8+ T cells, we described an increase in effector memory (EM) and terminally 
differentiated (TD) cells, as well as a decrease in naïve CD8+ T cells in the HIV positive 
donors; these differences were reflected in higher proportions of granzyme B and perforin in 
positive patients. In the gut, EM CD8+ T cells were decreased in HIV positive patients, whereas 
gB and perforin frequencies increase significantly, in keeping with findings in the blood; 
furthermore, in donors with detectable plasma viraemia, the differences observed in the gut 
were exacerbated. 
When CD4+ cells were studied, similar memory profiles were seen in controls and positive 
donors in the blood, whereas a marked increase in central memory (CM) and a decrease in 
EM CD4+ T cells was found in the mucosa of HIV positive patients. Finally, in both blood 
and gut there was a significant expansion of cytotoxic CD4+ T cells expressing one or more 
of the cytolytic enzymes granzyme B and perforin. 
Comparison of memory subsets between small bowel and colon, showed significantly higher 
EM CD8+ and CD4+ T cells in the duodenum, a finding reflected in the significantly higher 
frequency of cytotoxic CD4+ cells in the same compartment. 
Study of associations between magnitude of antigen-specific recall responses and memory 
phenotypes showed significant positive correlations between IFNγ /CD107 responses and 
proportion of CM CD8+ T cells in the gut, but not the blood; no correlation was shown 
between IFNγ /CD107 recall responses and EM CD8+ proportions in either compartment. 
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Finally, in the gut (but not the blood) a strong positive correlation was established between 
IFNγ/CD107 and granzyme B (but not perforin) expression in CD8+ T cells. 
5.8.2 Implications of study findings 
5.8.2.1 CD3+CD8-CD4- cells in the blood and mucosal immune system 
The effect of HIV-1 infection on the numbers and frequencies of the common lymphocyte 
subsets in the blood has been well documented (Douek et al. 2003; Simon et al. 2006). In 
keeping with those and other reports, the CD4+ T cell frequency was significantly reduced, 
whereas the frequency of CD8+ T cells was increased in the blood of the HIV positive group 
compared with the controls. Comparison of the frequencies of mucosal T cell subpopulations 
between the controls and the positive group showed the CD8+ T cells to be more abundant in 
the latter; although CD4+ T cells were less frequent in the group of positive patients, the 
difference between groups did not reach statistical significance. 
Several reports describe the higher frequency of CD3+TCRαβ+CD4-CD8- (“double negative“, 
“DN”) cell population in the HIV positive individuals in the blood (Marodon et al. 1999; 
Mathiot et al. 2001); this finding was confirmed in the present study. These cells were found 
to be a reservoir of HIV-1 in untreated patients and exhibited higher rates of viral 
transcription compared to CD4+ T cells (Kaiser et al. 2007). One other study found high 
levels of HIV-1 DNA only in DN cells from patients failing ART and not in those with 
equally high levels of viraemia who were untreated (Cheney et al. 2006). 
The origin of the increased numbers of DN cells in the blood remains obscure. It seems likely 
that they may originate from CD4+ T lymphocyte precursors after in vivo down-regulation of 
their cell surface CD4 molecules due to HIV-1. In support of this hypothesis, low levels of 
CD4 mRNA were found in the DN cells in the previous study (Kaiser et al. 2007). Another 
possibility is that they stem from thymic CD4-CD8- cells, which are infected in vivo and 
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expanded to become a latent reservoir for the virus, capable of robust replication under 
favourable conditions (e.g. ART failure). 
Rather surprisingly, the mucosal DN cell population exceeded 25% percent of the total CD3+ 
cells in both controls and HIV positive groups. It is not clear whether the DN population is 
homogenous or consists of smaller subpopulations of CD3+TCRγδ- cells (as the TCRγδ 
population was excluded with the gating strategy used); downregulation of CD4 receptors on 
the cell surface could account for the high percentage of DN cells in the HIV patients, but 
that would not explain the trend towards higher frequencies of those cells in the HIV negative 
group. Alternatively, we could hypothesise that DN cells in the mucosal compartment are 
susceptible to HIV-1 infection, resulting in lysis or apoptosis of the affected cells and thus 
proportionally reducing their numbers in HIV positive donors. There are several other 
possible explanations for the unusually high numbers of mucosal DN CD3+ cells observed in 
this study. The inclusion of IELs in the study CD3+ population may have resulted in 
enrichment of the CD3+ population with DN cells; at least a proportion of gut DN cells reside 
in the intraepithelial compartment, along with other “unconventional” lymphocyte 
populations; this DN intraepithelial population makes up ten percent of the IELs in the 
murine small intestine (Hayday et al. 2001). Several MMC isolation protocols include 
incubation of mucosal biopsy tissue with EDTA, in order to remove the epithelium and 
obtain a more purified lamina propria mononuclear cell population (Bell et al. 2001; 
Shacklett et al. 2003b; Ng et al. 2009). This step was omitted in this study, in order to include 
the IELs’ profiles in the analysis. Another possible explanation for the high frequencies of 
DN cells may involve the gating strategy used in this study. The characterization of CD4+ 
cells here is based both on their positivity for the surface CD4 molecule and their negative 
staining for CD8 (CD8 exclusion gate). Likewise, a cell characterised as CD8+ must also be 
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CD4- (application of the CD4 exclusion gate). This application of a “double filter“ may result 
in more accurate characterization of the DN population in the mucosa in the present study. 
The gut DN (CD3+TCRαβ+CD4-CD8-) population is less well characterised than their 
counterparts in the peripheral blood. The origin of these cells is debatable, but recent 
evidence favours thymic descent with migration to the gut intraepithelial compartment 
(Cheroutre 2005; Falk 2006; Cheroutre et al. 2008). 
The presence of large numbers of DN cells in the gut mucosa adds another layer of 
complexity to the existing controversies in the literature regarding CD4+ reconstitution with 
suppressive ART. Extensive CD4+ T cell depletion in the gastrointestinal mucosa in HIV 
infection has been well characterised (Veazey et al. 1998; Brenchley et al. 2004; Brenchley et 
al. 2008). Furthermore, numerous studies have confirmed the efficiency of ART in 
suppressing plasma viral replication and restoring blood CD4+ cell counts (Li et al. 1998; 
Mezzaroma et al. 1999). The ability of effective ART to restore the mucosal CD4+ T cell 
numbers, however, is debatable, with a number of studies showing complete or near-
complete reconstitution (Guadalupe et al. 2006; Sheth et al. 2008) and others reporting 
incomplete recovery of mucosal CD4+ cell numbers (Mehandru et al. 2006). Some 
longitudinal studies show better mucosal CD4+ reconstitution with commencement of ART 
early in the course of the infection (Guadalupe et al. 2003; Estes et al. 2008a). If we 
hypothesise that a proportion of the DN population originates from downregulated CD4+ T 
cells, these apparent CD4- cells need to be taken into consideration when addressing CD4 
depletion or immune reconstitution in the gut mucosa after suppressive ART. Indeed, if the 
DN populations were assumed to originate from downregulated CD4 precursors, the total 
CD4 frequencies (sum of apparent CD4 and DN cells) would be comparable to the CD4+ 
frequencies in the blood of those two donor groups. 
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5.8.2.2 Memory phenotypes and cytotoxic CD8+ T cells in blood and gut 
The study of memory subsets in the blood showed that the HIV positive population has 
significantly less naïve and more effector memory and terminally differentiated cells. As 
expected, significantly more CD8+ T cells in the HIV positive donors contain granzyme B 
and perforin, since these cytolytic enzymes are almost exclusively found in the effector 
memory and terminally differentiated subsets of CD8+ T cells. Interestingly, the memory 
subsets and granzyme B /perforin expression do not differ between donors with detectable 
and undetectable plasma viral load, arguing that it may not be the continuous exposure to 
antigen that drives the CD8 memory phenotype towards a more differentiated, 
immunologically “exhausted” profile. 
Several studies attempted to characterise the memory profiles of CD8+ T cells in various 
stages of HIV-1 and SIV infection. Acute SIV infection is characterised by a decline in naïve 
CD8+ cell counts; CD45RO+CD27- EM CD8+ T cells increase in numbers at the end of the 
acute phase (when plasma viraemia declines), whereas CD45RO+CD27+CD28- (CM CD8+ T 
cells) dominate at a later stage (Mattapallil et al. 2004). Relative depletion of naïve and 
expansion of memory CD8+ T cells has been documented at different stages of HIV-1 
infection (Prince et al. 1991). HIV-associated dysregulation of CD8+ memory subsets has 
been linked to the decreased expression of CD28 in acute infection (Borthwick et al. 1994; 
Brinchmann et al. 1994); in another study, decreased CD27 expression was observed in the 
HIV-specific fraction of CD8+ T cells (Appay et al. 2002a). A recent report showed that EM 
and CM frequencies in the HIV-specific and in the total CD8+ population move in tandem 
and demonstrate a strong positive correlation in the acute infection setting (Burgers et al. 
2009b). In the same study, there was a positive correlation between EM CD8+ frequencies 
and viral set points and a negative association between set point and CM fraction in CD8 
cells. In our study, total CD8+ (as opposed to HIV-specific) memory subsets were studied; the 
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decreased naïve CD8+ counts and increased EM subsets in the blood are in keeping with 
some of the above referenced reports. 
In the gut, the CD8+ memory profiles differ between controls and positive individuals, with a 
significant reduction in the EM subset and an increase in the TD fraction in the HIV patients 
(although the latter did not reach statistically significant proportions). Furthermore, the 
presence of detectable plasma viraemia appears to further reduce the effector memory 
population and is associated with an even higher percentage of expression of granzyme B in 
gut CD8+ T cells. Interestingly, the presence of detectable virus in the plasma appears to be 
associated with a significant increase in the CD8+ central memory population in the 
gastrointestinal mucosa. These results indicate that mucosal HIV infection and especially 
unsuppressed ongoing viral replication drive the CD8+ T cells to a more differentiated 
phenotype, with more cells capable of a rapid cytotoxic response as evident by the significant 
increase in cytolytic enzymes stored in their cytoplasm. 
5.8.2.3 Memory phenotypes and cytotoxic CD4+ T cells in blood and gut 
The memory phenotypes of CD4+ T cells did not differ significantly between controls and 
HIV positive individuals in the blood. Furthermore, the presence or absence of detectable 
viraemia had no impact on the frequencies of the CD4+ memory subsets. In contrast to the 
blood, HIV infection was associated with an increase in the frequencies of CM CD4+ cells in 
the gut, as well as a decrease in the EM subset; this effect of HIV-1 is more obvious in the 
group of donors with detectable plasma viral load, where also higher percentage of naïve 
CD4+ T cells is seen. The extensive loss of memory CD4+T cells at all stages of HIV-1 
infection (Brenchley et al. 2004) and in the acute phase of SIV infection in NHPs is well 
established (Mattapallil et al. 2004; Mattapallil et al. 2005); the extent of that depletion varies 
in different stages of the acute infection and in different tissues. Contrary to our findings 
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indicating similar memory subset frequencies in controls and HIV positive donors in the 
blood, a previous report found significantly decreased naïve CD4 and increases in the CM 
populations in HIV positive patients (Brenchley et al. 2004). The apparent differences 
between this study and our findings can perhaps be explained by the fact that the total study 
population of fourteen HIV positive patients was heterogeneous, including two LTNPs and a 
further five patients with acute/early infection; better preservation of CD4 CM cells is likely 
to be seen in early infection and with LTNP status. In keeping with that notion, survival of 
NHPs vaccinated with plasmid DNA and adenoviral vectors containing sequences for several 
SIV proteins correlated with preservation of CM CD4+ T cells (Letvin et al. 2006). 
The better preservation of CM and naïve CD4+ T cells in the mucosa of HIV positive subjects 
observed in our study may reflect a steady state in the chronic stages of the infection, 
established after relative viral containment and reactive expansion of these subsets. Rhesus 
macaques exposed to SIV showed better CD4+ reconstitution in the GALT (as well as IL-2–
dominated CD8+ responses) with earlier commencement of ART (Verhoeven et al. 2008); 
GALT CM CD4+ T cells were the source for the renewal of mucosal CD4+ T cells. 
HIV infection appears to have a profound impact on the expression of granzyme B and 
perforin in the CD4+ T cells in the blood, which is not affected by the presence of detectable 
virus in the plasma. This is in keeping with prior studies which characterised a small 
population of cytotoxic CD4+ T cells (positive for perforin) in healthy controls and reported a 
significant expansion in HIV, as well as other viral infections (Appay et al. 2002b). In 
keeping with our findings, Appay et al did not find significant differences between viraemic 
and aviraemic (either on suppressive ART or controllers) patients in the frequencies of 
cytotoxic CD4+ T cells. The driving force behind the dramatic expansion of cytotoxic CD4+ T 
cells in the blood of HIV positive patients is unclear; of note, these cells are predominately 
effector memory or terminally differentiated CD4+ T cells. 
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An interesting finding of this study is that (similar to the blood) there is significant cytotoxic 
CD4+ T cell expansion in the mucosal compartment of HIV positive subjects compared to 
controls. Moreover, the presence of replicating virus in the blood further increases 
significantly the frequencies of those granzyme B and perforin-containing CD4+ T cells in the 
mucosa. These findings may support a role for cytotoxic CD4+ T cells in antiviral immunity 
against HIV, especially in the intestinal mucosa and merit further investigation. 
5.8.2.4 Differences between small bowel and colon in memory subsets and cytolytic 
enzyme expression 
In view of the differences between the mucosal immune system in the small and large bowel 
and the differences in magnitude and quality of recall responses to HIV-1 peptides in the two 
gut compartments (described in Chapter 4), we hypothesised that the memory phenotypes of 
CD8+ and CD4+ cells in the small and large intestine may also differ. We showed here that in 
both CD8+ and CD4+ cells there was a significant reduction in the effector memory subsets in 
the colon compared to the duodenum and a trend towards higher naïve CD8+ fraction in the 
former compartment. When the expression of granzyme B and perforin was compared 
between mucosal sites, there were significantly higher proportions of cytotoxic CD4+ T cells 
in the duodenum, whereas no differences were observed in the CD8+ population. Although 
memory profiles in duodenum and colon were remarkably similar in several of the nine 
donors who provided parallel samples from both sites, the differences were quite dramatic in 
two of the nine individuals examined (B530 and S652). Notably, both those donors had 
detectable plasma viral loads; however, the size of this study did not allow for statistically 
meaningful comparisons between subgroups. 
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5.8.2.5 Correlation between recall response magnitude, memory profiles and 
cytolytic enzyme expression 
We showed here that the magnitudes of CD8+ T cell IFNγ and CD107 recall responses to gag 
and nef strongly correlate with the preservation of central memory (CM) CD8+ cells in the 
gastrointestinal mucosa of HIV infected individuals. Interestingly, no such correlation was 
found between CD8+ recall responses and memory phenotypes in the blood. Furthermore, 
there is no association between magnitudes of recall responses and the proportions of effector 
memory (EM) CD8+T cells in either blood or gut mucosa, as initially hypothesised. 
The identification of correlates of immune protection in HIV-1 infection remains elusive after 
nearly three decades. The ability to characterise those correlates is vital to the field of HIV 
vaccine research. Here we showed a strong tendency towards robust antigen-specific IFNγ and 
degranulation responses in those individuals who have preserved mucosal CM CD8+ T cells. 
Similar association between preservation of central memory CD4+ T cells and prolonged 
survival after vaccination was recently shown in the model of SIV infection of rhesus macaques 
(Letvin et al. 2006). Recently, it was reported that the HIV-gag specific (but not the nef-
specific) central memory (CD45RA-CCR7+) CD8+ T cells expressing high levels of CD27+ 
positivity were associated with lower levels of plasma viraemia (Xie et al.). In contrast, a recent 
study in a prospective cohort of HIV infected individuals failed to establish any association 
between either CD4+ or CD8+ CM T cells and rate of progression of the infection (Ganesan et 
al.). Of interest, the same study showed that CD127 expression in CD8+ T cells and low 
proliferation rates for CD8+ and CD4+ T cells were associated with slower disease progression. 
To our knowledge this is the first study showing a significant positive correlation of mucosal 
CM CD8+ proportions with higher mucosal CD107 and IFNγ recall responses; because higher 
IFNγ responses tend to be associated with more polyfunctional response profile (Chapter 3), 
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the preservation and expansion of the CD8+ T cell memory subset may be a novel immune 
correlate of protection against disease progression. 
IFNγ and CD107 recall responses to both gag and nef were also positively associated with the 
frequency of expression of granzyme B in the mucosal CD8+ T cells; no correlation was seen 
with the levels of perforin in either blood or gut. Perforin levels in HIV antigen specific CD8+ 
T cells were recently found to be higher in elite controllers compared to viraemic controllers 
and progressors, suggesting that this cytolytic enzyme may be a correlate of protection 
(Hersperger et al.). Little information is available on perforin levels in CTLs from the gut 
mucosa or other tissues in HIV infection; two reports show low levels of perforin in gut 
mucosa and lymph nodes in acute HIV-1 infection (Andersson et al. 2002; Nilsson et al. 
2007). With regards to granzyme B, one report shows that all polyfunctional gag antigen 
specific CD8+ T cells elicited post vaccination with a single dose of HIV DNA vaccine were 
expressing high levels of this cytolytic enzyme (Arrode-Bruses et al.). Also, long term 
protection after live attenuated SIV vaccine in macaques was mediated by high levels and 
rapid mobilisation of intracellular granzyme B, as well as surface expression of CD107. 
(Rollman et al. 2008). The association we report here between gut mucosal CD8+ granzyme 
B levels and magnitude of CD107 and IFNγ gag and nef memory immune responses may 
suggest a novel role for this cytolytic enzyme in the mucosa as an immune correlate of viral 
replication control. 
5.8.2.6 Novel aspects, limitations of the study and future work 
There are several novel findings outlined in this study: 
The characterisation of a significant proportion of mucosal T cells as CD3+CD8-CD4- would 
need to be confirmed in larger scale studies and in different patient cohorts. 
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In the present study of T cell memory phenotypes, the characterization of T cells as central 
memory, effector memory, naïve or terminally differentiated (effector) was based on the cell 
surface expression of CD45RO and CD27. Whereas the characterisation of the effector 
memory subset as CD45RO+CD27- in our study is accurate, since the vast majority of those 
cells are CCR7-, characterisation of the central memory population as CD45RO+CD27+ 
would generate a heterogeneous group of cells including “true” CM cells 
(CD45RO+CD27+CCR7+) as well a transitional memory population (CD45RO+CD27+CCR7-) 
(Burgers et al. 2009b). Compatibility and compensation issues of the available fluorochromes 
for CD27 monoclonal antibodies prevented its incorporation into a complex 11-colour flow 
cytometry panel. Future memory phenotype flow cytometry panels should probably include 
CCR7, as well as CD57 (marker of replicative senescence) (Brenchley et al. 2003) and 
possibly CD127 (marker for longevity) (Kaech et al. 2003). 
Similarly to the previous Chapter, the distinction between HIV positive individuals with 
detectable vs. undetectable VL in this study was exclusively based on the presence or absence 
of detectable plasma viral load (limit of detection: 50copies/ml), even when mucosal T cells 
were studied. The plasma viral load was then used as a surrogate for the presence and degree 
of HIV-1 antigenic burden in the mucosal milieu. However, the Gut-Associated Lymphoid 
Tissue (GALT), which contains by far the largest pool of CD4+ T cells susceptible to HIV-1 
infection, has emerged as a major viral reservoir, with persistent ongoing replication even in 
the face of apparently successful suppressive ART (Poles et al. 2006; Chun et al. 2008). 
Therefore, this classification of subjects may bear little relevance when the mucosal immune 
system is studied. Perhaps in future studies semi quantitative methods of assessing the 
“mucosal viral load” would provide a more accurate picture of the degree of antigenic 
exposure (continuous or intermittent) of the gut immune system in HIV-1 infection. This 
would be particularly relevant when memory phenotypes are studied, as there is evidence to 
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suggest that continuous high level antigenic exposure drives T cells towards effector 
phenotype; these cells are capable of immediate robust cytotoxicity, at the expense of 
developing long term memory and become eventually exhausted (Lanzavecchia et al. 2005). 
Another interesting correlation is that between the levels of immune activation and the 
proportions of central memory and effector memory subsets: the former decreases 
proportionally, whereas the effector memory subset appears to increase with higher levels of 
immune activation, as measured by the proportion of CD8+ T cells expressing CD38 (Burgers 
et al. 2009b). Perhaps this and other markers of immune activation in the gut should be 
incorporated in future studies of memory phenotyping of mucosal T cells 
The description of differences in memory phenotypes and cytolytic enzyme expression 
between small bowel and colon adds another layer of complexity in the attempt to 
characterise the immune responses of mucosal T cells, especially in the context of candidate 
HIV-1 vaccine trials. Larger scale comparisons between HIV subgroups (i.e. viraemic vs. 
aviraemic or progressors vs. non-progressors) ought to provide more information regarding 
the possible differences in memory profiles between different sites in the gut. In donors with 
marked differences in CD8+ and CD4+ memory profiles between small and large bowel, it 
would be interesting to attempt a correlation with antigenic burden in those sites, as well as 
levels of immune activation. 
The correlation between magnitude of recall responses to gag and nef with the proportion of 
central memory CD8+ T cells in the gut (but not in the blood) emphasises the importance of 
CM CD8+ cells in preserving anti-HIV T cell responses and contributing to control of viral 
replication. The correlation of those responses with granzyme B expression in the mucosa 
(but not with perforin) hints at the importance of this enzyme in cytotoxic responses against 
HIV-1; larger studies stratifying HIV positive patients based on the level of control of viral 
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replication (i.e elite controllers, viraemic controllers, progressors etc) will be needed to 
establish a possible role for this enzyme as a correlate of control of viral replication. 
5.8.3 Conclusion 
In this study, we described memory phenotypes and cytotoxicity profiles of CD8+ and CD4+ 
T cells in blood and mucosa and compared those parameters between controls and HIV 
positive donors. Differences in memory subsets between those groups were more pronounced 
in the mucosal compartment; those, as well as differences in memory profiles between small 
and large bowel will provide insights in to the mechanisms engaged by the gut immune 
system in attempting to control viral replication in HIV-1 infection. Finally, the correlation 
between central memory CD8+ T cells and granzyme B expression in the gut mucosa with the 
magnitude of HIV specific memory immune responses suggests a possible role for those 
parameters as correlates of protection against ongoing viral replication. 
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Chapter 6 Discussion 
Qualified assays are required to measure HIV-specific immune responses for the assessment 
of vaccine immunogenicity in preventative HIV vaccine trials. Whilst validated PFC 
protocols for blood samples have previously been described (Horton et al. 2007), similar 
extensively validated protocols for the PFC-based analysis of mucosal T cell responses are 
generally lacking. Furthermore, it can not be assumed that direct implementation of blood-
based protocols in the study of mucosal responses would be satisfactory, in view of the 
complexity of acquiring and processing mucosal tissue as well as the comparatively low 
yields of mononuclear cells. We have described the optimisation and subsequent qualification 
of a polychromatic flow cytometry-based protocol applied to T cells isolated from the blood 
and gut of HIV positive and negative volunteers. Internal quality controls, established 
protocols for real-time monitoring and strict adherence to standard operating procedures lead 
to significantly improved assay specificity, making it suitable tool for assessment of 
immunogenicity in HIV-1 candidate vaccine trials. 
Subsequently, we analysed the CD8+ T cell recall responses to the HIV-1 peptides gag and nef 
in the blood and gut, as well as in the groups of viraemic verses aviraemic HIV positive donors. 
Memory responses were also compared between different sites in the gastrointestinal tract, 
namely small bowel (duodenum) and colon. CD8+ responses were found to be of higher 
magnitude in the gut vs. the blood and either similar (gag) or higher (nef) in individuals with 
detectable plasma viraemia. Duodenal recall responses to gag and nef were generally higher 
than colonic responses in the small group of patients with parallel samples from both gut sites, 
although not always significantly so. Intrerestingly, antigen-specific responses to the positive 
control FEC were higher in the colon. 
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When the flavour of the CD8+ T cell responses to gag and nef was studied, no significant 
differences were seen in the functionality of these cells between blood and gut, in any of the 
above groups.  A significant difference in the quality of the response was found between 
viraemic and aviraemic donors in the blood as well as in the gut; the latter group was found to 
have more polyfunctional responses to both gag and nef. Also, the quality of the response to 
gag and nef in the duodenum was superior to the colon in the group with parallel samples. 
Finally, the phenotypes of T lymphocyte populations, as well as the memory phenotypes of 
CD8 and CD4 T cells were studied and compared in the above compartments and groups of 
donors. The cytolytic potential of subsets of these T cells was then studied by analysing the 
intracellular expression of granzyme B and perforin. An intriguing finding in this study was 
the characterisation of a sizable proportion (over 25%) of mucosal T cells as 
CD3+TCRαβ+CD4-CD8- population (“double negatives”). The origin of these cells is 
debatable and it possibly different than their counterparts in the blood. The presence of large 
numbers of DN cells in the gut mucosa adds another layer of complexity to the existing 
controversies in the literature regarding CD4+ reconstitution with suppressive ART. 
We found significant differences in the effector memory and central memory CD8+ T cell 
populations between controls and HIV-positive patients in the gut but not in the blood. 
Similar differences were observed between HIV donors with detectable verses undetectable 
plasma viraemia. HIV positive donors generally expressed granzyme B and perforin more 
frequently than controls. Significant differences in EM and CM CD4+ subsets were also 
found in the gut, but not the blood, between controls and positive volunteers. HIV donors had 
significantly higher expression of granzyme B and perforin in both blood and gut CD4+ T 
cells; comparison of cytolytic enzyme levels between duodenum and colon showed 
significantly higher expression in the mucosal CD4+ population of the small bowel and no 
difference in the CD8+ T cells. 
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When the magnitude of peptide recall responses to gag and nef was studied in relation to the 
memory phenotypes and cytolytic enzyme expression in CD8+ T cells, significant positive 
correlation between IFNγ /CD107 responses and central memory CD8+ proportions was 
established in the mucosal compartment, but not in the blood. No such correlation was seen 
between recall responses and effector memory CD8+ proportions in any compartment. 
Additionally, the magnitude of IFNγ /CD107 recall responses correlates positively with the 
level of expression of granzyme B, but not with perforin, in the mucosal compartment. No 
such correlation was shown for the blood CD8+ T cells. This novel finding alludes to a 
possible role of granzyme B in the mucosa as a correlate of protection in HIV-1 infection. 
Measurement of immune responses in the mucosal compartments may be important to the 
HIV vaccine field, since transmission of the virus occurs through the mucosal barrier. It is 
conceivable that systemic vaccine-induced HIV specific T-cell populations may respond too 
slowly or be inadequate for controlling the initial infection. This may explain the outcome of 
the STEP trial, where vaccine-specific responses were only characterised in the peripheral 
blood (Buchbinder et al. 2008). Similarly, the partial protection afforded by the RV144 
vaccine trial (Rerks-Ngarm et al. 2009), could be attributed to effective antibodies or local 
mucosal T cell responses at the sites of entry; unfortunately, neither mucosal biopsies nor 
secretions were collected from the study participants for retrospective analysis of gut immune 
responses. Such assessment of vaccine-induced mucosal HIV-1-specific responses in future 
trials may provide a more comprehensive assessment of immunogenicity profiles of 
candidate vaccines. 
We did not find a close correlation in this study between HIV-specific CD8+ T-cell responses 
in blood and gastrointestinal tract for individual patients, confirming previous reports that T-
cell responses to HIV in those two sites may be compartmentalised (Guadalupe et al. 2006; 
Critchfield et al. 2007; Ferre et al. 2009). The FEC pool was selected as a positive control to 
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maximize detection of CD8 T cell responses; in retrospect, it would have been preferable to 
use an additional or alternative antigen pool such as 15-mer CMV peptides or a protein 
antigen capable of eliciting CD8 and CD4 T-cell responses in mucosal tissues. Unfortunately, 
this was not feasible due to the limited number of lymphocytes obtained from gut biopsies. 
Responses to FEC were not significantly different between PBMC and MMC compartments 
in either HIV seropositive or negative subjects. These may be due to recirculation of the same 
CD8+ T cell clones between gut and PBMC as has been demonstrated in NHP chronically 
infected with HIV (Sircar et al.) 
Another novel aspect of this study is the analysis of the quality of blood and gut CD8+ T cell 
responses to nef. This peptide is an important virulence factor for all lentiviruses and there 
are data to support its role in accelerating the progression of HIV infection (Piguet et al. 
1999; Arien et al. 2008). It is produced in large quantities at the early stages of infection 
(Cullen 1994) and is capable of downregulating cell surface CD4 (Garcia et al. 1992; Aiken 
et al. 1994), as well as MHC class I molecules (Schwartz et al. 1996; Piguet et al. 2001), thus 
promoting  evasion of cytotoxic T cell responses. These properties make nef theoretically an 
attractive target for an HIV vaccine. The superior quality of the nef response in the gut 
compartment would suggest that it may be a promising candidate immunogen for mucosal 
vaccines. 
A further novel approach of this study is the comparison of the immune response between 
different sites of the gastrointestinal tract, namely the duodenum and the colon. In the small 
group of donors with parallel samples from both sites, the CD8 recall responses to gag and 
nef were found to be discordant. The analysis of memory phenotypes in duodenum and colon 
revealed similar profiles in the majority of studied donors, but rather dramatic differences in a 
minority of them. Similarly, higher frequencies of EM CD8+ and CD4+ T cells, as well as 
higher expression of granzyme B and perforin in CD4+ cells were observed in the duodenum. 
210 
These findings point out significant differences between the small bowel and the colonic 
mucosal immune systems in HIV-1; these are important considerations when mucosal tissue 
sampling is required for assessment of T cell responses, such as in the context of a clinical 
vaccine trial. 
Since reliable identification of immune correlates of protection from HIV-1 remains elusive 
after nearly three decades of intensive research, future work in the field should focus on 
methods such as microarrays and PFC to investigate as many immune markers as possible for 
monitoring clinical trials. Our initial data demonstrate different responses to HIV antigens 
between peripheral blood and gut compartments. 
In conclusion, we have outlined a protocol to analyse HIV-specific CD8+ T-cell responses in 
gastrointestinal tissue samples in a robust and meaningful manner. We have demonstrated 
differences in quality and magnitude of the recall responses to HIV peptide antigens between 
blood and gut as well as between different sites in the gastrointestinal tract; in addition, we 
reported differences in memory phenotypes and cytolytic enzyme contents between 
compartments, indicating that comprehensive assessment of HIV-1 vaccine candidate 
immunogenicity will require mucosal sampling, perhaps from more than one site. Such 
assessment will be informative on vaccine design and will assist in prioritizing and 
rationalizing the selection of candidate vaccines for further large-scale clinical trials.   
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Chapter 7 Appendix 
Table 7.1. Clinical characteristics of the HIV positive donor group (n=35). 
These include the CD4 count and plasma viral load recorded nearer the time of the sampling, the 
presence or absence of antiretroviral treatment, the lowest CD4 cell count on record for each 
individual (CD4 nadir), the time between initial HIV diagnosis and sampling, the time on 
antiretroviral treatment, as well as the time ( after the diagnosis) before ART was commenced for the 
first time. Data on CD4 nadir, length of diagnosis and treatment could not be obtained for two donors 
(J520 B and M420), as their records were incomplete. For the same reson, CD4 nadir data could not 


























R300 295 21847 YES 90 8 1 7 
V260 544 <50 YES 248 0 1 0 
B250 107 <50 YES 21 4 2 2 
P230 1072 <50 YES 131 15 4 11 
M210 529 7365 NO 468 6 N/A N/A 
W625 307 <50 YES 294 13 12 1 
H300 399 <50 YES 201 6 6 0 
M535 408 25773 NO 260 3 N/A N/A 
P510 575 <50 YES NO 
DATA 
13 13 0 
W630 154 666 YES 20 10 10 0 
B630 P 208 <50 YES 66 5 0 4 
P300 553 <50 YES 66 5 1 4 
C425 489 <50 YES 3 14 12 2 
V520 451 420 NO 347 11 N/A N/A 
H526 565 <50 YES 182 18 13 5 
F425 797 <50 YES 38 9 9 0 
G320 670 <50 YES 294 9 8 1 
R500 388 8143 NO 345 13 N/A N/A 
G650 585 <50 NO 525 1 N/A N/A 
T525 771 <50 YES 43 8 4 4 
F630 533 <50 YES 308 2 1 1 


























C230 272 13029 NO 233 2 N/A N/A 
G400 596 5930 NO 618 5 N/A N/A 
P456 1115 <50 YES 560 2 1 1 
A452 398 1907 NO NO 
DATA 
8 N/A N/A 






O420 625 <50 YES 154 23 13 10 
S652 611 111610 YES 339 13 12 1 
C600 390 808 NO 320 2 N/A N/A 








B530 335 153145 NO 335 2 N/A N/A 
C220 356 299228 NO 356 0 N/A N/A 
W623 732 11884 NO 651 1 N/A N/A 
J522  550 359834 NO 456 5 N/A N/A 
 
 
Table 7.2. Characteristics of the control donors (n=38). 
All patients had macroscopically normal mucosa, as assessed by the endoscopist. Diagnostic biopsies 
were obtained in 24 out of the 38 patient and there were all normal (in the remaining 14 patients, 









1 K525 M 43 Dyspepsia OGD1 Normal 
2 B400 F 30 Epigastric pain OGD Normal 
3 C552 F 39 Diarrhoea Colonoscopy Normal 
4 P650 F 44 CIBH2 Colonoscopy Normal 
5 A610 M 38 CIBH Colonoscopy Normal 
6 G530 M 28 CIBH  Colonoscopy Normal 









8 A216 F 49 Polyp surveillance Colonoscopy N/A 
9 B340 F 39 Dyspepsia OGD  Normal 
10 C165 M 45 Bleeding PR3 Colonoscopy N/A 
11 E152 F 43 Diarrhoea Colonoscopy Normal 
12 S455 F 28 CIBH Colonoscopy Normal 
13 E163 M 44 Iron deficiency anaemia OGD Normal 
14 B353 M 46 Abdominal pain Colonoscopy N/A 
15 R330 M 40 Dyspepsia OGD N/A 
16 B450 M 43 Nausea and vomiting OGD N/A 
17 G345 M 43 Dyspepsia OGD Normal 
18 H400 F 50 Abdominal pain Colonoscopy Normal 
18 G162 F 37 Diarrhoea Colonoscopy Normal 
20 G363 F 24 CIBH1 Sigmoidoscopy Normal 
21 H655 M 28 Diarrhoea and bleeding 
PR3  
Colonoscopy Normal 
22 L200 F 23 Dyspepsia and weight loss OGD Normal 
23 B656 F 49 GORD4 OGD N/A 
24 H520 F 39 HNPCC5, polyp 
surveillance 
Colonoscopy N/A 
25 O160 M 45 Bleeding PR Colonoscopy N/A 
26 G125 F 43 Diarrhoea Colonoscopy Normal 
27 B630 F 28 Nausea and vomiting OGD Normal 
28 H630 F 44 Polyp surveillance Colonoscopy N/A 
29 S323 M 46 Abdominal pain Colonoscopy N/A 
30 P200 M 36 Bleeding PR Sigmoidoscopy N/A 
31 L516 M 21 Bleeding PR Colonoscopy N/A 
32 H220 M 42 Diarrhoea Sigmoidoscopy Normal 
33 H560 F 29 Dysphagia OGD N/A 
34 B412 F 36 Dyspepsia OGD Normal 
35 F236 M 31 Diarrhoea Colonoscopy Normal 
36 D120 F 41 Bleeding PR Colonoscopy N/A 
37 B516 F 40 Diarrhoea Colonoscopy Normal 




2. Change in bowel habit 
3. Per pectum 
4. Castro-Oesophageal Reflux Disease 
5. Hereditary Non-Polyposis Colorectal Cancer 
 
Table 7.3. Characteristics of the HIV positive donors (n=46) 
All patients had macroscopically normal mucosa, as assessed by the endoscopist. All available 
clinical biopsies with the exception of one (23 out of 46 individuals) were also reported as normal. 
Donor M535 had infectious proctitis involving the distal rectum; however, research biopsies were 





Sex Age Indication for 
endoscopy 
Procedure Clinical biopsy 
results 
 
1 G400 M 33 Nausea OGD N/A 
2 G650 M 28 Dyspepsia OGD N/A 
3 T525 M 42 Dyspepsia OGD N/A 
4 S350 M 42 Dyspepsia OGD N/A 
5 J520 A M 47 Dysphagia OGD Normal 
6 H526 M 48 Dyspepsia OGD N/A 
7 R500 M 49 Dyspepsia OGD N/A 
8 G320 M 49 Polyp surveillance Colonoscopy N/A 
9 F425 M 50 Iron deficiency anaemia OGD Normal 
10 V520 M 35 Epigastric pain OGD N/A 
11 B630 P M 46 Diarrhoea Colonoscopy Normal 
12 P300 M 30 Epigastric pain OGD N/A 
13 W630 M 41 Diarrhoea Sigmoidoscopy Normal 
14 P510 F 50 Dyspepsia OGD N/A 
15 M535 M 43 Diarrhoea and bleeding  Colonoscopy Infectious 
proctitis 
16 C425 M 47 Dyspepsia OGD N/A 
17 C230 M 43 Dyspepsia OGD N/A 
18 C240 M 33 CIBH Colonoscopy N/A 
19 R260 M 40 Dyspepsia OGD N/A 
20 T225 F 32 Dyspepsia OGD N/A 





Sex Age Indication for 
endoscopy 
Procedure Clinical biopsy 
results 
 
22 A536 M 38 Rectal bleeding, 
diarrhoea 
Sigmoidoscopy Normal 
23 R164 M 50 Nausea OGD N/A 
24 A452 M 29 Diarrhoea Sigmoidoscopy Normal 
25 J520 B M 50 Diarrhoea Colonoscopy Normal 
26 M562 M 35 Diarrhoea Sigmoidoscopy Normal 
27 R553 M 43 Diarrhoea Colonoscopy Normal 
28 Y550 F 24 Dyspepsia OGD N/A 
29 B530 M 45 Dyspepsia, diarrhoea OGD/Sigmoidos
copy 
Normal 
30 C600 M 31 PR bleeding OGD/Colonosco
py 
N/A 
31 M420 M 47 Diarrhoea OGD/Sigmoidos
copy 
Normal 
32 S652 M 44 Diarrhoea OGD/Colonosco
py 
Normal 
33 O420 M 42 Diarrhoea OGD/Sigmoidos
copy 
Normal 
34 D100 F 34 Dyspepsia, diarrhoea OGD/Colonosco
py 
Normal 
35 W623 M 39 Anaemia, diarrhoea ODG/Colonosco
py 
Normal 
36 J522 M 47 Dyspepsia, diarrhoea OGD/Colonosco
py 
Normal 
37 C220 M 41 Anaemia, CIBH ODG/Colonosco
py 
Normal 
38 R300 F 34 NUD1 OGD N/A 
39 V260 M 28 Dyspepsia OGD N/A 
40 B250 M 28 GORD OGD N/A 
41 P230 M 36 GORD OGD N/A 
42 W625 M 41 Diarrhoea Sigmoidoscopy Normal 
43 M210 M 42 Polyp surveillance Colonoscopy N/A 
44 H300 M 46 Dysphagia OGD Normal 
45 F630 M 23 Spontaneous 
pneumomediastinum 
OGD2 Normal 
46 P456 M 47 Barrett’s oesophagus OGD Normal 
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1 G400 618 5930 NO 596 5 N/A N/A 
2 G650 585 <50 NO 525 1 N/A N/A 
3 T525 771 <50 YES 43 8 4 4 
4 S350 679 <50 YES 226 3 2 1 
5 J520 A 585 <50 YES 163 1 1 0 
6 H526 565 <50 YES 182 18 13 5 
7 R500 388 8143 NO 345 13 N/A N/A 
8 G320 670 <50 YES 294 9 8 1 
9 F425 797 <50 YES 38 9 9 0 
10 V520 451 420 NO 347 11 N/A N/A 
11 B630 P 208 <50 YES 66 5 0 4 
12 P300 553 <50 YES 66 5 1 4 
13 W630 154 666 YES 20 10 10 0 
14 P510 575 <50 YES NO 
DATA 
13 13 0 
15 M535 408 25773 NO 260 3 N/A N/A 
16 C425 489 <50 YES 3 14 12 2 
17 C230 272 13029 NO 233 2 N/A N/A 
18 C240 482 <50 YES 296 5 1 4 








20 T225 398 <50 YES 109 6 6 0 
21 M323 P 401 <50 YES 190 4 2 2 
22 A536 465 8140 NO 403 2 N/A N/A 
23 R164 467 <50 YES 212 5 3 2 
24 A452 398 1907 NO NO 
DATA 
8 N/A N/A 






26 M562 290 39,878 NO 290 1 N/A N/A 
27 R553 578 <50 YES 366 12 8 4 






















29 B530 335 153145 NO 335 2 N/A N/A 
30 C600 390 808 NO 320 2 N/A N/A 








32 S652 611 111,610 YES 339 13 12 1 
33 O420 625 <50 YES 154 23 13 10 
34 D100 475 <50 YES 177 6 6 0 
35 W623 732 11884 NO 651 1 N/A N/A 
36 J522 550 359834 NO 456 5 N/A N/A 
37 C220 356 299228 NO 356 1 N/A N/A 
38 R300 295 21847 YES 90 8 1 7 
39 V260 544 <50 YES 248 0 1 0 
40 B250 107 <50 YES 21 4 2 2 
41 P230 1072 <50 YES 131 15 4 11 
42 W625 307 <50 YES 294 13 12 1 
43 M210 529 7365 NO 468 6 N/A N/A 
44 H300 399 <50 YES 201 6 6 0 
45 F630 533 <50 YES 308 2 1 1 
46 P456 1115 <50 YES 560 2 1 1 
 
Table 7.5. Clinical characteristics of the HIV positive donor group who provided samples for the 






















1 M535 408 25773 NO 260 3 N/A N/A 
2 P510 575 <50 YES NO 
DATA 
13 13 0 
3 W630 154 666 YES 20 10 10 0 
4 B630 P 208 <50 YES 66 5 0 4 
5 P300 553 <50 YES 66 5 1 4 






















7 V520 451 420 NO 347 11 N/A N/A 
8 H526 565 <50 YES 182 18 13 5 
9 F425 797 <50 YES 38 9 9 0 
10 G320 670 <50 YES 294 9 8 1 
11 R500 388 8143 NO 345 13 N/A N/A 
12 G650 585 <50 NO 525 1 N/A N/A 
13 T525 771 <50 YES 43 8 4 4 
14 A536 465 8140 NO 403 2 N/A N/A 
15 C230 272 13029 NO 233 2 N/A N/A 
16 G400 596 5930 NO 618 5 N/A N/A 
17 A452 398 1907 NO NO 
DATA 
8 N/A N/A 






19 O420 625 <50 YES 154 23 13 10 
20 S652 611 111610 YES 339 13 12 1 
21 C600 390 808 NO 320 2 N/A N/A 








23 B530 335 153145 NO 335 2 N/A N/A 
24 C220 356 299228 NO 356 0 N/A N/A 
25 W623 732 11884 NO 651 1 N/A N/A 












































































Pie Category Test Results











Figure 7.1. Quality of CD8+ T cell responses to gag vs. nef in the blood of HIV positive donors 
(n=34). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell level after stimulation with gag and nef respectively. The y-axis scale 
indicates the absolute percentage (of the total responding cells) that corresponds to a particular 
combination of functions; each blue or red bar represents the interquartile range (IQR) for that 
combination after gag or nef stimulation respectively, whereas the horizontal solid black bars denote 
median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared after stimulation with gag or nef (Wilcoxon matched pairs test). The right lower table 
shows p values when the total responses to those stimuli are compared (permutation test). P values 
indicative of statistically significant differences (p<0.05) are highlighted red. However, for the 
comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied to 












































































Pie Category Test Results











Figure 7.2. Quality of CD8+ T cell responses to gag vs. nef in the gut of HIV positive donors 
(n=34). 
Bar chart: The solid blue and red bars represent all 15 possible combinations of the 4 functions 
expressed at the single cell after stimulation with gag and nef respectively. The y-axis scale indicates 
the absolute percentage (of the total responding cells) that corresponds to a particular combination of 
functions; each blue or red bar represents the interquartile range (IQR) for that combination after 
gag or nef stimulation respectively, whereas the horizontal solid black bars denote median values. 
Pie Charts: The colour-coded pie charts represent the total responding cells and the 4 different 
colours correspond to the number of functions simultaneously expressed at the single cell level. 
Statistical analysis: The right top table shows p values when the 15 combination functions are 
compared after stimulation with gag or nef (Wilcoxon matched pairs test). The right lower table 
shows p values when the total responses to those stimuli are compared (permutation test). P values 
indicative of statistically significant differences (p<0.05) are highlighted red. However, for the 
comparisons between the Boolean combinations, a nominal value of p<0.003 would be applied to 




























































































































Figure 7.3. Comparison of memory subsets of CD8+ and CD4+ T cells in the duodenum vs. the 
colon of 2 HIV positive donors . 
A total of 2 patients (B530 and S652) and 2 different T cell populations in each patient (CD8 and 
CD4) are compared between duodenum and colon. The first row shows memory phenotypes of CD8+ 
(1st and 2nd column from the left) and CD4+ T cells (3rd and 4th column) in the duodenum, whereas the 
second row shows the parallel colonic CD8+ and CD4+ phenotypes 
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